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PREVALENCE, INCIDENCE AND RISK FACTORS OF ERECTILE 
DYSFUNCTION IN MALES WITH TYPE 1 DIABETES ENROLLED IN THE 
PITTSBURGH EPIDEMIOLOGY OF DIABETES COMPLICATIONS STUDY (EDC) 
(1986-2007) 
Andrea F. Rodgers Fischl, PhD 
University of Pittsburgh, 2008 
Objective:  To: 1)determine the prevalence and incidence of ED in males with T1D enrolled in 
the Pittsburgh Epidemiology of Diabetes Complication (EDC) study from 1986 to 2007; 
2)identify risk factors for development of ED; 3)identify the development of ED in relation to 
other markers of neuropathy; and, 4) determine behavioral and cognitive risk factors associated 
with the development of ED.  
Design:  The EDC was a cohort study of 333 males with T1D: mean age of 27.53years (SD±7.8, 
range 8.5-47.4); 331 Caucasians and 2 African Americans; and, duration of diabetes of 19.6years 
(SD±7.5, range 7.7-37.4).  Age-specific ED prevalence was determined from baseline (1986-
1988) while age-specific incidence was determined from longitudinal data (1988-2007).  
Results:  Prevalence rate was 10.4 %. Thirty-one had ED: mean age of 35.8years (SD±5.3, 
range 22.9-44.8) and mean duration of diabetes 26.9years (SD±5.9, range 8.1-37.4).  Males with 
prevalent ED did not statistically differ from males without ED in metabolic control (HbA1), 
education, income, or the current use of ACE or lipid lowering medications.  Associated risk 
factors for the 31 prevalent cases included; CDSP, HDL and BDI score. Incidence rate was 
17.78 % (n=54) from 1989-2007 with a mean age of 40.61years (SD±5.9, range 26.7-60.8) and 
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mean duration of diabetes of 32.54years (SD±5.88, range 20.9-51-9).  Mean HbA1 was 10.68% 
(SD±2.19).  Associated risk factors for the 54 incident cases included; CDSP, nonHDL 
cholesterol, and BDI score. E/I Ratio was significant (p<.01) at the time of the event, but not in 
the preceding event cycle (p=.18).  CDSP was significant (p<.01) in the preceding cycle to ED 
development and at the time of event (p<.01).  For the repeated measure analysis, CDSP was 
significant in the preceding cycle to the ED development but not at the time of the event.  The 
following differences were found between those with and without ED: knowledge of diabetes 
(p=.04); self-management (p=.10); and, perception of severity (p=.08).  However no significant 
difference was found between the two groups for self-efficacy.   
CONCLUSION: CDSP, HDL, nonHDL and total BDI score were risk factors for development 
of ED in males with T1D.  Therefore, these should be assessed for frequently in males with T1D. 
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1.0  INTRODUCTION 
The focus of this dissertation is erectile dysfunction (ED) in males with Type 1 Diabetes (T1D) 
enrolled in the Pittsburgh-Epidemiology of Diabetes Complications Study (EDC) (1986-2007).  
This chapter provides a brief introduction to erectile dysfunction (ED) in males with T1D, the 
problem statement and purpose of this research, as well as the specific aims and research 
questions followed by the significance of this study. 
Expanding a previous definition of sexual dysfunction that only included impotence, 
the National Institutes of Health Consensus Conference, in 1993, defined the complication of 
erectile dysfunction (ED) as an inability to achieve and maintain an erection sufficient for 
satisfactory sexual performance to include libidinal, orgasmic and ejaculatory dysfunctions 
(Conference, 1993).  Worldwide estimates of ED are approximately 150 million men.  Within 
the United States alone, it is estimated that approximately 30 million males are affected with 
erectile dysfunction (MacDonagh, Ewings, & Porter, 2002; A. D. Seftel, Sun, & Swindle, 
2004).  In a retrospective cohort study of a representative national managed care database 
including 51 commercial health plans and 28 million members in the United States, Sun et al 
(Sun, 2006) found 285,436 males reported an ED diagnosis from 1995-2001.   Table 1.1 
depicts the diagnosis of ED by percentage of claims filed, reported by region within the United 
States. 
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             Table 1.1. Percentages of Claims Reporting ED Diagnosis by Region within the US (1995-2001) 
Region % Reporting ED Population 
East 21.96% n=62,694 
South 32.78% n=93,560 
Midwest 33.95% n=96,902 
West 11.13% n=32,280 
 
The mean age of males with ED was found to be 8.1 to 12.3 years older than the mean 
age of males without ED.  Of the males reporting ED, 87% were between the ages of 36 and 65 
years of age (See Table 1.2).  The actual prevalence of ED is probably somewhat higher than 
reported by Sun et al (Sun, 2006) in this review.  Males with Medicaid, Medicare or non-
managed insurance plans were not part of this claims database review and only those males 
with ED who sought care for ED were included for analysis, therefore, actual prevalence rates 
of ED are suspected to be somewhat higher.  
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 Table 1.2 Age Distribution of Males with ED (bolded area represent 87% of Males between 36-65  
Years of age) 
Age Groups (Years) % of Cohort Reporting ED 
18-25 0.8 
26-35 4.9 
36-45 16.1 
46-55 35.7 
56-65 35.3 
66-75 5.2 
76-85 1.9 
86+ 0.2 
 
ED significantly affects males with co-morbidities.  Approximately 42% of males with 
hypertension, 42% for hyperlipidemia, 20% with diabetes, 11% with depression, 24% for 
hypertension and hyperlipidemia, and 13% for hypertension and diabetes mellitus, also have 
ED (A. D. Seftel et al., 2004).  
 ED is a well documented and prevalent complication of type 1 and 2 diabetes. It is 
estimated that approximately 50-70% of all males with type 1 diabetes (T1D) will develop a 
functional sexual disorder within 10 years of their initial diabetes diagnosis. For males with 
Type 2 Diabetes (T2D), ED will develop in approximately 46% of those males (Vickers, 
2002). 
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The prevalence of ED will increase as the proportion of diabetes cases continues to 
escalate.  It is predicted that in the year 2025, the countries with the most number of diabetes 
cases will be India, China, and the United States (King, 1998) and in the year 2050 there will 
be 48.3 million people in the United States alone with diabetes (Venkat Narayan, Boyle, Geiss, 
Saaddine, & Thompson, 2006). Diabetes is a major health burden for American males. In 2005, 
it was estimated that approximately 20.8 million people or 7.0% of the U.S. population had 
type 1 and 2 diabetes (www.diabetes.org/diabetes-statistics, 2/18/2007). There are 10.9 million 
men within the United States with diabetes (www.diabetes.org/diabetes-statistics, 2/18/2007). 
TID, previously known as juvenile onset diabetes or insulin dependent diabetes mellitus 
(IDDM), is a major chronic disease causing significant public health problems.  T1D is 
commonly diagnosed during childhood and early adolescence, though can be diagnosed at any 
age.  T1D is seen in about one in every 400 to 600 children and adolescents.  Data from the 
Allegheny County Registry, Pennsylvania, showed a rather rapid increase in incidence for the 
period 1985-1989, within the total observed period 1966 to 1989.  This reflects an 83% 
increase in incidence.  Most rapid increase in incidence was noted in the 0-4 year age group 
and non-white males.  Also contributing to the increase was a higher incidence of diabetes for 
the African-American group noted as 17.6/100,000.  This is higher than the incidence for 
Caucasians, which was noted as 16.5/100,000.  A threefold higher incidence of diabetes among 
the African-American group, ages 15-19 years, was 30.7/100,000 as compared to the 
Caucasian group of 11.2/100,000.  The 1990-1994 incidence rates for Allegheny County for 
the African-American group were two and three times higher than the incidence reported for 
this group in the years 1985-1989 and 1980-1984 respectively (IM  Libman & LaPorte, 2005). 
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Diabetes can cause short and long term complications. Long term complications 
account for over 200,000 deaths per year (www.diabetes.org/diabetes-statistics, 2007).  The 
increase in morbidity and mortality is due to chronic conditions resulting from retinopathy, 
nephropathy, neuropathy and cardiovascular system involvement. 
ED is a form of autonomic neuropathy (AN) .  ED may be considered an important 
precursor in the development of cardiac and vascular disease.  Males with ED and T1D have an 
increase in the severity of coronary heart disease as well (A  Vinik, Maser, Mitchell, & 
Freeman, 2003). 
The American Diabetes Association cites the importance of early recognition and 
appropriate management of neuropathies (Boulton et al., 2005).  Diabetic autonomic 
neuropathy (DAN) can potentially affect every system within the body and cause an increase in 
morbidity and mortality in those with T1D (Maser, Pfeifer, Dorman, Becker, & Orchard 1990; 
A  Vinik et al., 2003). Approximately 20% of those with diabetes will have cardiovascular 
autonomic neuropathy (CAN) (A  Vinik et al., 2003). In a 1990 study by Orchard and Maser 
(Maser et al., 1990),168 people with insulin dependent diabetes, between 25-34 years of age, 
were assessed for AN and cardiovascular risk factors using the office based 
Expiration/Inspiration Ratio Test (E/I Ratio).  An abnormal E/I Ratio, a measurement of 
heart rate response to deep breathing, was indicative of parasympathetic nervous system 
damage.  With continuous electrocardiogram monitoring, a one minute coached deep breathing 
exercise comprised of six maximal expirations and inspirations was performed. This procedure 
was repeated a second time.  The E/I ratio was then calculated by determining the mean value 
of the longest RR interval from the electrocardiogram during expiration and the shortest RR 
interval from inspiration. An abnormal ratio was considered ≤ 1.1.  Findings confirmed that 
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cardiovascular risk factors are correlates of AN (Maser et al., 1990).  AN can be isolated or 
coexist with other diabetic complications or peripheral neuropathies, such as distal 
symmetrical polyneuropathy (DSP ).  In addition to a negative impact on survival, AN can 
also have a significant negative impact on quality of life. 
    Leading to this decline in their quality of lif e (QOL) , males with ED may also develop 
depression and/or anxiety which can impact negatively on their relationship with  their spouse 
or partner (MacDonagh, Porter, Pontin, & Ewings, 2004).  Themes resulting from qualitative 
research contributing to depression and/or anxiety include the male’s sense of loss with regard 
to manhood, isolation and stigma associated with ED, and a sense of isolation with the problem 
(MacDonagh et al., 2004).  Some of the males with ED expressed the lack of an acceptable 
“quick fix” to their “problem” and this lack in a “fix” to the ED was seen as a further source of 
anxiety (MacDonagh et al., 2004). The male perception of self control is also adversely 
affected by ED and admitting lack of control, confers a need for help. It also requires the man 
to expose his problem.  Males with ED and diabetes are reluctant to do so in that they may be 
perceived as weak by their peers and partners (Jack, 2005).  Since ED can be chronic, it is 
estimated that the cumulative effect on the quality of life is considerable (MacDonagh et al., 
2004). 
       There is also an economic burden seen with T1D and ED. Direct costs and indirect 
expenditures attributed to diabetes in 2002 totaled $132 billion.  Of the $91.8 billion spent  for 
direct medical expenditures, $24.6 billion resulted from chronic complications due to diabetes, 
$23.2 billion for diabetes care and $44.1 billion  for excess general medical  conditions 
(Association, 2003).  In addition, indirect costs, that is, money spent due to disability, work 
loss, restricted activity, and mortality due to diabetes totaled $39.8 billion (Association, 2003).  
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Those with diabetes had medical expenditures that were 2-4 times higher than expenditures for 
persons matched for age, sex, race/ethnicity without diabetes (Association, 2003). However, 
these are approximate estimates and considered to be underestimates of the true cost 
(Association, 2003).  There is also an economic impact of ED that is not only limited to 
treatment and costs at diagnosis.  There are subtle impacts that are difficult to quantify such as 
loss of work, decreased productivity due to psychological distress, and stress placed on the 
partner and family (Sivalingam, Hashim, & Schwaibold, 2006). Reported 1985 total direct 
costs for ED were $146 million (Wessells, 2007).  Pharmaceutical sales for products for ED 
has risen from $0.9 billion in 1998 to $5 billion in 2002 (Sivalingam et al., 2006).  
The information thus far has focused on the prevalence, burden and cost of diabetes and 
ED as well as the demographic and biological risk factors associated with ED.  The following 
section presents behavioral and cognitive factors that could potentially prevent or delay the 
development of ED.   
Data from the Diabetes Control and Complications Trial (DCCT) suggest that most 
complications can be prevented or delayed in onset by adherence to a diabetes regime of tight 
metabolic control (DCCT, 1990).  This complex treatment regime includes insulin, diet, 
exercise and glucose monitoring. Cognitive factors, such as knowledge and health belie fs 
(self-efficacy and perceptions of severity ) influence self-management behaviors (Glasgow, 
Ruggerio, Eakin, Dryfoos , & Chobanian, 1997).  Intensive treatment reduced the risk of 
nephropathy, neuropathy and retinopathy by 35% to 90% compared to the conventional 
treatment.  Although for specific manifestations like ED, this has not been directly documented 
(DCCT, 1998, 2002).  Therefore, the public health burden of this disease and the development 
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of complications, such as ED, can be reduced by identifying and reducing risk factors and 
assessing self-management behaviors.   
1.1 PROBLEM STATEMENT 
Although ED is not considered life threatening, family planning problems and quality of life 
issues can result from this complication (DeBeradis et al., 2002).  As mentioned, prevalence, 
the number of cases that are present, at or, during a specified period of time, for ED in males 
with T1D range from 27%-75% (Fedele, 1998; Klein, Klein, & Moss, 2005; Siu, Lo, Ip, & 
Wong 2001)For males with diabetes between the ages of 30-34 years, ED is present in 
approximately 15%, and increases to approximately 55% by age 60 years (Moore & Wang, 
2006)..Males with T1D are twice as likely to develop ED than males without diabetes, (Bacon 
et al., 2002; http://www.diabetes.org/diabetes-statistics/complications.jsp, 2007; A  Vinik et al., 
2003)and at an earlier age, some as early as age 25 years.  Risk factors for the development of 
ED in men with T1D are increasing age, a longer duration of the T1D , poor metabolic  
control, smoking, alcohol intake,  selective anti-hypertensive med ications, depression, 
hypertension, and the number and presence of other d iabetes co mplications (Close & 
Ryder, 1995; Enzlin, 2003; Fedele, 1998; Klein et al., 2005) .  These risk factors can be 
categorized as demographic, biological, psychosocial, behavioral and cognitive.  Although 
several studies have estimated the prevalence and incidence of ED in males with T1D, there 
have been no studies that have fully detailed the sequence of developing ED in relation to risk 
factors and other complications.  With regard to psychosocial factors, almost all studies have 
examined the effects of ED on the quality of life, depression, and anxiety rather than reversing 
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the temporal order and identifying pre-existing correlations. This study also is unique in its 
significance in that it has baseline data for QOL and depression prior to the development of ED 
and identification of other risk factors.  Also, there have been no studies, to date, that have 
investigated longitudinally the self-management behaviors of males with ED and diabetes. 
1.1.1 Purpose 
Primary objectives of this study include: 1) to determine both the prevalence and incidence of 
ED in the Epidemiology of Diabetes Complications Study (EDC) population; 2) to identify risk 
factors for development of ED; 3) to determine the natural history of ED particularly if ED 
development occurs at a particular stage of neuropathic disease. The secondary objective is to 
identify longitudinal self-management behaviors of males with ED in the EDC as related to 
knowledge and health beliefs (self-efficacy, perceptions of severity of complications of 
diabetes). 
The sample population will be males from the Pittsburgh Epidemiology of Diabetes 
Study (EDC). This is a NIH funded representative longitudinal study designed to follow a well 
defined T1D cohort to determine risk factors for the development of major diabetic 
complications. A potential eligible participant pool of 1,124 included those with T1D who had 
been either diagnosed or seen within one year of their diagnosis at the Children’s Hospital of 
Pittsburgh between January 1, 1950 to May 31, 1980 who lived within 100 miles or 2.5 hours 
of Pittsburgh.  Seven hundred eighty-eight participants (658 full participation and 130 survey 
information only) resulted from those eligible and baseline EDC examinations were completed 
for study participants during 1986-1988.  Data were then collected biennially on this cohort, 
for a period of 20 years (1986-2006), by face-to-face clinic visits, physical assessments, 
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laboratory testing and self report.  Collection of data continued to be ascertained in the 21st 
year (2007) of this longitudinal study by the above methods. 
1.1.2 Specific Aims/Research Questions 
The specific aims and research questions of this study were to: 
Specific Aim #1:  Determine both the age-specific prevalence and incidence of ED obtained 
by self-report during physician interview 
Question #1a: What is the age-specific prevalence of ED for males enrolled at baseline as 
compared to age-specific normative data? 
Question #1b: What is the age-specific incidence of ED? 
Specific Aim #2: Determine baseline predictive risk factors for the development of ED.  
Question #2a: Which baseline demographic factors (age, income, marital status, level of 
education) and biologic factors [HbA1c, age at diagnosis, duration of diabetes, E/I ratios, type 
and number of complications, systolic and diastolic blood pressure, lipid profile (High Density 
Lipoprotein (HDL) and non-HDL cholesterol)], lifestyle behavior (smoking, alcohol intake) 
and the use of anti-hypertensive medication predict prevalent and incident cases of ED? 
Question #2b: Do baseline psychosocial factors [quality of life (modified DCCT-QOL 
Questionnaire), depression (Beck Depression Inventory)] predict ED?  
Specific Aim #3 Determine the sequence of the development of ED in relation to other 
markers of neuropathy, i.e., Autonomic Neuropathy (AN)( E/I ratio <1.1),  Confirmed Distal 
Symmetrical Polyneuropathy (CDSP), and Symptomatic Autonomic Neuropathy (SAN ) ( 
excluding ED) using longitudinal data. 
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Question# 3a: What is the sequence to the development of ED in relation to other markers of 
neuropathy, i.e., AN, CDSP, and SAN? 
Secondary Specific Aim: Determine behavioral and cognitive risk factors, as represented by 
self-management behavior, self-efficacy, perception of severity and knowledge associated with 
the development of ED using EDC self-reported longitudinal data.    
Question #1.: Does self-management behavior, self-efficacy, perceptions of severity and 
knowledge of diabetes predict ED? 
Question #2: Is self-management a mediator between cognitive variables (self-efficacy, 
perceptions of severity and knowledge) and ED? 
1.2 DEFINITION OF TERMS 
The following define the terms used throughout this dissertation: 
Type 1 Diabetes (T1D) - insulin dependent diabetes mellitus. 
Pittsburgh Epidemiology of Diabetes Complication Study (EDC)-longitudinal study conducted 
in Pittsburgh from 1986-2007 following a (youth onset of diabetes) cohort of  individuals 
diagnosed with type 1 diabetes between 1950-1980, and evaluated at Children’s Hospital of 
Pittsburgh within one year of diagnosis. 
Erectile Dysfunction(ED)-sexual dysfunction resulting from autonomic neuropathy of diabetes 
and not due to any other medical or psychological problem or medical treatment as determined 
by the examining EDC physician. 
Prevalence-the number of cases present at, or during a specified period of time (Lilienfeld, 
1976). 
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Incidence-the probability, or risk, of developing the disease within a specified period of time 
(Lilienfeld, 1976). 
E/I ratio-physiologic indicator of autonomic neuropathy (AN) defined as an abnormal heart 
rate response to deep breathing calculated by the mean value of the longest RR interval  during 
expiration and the shortest RR interval during inspiration (abnormal reading : E/I ratio less 
than 1.1). 
Symptomatic autonomic neuropathy (SAN)-E/I ratio less than 1.1 and 2 or more of the 
following clinical symptoms; postural hypotension, gastroparesis, diabetic diarrhea, colonic 
atony, genitourinary, sudomotor abnormality, or hypoglycemic unawareness as documented by 
physician exam. 
Distal Symmetrical Polyneuropathy (DSP)-Clinically evident diabetic peripheral neuropathy 
confirmed by physician's exam defined as at least 2 of the following: 1) symptoms consistent 
with DSP; 2) abnormal sensory exam consistent with DSP; 3) decreased or absent deep tendon 
reflexes. 
Confirmed Distal Symetrical Polyneuopathy (CDSP)-Clinically evident DSP (as described 
above) and vibratory threshold of >2.39 for ages < 36 years, >2.56 for ages 36- 50 years, and, 
> 2.89 for ages >50 years.. 
Social Cognitive Theory-Theory derived from the Social Learning Theory credited to Albert 
Bandura in 1962 that posits that behavior, cognition and environmental events operate as 
interacting determinants influencing each other bidirectionally.   
Self-efficacy –Construct of the Social Cognitive Theory (SCT); perception that one possesses 
the capabilities to organize and execute the course of action required to produce prescribed 
outcome. 
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1.3 SIGNIFICANCE OF THE STUDY 
Diabetes is one of the major chronic diseases seen today that imparts significant public health 
burden on society.  Complications from diabetes are costly and result in excess morbidity and 
mortality.  Understanding the long term complications of diabetes, the intra-relationships 
among these complications and the risk factors is important.  It is with this understanding that 
complication rates will decrease and an improvement in the quality of life of those affected by 
diabetes will occur. Although ED is not considered to be a life threatening complication, the 
development of ED is associated with other more life threatening concurrent complications so 
there is necessity in investigating this further.  Prevalence can estimate public health burden of 
a disease. However, these types of studies tend to underestimate total disease frequency. On the 
other hand, incidence can determine actual risk and likely causality and, serve as the basis for 
preventative services. Prior research has not documented the temporal relationship between 
risk factors and the development of ED.  Since data from the Diabetes Control and 
Complications Trial (DCCT) suggests that complications can be delayed or prevented by 
achieving tight metabolic control, it is imperative that risk factors associated with ED be 
identified to focus intensification of therapy. Partial significance to this study results from   
determining the demographic and biological risk factors for the development of ED. However, 
adding additional significance to this study is determining the temporal relationship of the 
psychosocial risk factors as well.  
Previously, published literature has focused on the physical aspects of ED.  There is 
little research that focuses on the male’s perceptions of his sexuality, self-efficacy and control 
of diabetes  and their role in the development of ED (Jack, 2005). Typically what is applied to 
treating and educating males about diabetes is largely derived from studies in which females 
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dominate the population (Hardy & Bell, 2004 ; Jack, 2005)  Since diabetes treatment is a 
cooperative process, there is necessity to understanding the self-management behaviors of 
males in relationship to the development of ED. This study is also appropriately timed in that it 
coincides with a national effort to engage men in addressing health issues.  
The mission of the American Diabetes Association is to prevent and cure diabetes and 
to improve the lives of all people affected by diabetes.  The significance of this study is in 1) 
further examine the prevalence and incidence of ED attempting to understand the temporal 
relationship between the risk factors and the development of ED and, 2) exploring the self-
management behaviors of those with ED.  Findings of this study could potentially raise 
awareness and understanding of the risk factors in the development of ED in an attempt to 
modify the risk of developing this complication. 
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2.0  REVIEW OF THE LITERATURE 
2.1 INRODUCTION 
The relationship between diabetes and sexual problems has long been recognized.  Avicenna, 
who lived between the years of 960-1037A.D., was the first to mention the “collapse of 
sexual function” as a specific complication of diabetes in his medical encyclopedia (Enzlin, 
2003).  Estimates are that 50-70% of all males with diabetes will develop a functional sexual 
disorder in which the primary complaint is erectile dysfunction (Enzlin, 2003). Prior 
community research reports the prevalence of ED to be within the range of 10% to 52% 
(Laumann, Paik, & Rosen, 1999) while 10 year overall incidence  of self-reported ED was 
25% in males 21 years of age and older with 10 or more years duration of  T1D (Klein et al., 
2005).  ED in males with diabetes develops at an earlier age than the general population , can 
occur as early as age 25 and can cause significant family planning problems.  
ED is a multifaceted disease, having potential psychological, neurological or vascular 
etiologies, seen not only in the general public but also as a complication of T1D.  The 
following is an extensive review of the literature describing the physiologic etiology of ED, 
the epidemiology of ED, identification of the demographic, biologic, lifestyle behavioral 
psychosocial risk factors, cognitive risk factors, and their interrelationships in the 
development of ED, a review of T1D, and the epidemiology of diabetes and complications. 
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Studies on the physiological mechanisms of ED have been documented throughout 
history.  To evaluate the erectile process, modern neurological techniques are documented in 
the literature dating back to Eckard in 1863 (Stief, 2002). Even though the research continued 
in physiology, the psychological theories became the front runners as the etiology of ED, and, 
especially dominated medicine as a result of the work completed by Sigmund Freud.  In the 
1940’s, Joslin  remarked on ED , “ a rare complaint that is best purposely neglected because it 
may disappear with general improvement of therapy, or if not, the less the attention of the 
patient is directed to it, the better.”   This philosophy of treatment prevailed until Kinsey in the 
late 1940’s openly discussed aspects of male sexuality (Sullivan et al., 1997).  The last 15 years 
have provided advanced molecular and pharmacological studies that have enriched the body of 
knowledge in the pathophysiology and pharmacotherapy of erectile disorders. Although today, 
the exact etiology is still not yet known, research continues.  A brief review of this literature 
was presented. Because within this literature lies the physiological rationale for the present 
treatment options available to males with ED, both with and without diabetes.   
“Probably the most clinically significant epidemiological task is the determination of 
risk factors because of the implications for intervention of modifiable risk factors and for 
patient screening” (Maser et al., 1991).  By reviewing both epidemiology of ED in those with 
and without diabetes the possible interrelationships for risk are determined. 
T1D is a disease that manifests a global burden on society.  Estimates are that the 
incidence of T1D will continue to increase.  If ED can be prevented or delayed in occurrence, 
then it is in the public health interest that issues surrounding self-management behaviors and 
self efficacy be explored as well. Therefore, a review of the literature is necessitated for these 
areas as well. 
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2.1.1 Anatomy of the Penis 
The male penis is an external genital organ having a sexual and urinary function. It is attached 
to the pubic symphysis by two ligaments and located above the scrotum.  There are three 
cylindrical bodies of erectile tissue within the male penis: one ventral corpus spongiosum 
(wherein lies the urethra), and two corpora cavernosa located side by side in the dorsal half of 
the penis.  A thick bilayer fibrous sheath, called the tunica albuginea, encloses the corpus 
cavernosa.  These fibers unite medially forming a septum which allows the two corporal 
cavernosa bodies to function as one unit.  The corpus spongiosum also has a somewhat thinner 
tunica albuginea.  Deep fibrous and resistant tissue called Bucks fascia , surrounds all three 
corporal bodies (Kirby, Culley, & Goldstein, 1999; Meeting, 2003; Melman & Gingell, 1999).  
Lacunar spaces, a lattice of vascular sinusoids, are lined with vascular endothelium.  These 
comprise the erectile tissue and are surrounded by a trabecular of smooth muscle fibers with an 
extracellular matrix of fibroblasts, elastin and collagen.  
Penal blood supply is from a branch of the hypogastric artery called the internal 
pudendal artery which divides to form the cavernosal, the dorsal, the bulbar and the urethral 
arteries.  The cavernosal artery is the main blood supply to the corpora cavernosa.  This artery 
divides further into the helicine arteries whose branches open into the cavernosal spaces.  
Venous drainage occurs through the superficial, intermediate and deep veins (Kirby et al., 
1999).  It is the deep veins that drain the corpora cavernosa and the corpus spongiosum 
(Melman & Gingell, 1999). 
Innervation of the penis is autonomic (parasympathetic and sympathetic) and somatic 
(motor and sensory).  The parasympathetic nerves arise from neurons in the sacral spinal 
chord, whereas, the origin of the sympathetic nervous system is the thoracolumbar spinal 
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chord.  These enter the corpora cavernosa and corpus spongiosum to affect the neurovascular 
events of erection and detumescence.  Innervation by  somatic nerves, namely  the pudendal 
nerve, to the bulbocavernosus and ischiocavernosus muscles, is responsible for sensation to 
and contraction of the penis (Dean & Lue, 2005).  
2.1.2 Physiology of the Penile Erection 
The physiology of penile erection and detumescence are active neural-hemodynamic events 
regulated by contraction and relaxation of corporal smooth muscles.  There are three types of 
stimuli for erection, namely, reflexogenic (genital stimulation), nocturnal   (post rapid eye 
movement sleep) and psychogenic or central (can be multiple or single psychological stimuli).  
The flaccid state is caused by predominate sympathetic influence in which the corporal and 
arterial muscles are contracted.  There is minimal blood flow as a result to the cavernosal 
spaces from the cavernosal artery.  After an initiation by a psychogenic stimuli (sexual, desire, 
perception) ,there is a release of neurotransmitters from the cavernous nerve terminals 
(Conference, 1993).  This stimulus to the parasympathetic system causes a decrease in 
peripheral resistance from vasodilatation and an increase in the blood flow through the 
cavernous and helicine arteries further causing an increase in intracavernous pressures.  This 
then traps the incoming blood by the expanding sinusoids causing compression of the 
subtunical venular plexuses which lies between the tunica albuginea and the peripheral 
sinusoids thus reducing venous outflow.  The tunica is then stretched to its capacity occluding 
the emissary veins between the outer longitudinal and inner circular layers further decreasing 
the venous outflow.  The full erection phase, also referred to as the venous occlusive 
mechanism, occurs when there is a PO2 increase to around 90mmHg and an intracavernous 
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pressure increase of around 100mmHg.  There is an increase in intracavernosal pressure above 
systemic pressure due to contraction of the ishiocavernous and bulbocavernous muscles.  
During the rigid erection phase there is a further increase in the pressure with resultant 
contraction of the ischiocavernosus muscles and cessation of blood flow through   the 
cavernous artery.  In summary, erection involves; 1) relaxation of the sinusoids, 2) arterial 
dilatation and 3) rapid venous compression. 
There are three phases of detumescence. The first phase includes a transient increase in 
intracorporeal pressure causing the beginning of smooth muscle contraction against a closed 
venous system.  Detumescence is caused by increased sympathetic nervous system activity 
with resultant increases in helicine artery tone and trabecular smooth muscle contraction.  
During the second phase there is a decrease in pressure allowing the re-opening of the venous 
pathways and return of basil arterial flow.  In the  final  and third phase there is full restoration 
to the venous outflow capacity after a rapid pressure decrease due to venous-occlusive 
mechanism deactivation (Dean & Lue, 2005; Kirby et al., 1999; Melman & Gingell, 1999).   
Erection begins in the brain.  Integration of the stimuli occurs at the limbic system, 
hypothalamus and brainstem (Christ & Hodges, 2006).  Stimulation to the  autonomic nervous 
system  of the penis by the sacral (S2-S4) parasympathetic cavernous nerves is responsible for 
initiating an erection (tumescence) whereas stimulation to the thoracolumbar (T11-L2) 
sympathetic nerves is responsible for detumescence (Dean & Lue, 2005).  The pudendal nerve 
sends the sensory signals to the spinal chord to the appropriate brain centers.  Several areas 
within the central nervous system play a role in the process of erection.  Those most studied 
include the paraventricular nuclei, the medial preoptic area and the hippocampus areas (Kirby 
et al., 1999).  Neurotransmitters released as a result of sexual stimulation that are excitatory are 
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acetylcholine, serotonin, oxytocin and dopamine.  Major neurotransmitters that are inhibitory 
include epinephrine, norepinephrine, gamma aminobutyric acid and prolactin.  Corporal 
smooth muscle cell tone then, is the response of complex integration of the effects of the 
neurogenic-origin neurotransmitters and the endothelial-origin neurotransmitters. 
The release of the neurogenic-origin neurotransmitter norepinephrine causes activation 
of the post-synaptic α1-adrenergic receptors by the sympathetic nervous system causing 
smooth muscle contraction and erection.  A second neurotransmitter, nitric oxide (NO) or nitric 
oxide releasing substance, previously known as endothelium derived relaxing factor, induces 
smooth muscle relaxation (Melman & Gingell, 1999). NO is produced from an amino acid, L-
arginine, thru the enzymatic action of nitric oxide synthase (NOS).  There are two endothelial 
forms of NOS, namely cNOS; type III, and iNOS: type 1.  There is also one neural form 
(nNOS;type 1) which is of importance to the non-adrenergic, non-cholinergic(NANC) 
autonomic nerves that innervate penile erection tissue causing vasodilatation (Klabunde, Ryan, 
& Paxson, 2007).  Nitric oxide is the first neurotransmitter produced by nitric oxide synthatase 
that is released into the non-adrenogeric, non-cholinergic nerve terminals and into the 
endothelial cells that line the corporal sinusoids.  NO initiates the erection process and 
mediates penile vasodilatation by converting quanosine triphospate (GTP) into cyclic 
guanidine monophosphate (cGMP second messenger) via the enzyme guanylyl cyclase.  cGMP 
is responsible for activation of protein kinase G (PK-G).  As a result of the activation of PK-G, 
calcium channels are affected resulting in an alteration of calcium sensitization, decreased 
intracellular calcium and diminished corpora cavernosa smooth muscle tone thus enabling 
erection to occur (Christ & Hodges, 2006; Meeting, 2003; Pegge  et al., 2006).  
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Mediating detumescence is the release of acetylcholine by the parasympathetic nervous 
system.  A decrease in the nitric oxide release and inactivation of the second 
messenger(cGMP) causes detumescence (Meeting, 2003; Melman & Gingell, 1999). 
2.1.3 Pathophysiology of Erectile Dysfunction 
Erectile dysfunction (ED) is defined as the persistent inability to obtain and/or maintain a 
penile erection sufficient for satisfactory sexual activity (Conference, 1993; Jardin et al., 2000).  
In order to establish this diagnosis, ED must be present for a minimum of least 3 months.  
There is an exception to this if ED if preceded by pelvic surgery or penile trauma. 
For normal erectile function to occur there is a need for a delicate balance between 
vasoconstriction and vasorelaxation of the corporal smooth muscle.  There must occur a critical 
level of relaxation or there will be incomplete resistance to the outflow of blood from the 
corpora causing a spectrum of penile tumescence ranging from flaccidity to non-complete 
erection (Kirby et al., 1999).  This incomplete corporal smooth muscle relaxation, termed 
veno-occlusive dysfunction, may have multiple etiologies.  Since it is widely recognized that 
erections combine neurovascular phenomena and vascular biologic responses, ED may result 
from an interruption of any of the natural sequencing mechanisms.   In addition, hormonal 
stimuli, biomechanical mechanisms, or localized biochemical reactions influence 
neurovascular control.   
Several classification systems have been proposed for ED.  Based on the cause of ED, 
ED can be classed by neurovascular mechanisms of penile function, i.e., neurogenic (failure to 
initiate), arterial (failure to fill), or, venous (failure to store) (Dean & Lue, 2005).  The 
International Society of Impotence Research recommended the following classification: 
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psychogenic or organic (Dean & Lue, 2005; Lizza & Rosen, 1999).  This taxonomy for ED by 
the International Society for Sexual and Impotence Research has deleted the term psychogenic 
and categorizes ED as either  situational or organic (Sachs, 2003).  Situational ED results in 
certain environments, with certain partners or under certain circumstances (Lewis, 2004).  
Currently, ED is seen as exhibiting both psychogenic and organic factors frequently referred to 
as mixed. 
2.1.4 Psychogenic Causes of ED  
Prior to 1980, approximately 90% of ED cases were thought to be psychogenic in origin.  The 
limbic system, the hypothalamus and the cerebral cortex control sexual behavior and penile 
erection.  Thus, messages that are either stimulatory or inhibitory can be relayed from the 
spinal centers with resultant erection or erection inhibition.  There are two mechanisms that 
may explain erection inhibition in psychogenic dysfunction.  These two are as follows:1) In an 
anxious man, there may be elevated peripheral catecholamines causing an increase in smooth 
muscle tone preventing relaxation necessary for erection or, 2) there is a direct inhibition to the 
spinal centers within the brain by excessive sympathetic outflow.  By stimulation of the 
sympathetic nerves or systemic epinephrine influence, detumescence results.   
Several common causes of psychogenic ED are recognized and include (Kirby et al., 
1999; Weeks & Gambescia, 2000); 
 Depression 
 Sexual Inhibition 
 Performance Anxiety 
 Relational conflict/loss of attraction 
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 Sexual Abuse in Childhood 
 Conflict over sexual preference 
 Fear of Pregnancy or sexually transmitted diseases (Kirby et al., 1999) 
2.1.5 Organic Etiologies of ED 
2.1.5.1 Arterial ED 
Atherosclerosis is the most common cause of vasculogenic ED (Blumentals, Gomez-Caminero, 
Joo, & Vannappagari, 2003; Meeting, 2003).  Investigationally, it has been shown that 
obstructing the arterial inflow to the corporal bodies by atherosclerotic lesions is associated 
with ED.  Atherosclerotic lesions, produced by feeding rabbits a high cholesterol diet, resulted 
in vasculogenic ED.  These  cause an obstruction , or limit to in the blood flow from the iliac 
arteries (Saenz de Tejada et al., 2005).  Angigraphically shown, ED occurs when more than 
half the lumen of the internal pudendal, common penile and cavernosal arteries are narrowed.  
Mechanisms of atherosclerosis morphologically include vascular smooth muscle cell 
proliferation, endothelial injury, and cellular migration.  Cytokines, atheroma, metabolic 
alterations (i.e. diabetes), thrombosis, blood components, growth factors, antioxidants, heparin 
sulphate and gene mutations ( eg., apolipoprotein E, and lipoprotein lipase) are factors that 
influence these changes (Sullivan, Keoghane, & Miller, 2001). 
One category of risk factors is demographic in nature.  A strong risk factor for the 
development of atherosclerosis is age.  In the rat penis, age has been shown to correlate with 
altered nitrous oxide (NO) synthesis and erectile responses (Garban, Vernet, Freedman, Rajfer, 
& Gonzalez-Cadavid, 1995).  As a compensatory mechanism to endothelial dysfunction 
associated with aging, Haas et al (Haas et al., 1998)  have shown an  upregulation of 
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endothelial NO synthase (eNOS) in aging rabbits’ corporal smooth muscle cells and 
endothelium with impaired endothelial-mediated cavernosal relaxation.  
Endothelial cell dysfunction, defined as an abnormal endothelial response causing 
reduction in the bioavailability of nitric oxide (NO) leading to impairment in vasodilatation, 
results in failure of the smooth muscles lining the arterioles to relax (Montorsi, Briganti, 
Salonia, Rigatti, & Burnett, 2006).  Endothelial NO modulates vascular tone at rest, 
vasodilatation during stress and inhibits platelet aggregation.  Thru inhibition of platelet 
aggregation, there is activation of intracellular guanlate cyclase, which then generates cyclic 
GMP.  Endothelial dysfunction is considered important in the pathophysiology of ED because 
of the vasodilatation and effects on smooth muscle proliferation.  The cardiovascular risk 
factors of hypertensio n, diabetes  mellitus,  smoking and dyslipid emia are linked to 
endothelial dysfunction and are often present in those presenting with ED as well.  It is also 
theorized that endothelial dysfunction is the initiating event in atherosclerosis and is also linked 
to ischemic coronary disease. 
2.1.5.2 Neurogenic ED 
Approximately 10%-19% of ED is neurogenic in origin (Dean & Lue, 2005; Saenz de Tejada 
et al., 2005).  There are three etiologies of neurogenic ED as follows; 1) Peripheral (peripheral 
ED), 2) Spinal (sacral-peripheral, suprasacral-central ED), and 3) Supraspinal (suprasacral ED) 
(Saenz de Tejada et al., 2005).  Disorders that affect the peripheral efferent autonomic nerves 
or the parasympathetic sacral spinal chord can cause complete or partial ED by compromising 
relaxation of the corpora cavernosa smooth muscle fibers (Kirby et al., 1999; Meeting, 2003; 
Sullivan et al., 2001).  Central origin ED can originate from lack of excitement or an increase 
in inhibition of central autonomic pathways (Saenz de Tejada et al., 2005).  Men who sustain 
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spinal chord injury can have erectile dysfunction.  The level of the spinal chord injury 
determines the degree of erectile function.  Injuries to the upper portion of the spinal chord 
results in the likely retention of erectile function where as injuries to the lower chord results in 
unlikely erectile function.  Several other diseases are associated with ED that include multiple 
sclerosis, and peripheral neuropathy due to alcoholism or diabetes mellitus, tumors, disk 
disease and transverse myelitis (Kirby et al., 1999).  Because of the close proximity of the 
cavernous nerves and the pelvic organs, surgery in these anatomical areas can cause 
neurogenic ED as well.  Another neurogenic cause is pelvic fracture. 
2.1.5.3 ED related to toxins and drugs  
It is estimated that one in every four males presents with ED because of a drug related 
problem.  Cocaine use and long term excessive alcohol consumption have been linked to ED 
(Kirby et al., 1999; Meeting, 2003).  It is known that over 100 commonly prescribed 
medications can affect /alter sexual desire, erection and/or ejaculation.  Antianxiety agents, 
antidepressants, antipsychotics, antihypertensive agents , diuretics, and antiandrogenics are 
examples of these medications.  Smoking can cause an imbalance between thromboxane and 
prostacyclin concentration thus causing a direct toxic effect on the vascular endothelium 
resulting in ED. 
In summation of the above review, the demographic risk factor (age), the biologic risk 
factors (diabetes, dyslipidemia, hypertension), lifestyle behavioral risk factors (smoking, 
alcohol consumption), and, anti-hypertensive medications have been supported physiologically 
in their relationship to the development of ED. 
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2.1.6 Epidemiology of Erectile Dysfunction 
When reviewing the literature concerning the epidemiology of ED, it is important to note the 
population from which the data were generated.  There were two fundamental methods used to 
ascertain the samples, each presenting with strengths and weaknesses in design.  The first, the 
clinical study, recruited those patients who presented for a specific reason of sexual 
dysfunction.  Although this type of sample generated opportunities to collect information 
lending to understanding complex etiologies of ED through the use of sophisticated diagnostic 
procedures and comorbid conditions in those presenting with the disease, they are highly 
biased and result in data that is selective and an underestimate of the actual disease prevalence 
(Rothman, Greenland, & Lash, 2008).  The second method used population based probability 
survey sampling techniques.  Those recruited were from representative population samples.  
These studies relied on self-report that are also known to present reliability and validity issues.  
Under-reporting, particularly of ED, can occur because of concerns for social stigmatization 
that sometimes accompanies ED (Rothman et al., 2008). Also contributing to under-reporting 
is the fact that particularly as males age there is belief that ED can be part of the aging process 
and therefore ED is under-played.  In essence then both sample designs result in an 
underestimation of ED and probably account for the differences in prevalence rates reported in 
the literature.   
In addition, prior to the 1993 standardization of the definition for ED, ED was included 
in the overall definition of impotence, which also captured other male sexual function 
disorders, and ejaculatory and orgasmic dysfunctions (Melman & Gingell, 1999).  This then 
also affected the reliability and validity of the studies under review.  Therefore, when 
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completing a review into the epidemiology of ED, the prevalence of ED generated by these 
previous studies should be viewed with caution.  
Research completed by Kinsey, in the 1940’s, was one of the first if, not most famous 
studies focusing on male sexual problems. Kinsey et al (Derby, Araujo, Johannes, Feldman, & 
McKinlay, 2000) relied on a volunteer population from an ill-defined region in Illinois to study 
sexual phenomenon.  Since it is known that volunteer samples can potentially present bias 
(Rothman et al., 2008), this study can only be used as suggestive and will not be discussed in 
this review.  Furthermore, the definition of ED was not consistent with the present parameters 
recommended by the NIH Consensus Conference.  There are however, two other population 
based samples completed within the United States worth discussing in this literature review; 
the Massachusetts Male Aging Study (MMAS) and the National Health and Social Life Survey 
(NHSLS).   
The MMAS provided information on the prevalence of ED from a random community 
based sample of 1290 males between the ages of 40 and 70, conducted between the years 1987-
1989 in cities near Boston Massachusetts.  The definition of ED was assessed from a sexual 
activity questionnaire that asked specific questions concerning frequency and quality of 
erection.  Using probabilities proportion to the population, communities were randomly 
selected within each of six strata for this prospective observational study.  The strata were 
defined by community size and income.  Response rate was 52%, however, participants were 
similar to men aged 40 to 70 from the Third National Health and Nutrition Survey with respect 
to comorbid conditions of diabetes, hypertension, weight issues and smoking behavior, and 
therefore findings are considered somewhat valid.  The MMAS was not considered racially 
balanced by US Census Bureau standards, in that there was only 5% participation by racial 
  27
minorities but was however considered overall to be consistent with the Massachusetts 1990 
population for males 40-69 years of age.  In the subject’ s home, by trained interviewers, 
information on health status, medications, life style, socio-demographics, psychological 
indexes and blood samples were obtained.  Sexual activity information was ascertained from a 
self-administered questionnaire.  Prevalence for combined minimal, moderate and complete 
impotence was 52%.  Between 40 and 70 years of age, p revalence of complete impotence 
tripled from 5% to 15%.  The strongest predictor of impotence was the participant’s age and 
the overall prevalence rate after longitudinal follow-up of this population was 24%.  Incident 
ED figures for the 40 year old age group was 10.3%annually , while the incident  rates for the 
50 year old and 60 year old age groups were 25.5%  and 38.4% annually respectively (Araujo, 
Johannes, Feldman, Derby, & McKinlay, 2000).  After adjusting for age, higher probabilities 
of impotence were positively correlated with diabetes, heart disease , indexes of anger and 
depression, and, hypertension.  Index of dominant personality and HDL-cholesterol were 
inversely correlated with impotence.  There was a greater probability of complete impotence in 
men with heart disease and hypertension associated with cigarette smoking (Feldman, 
Goldstein, Hatzichristou, Krane, & McKinlay, 1994).  Prevalence of diabetes in this sample 
was 7.8%, high blood pressure was 30.3%, 40.1% were overweight and 24.4% were current 
smokers (Aytac, Araujo, Johannes, Kleinman, & McKinlay, 2000).  Findings from this study 
also confirmed that ED is inversely associated with income and education.  A significant 
association for socioeconomic factors and ED was found for the occupation only after 
adjusting for age, lifestyle and medical comorbidites.  Although this study focused on specific 
erectile function only, it was one that identified potential risk factors, associated comorbidites 
and socioeconomic factors for further study.   Projected data from this study   (Johannes et al., 
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2000) suggest that there can potentially be 617,715 new cases occurring annually in US white 
males between the ages of 40-69.  It is alarming to note that by the year 2025 the world 
projections for ED exceed 320 million cases (Aytac, Mckinlay, & Krane, 1999).  Therefore, the 
MMAS confirmed the prevalence in the male population and identified significant risk factors 
with ED.  Based on this study then, demographic factors (age, income, marital status, level of 
education), biologic factors (hypertension, dyslipidemia), lifestyle behavioral (smoking, 
alcohol) and psychosocial factors (depression) were examined in our analysis. 
The NHSLS was a national probability survey of 1410 men between the ages of 18 and 
59 years residing in United States households in 1992 of which there was greater than a 79% 
completion rate.  Sexual dysfunction was reported in 31% of the 1410 males enrolled.  Sexual 
dysfunction was indexed to seven dichotomous items, each measuring a critical problem or 
symptom in the past 12 months.  Those who reported emotional or stress related problems were 
more likely to report sexual dysfunction as was deterioration in ones socioeconomic position.   
Found also in this survey was that age was a strong predictor of sexual dysfunction (Laumann, 
Paik, & Rosen, 2007).  The association between race and ED was also reported.  For blacks the 
adjusted Odd’s Ratio of reporting an inability to achieve orgasm was 1.14 (95% C.I. 0.57-
2.26), Hispanics was 1.24 (95% CI, 0.54-2.83) and for ‘others’ was 2.83 (95% CI, 1.24-6.50, 
p<0.05) with whites as the referent statistical group (Laumann et al., 2007).  The NHSLS also 
confirms the risk associated with age and income. Stress and race as risk factors were 
additional risk factors identified by this study.  Race and stress were not two variables of 
interest for study.  The Pittsburgh-EDC male population was 99% Caucasian.  Therefore, race 
was not considered for this analysis. 
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Another study of interest includes one that generated age specific prevalence  and 
correlates from the Health Professionals follow-up study.  This was a selected occupation 
based study.  There were a total of 31,742 male dentists, optometrists, osteopaths, podiatrists, 
pharmacists and veterinarians in the United States who self-reported erectile dysfunction and 
were between the ages of 53 to 90 years.  Fewer than 2% of the men reported ED before age 
40, 4% reported ED between 40 and 49, 26% in men ages 50-59 years, and 40% in males 60-
69 years.  For males younger than 60 years and with comorbid conditions, the prevalence was 
twice that of healthy men.  Of note, physical activity and ED was explored in males within this 
group.  Younger men who were less than 60 years benefited more from physical activity than 
do men greater than 80 years.  Negative health behaviors, watching more than 20 hours of TV 
per week, and smoking were more strongly associated with ED with younger males being at 
increased risk (Bacon et al., 2003).   Comorbid conditions of diabetes, cancer, stroke and 
hypertension were also associated with ED among these study participants.  In summary of the 
Health Professionals Follow Up Study then, age specific prevalence rates were generated for 
age groups of 10 year increments starting at age 40 years and demographic risk factors (age,) 
biologic risk factors( diabetes, cancer, stroke, hypertension), lifestyle behavioral (smoking, 
physical activity).  As stated previously, this study will assess the demographic risk factor of 
age, the biologic risk factors (hypertension, cerebral vascular disease ) and the lifestyle 
behavioral risk factor (smoking).  Physical activity will not be assessed.  Age-specific 
prevalence rates were generated.   
In a retrospective cohort study of a representative national managed care database of 
51commercial health plans and 28 million members in the United States, Sun et al (Sun et al., 
2006) found  285, 436 males  reported an ED diagnosis from 1995-2001.  The following table 
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illustrates the region adjusted prevalence rates by age and for concurrent diseases of 
hypertension, hyperlipedemia, diabetes mellitus and depression. 
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 Table 2. 1 Re gion Adjusted Prev alence Ra tes ( 2000 Censu s Stand ard) by Age,  and Conc urrent 
Disease (A. D. Seftel et al., 2004) 
Age group 
(years) 
% with 
ED 
% of age group
with 
Hypertension
% of age group 
with 
Hyperlipidemia
% of age group
with Diabetes 
Mellitus 
% ofage group 
with 
Depression 
18-24 0.8 4.3 3.9 2.6 14.4 
25-35 4.9 10.6 12.1 7.0 15.9 
36-45 16.1 23.8 26.4 13.1 16.1 
46-55 35.7 39.3 41.3 19.4 13.3 
56-65 35.3 51.3 51.8 23.4 8.9 
66-75 5.2 61.4 51.0 27.8 5.8 
76-85 1.9 66.3 48.2 25.7 7.5 
86+ 0.2 63.0 30.3 22.3 8.0 
 
Overall, the region adjusted prevalence rates for hypertension were 41.2%, 
hyperlipedemia was 41.8%, diabetes mellitus 19.7% and depression 11.9%.  Because this 
database review was from managed care records excluding the aged population of males on 
Medicare, the hypothesis that ED increases in prevalence with increasing age was not as 
strongly shown as with the previous studies.  More interestingly however, this study looked at 
ED as a marker for diabetes.  Unadjusted prevalence rate for males having diabetes and ED 
was 20.0% while for those without diabetes was only 7.5%.  After adjusting for age, census 
region, and 7 concurrent diseases, men with ED are still 60% more likely to have diabetes than 
men without ED as reflected in the calculated Odd’s Ratio of  1.6, p<0.001(Sun et al., 2006).  
Interpretation of these results reinforces that ED and diabetes mellitus, hypertension, 
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hyperlipidemia and depression share common risk factors. (The definition of diabetes mellitus, 
however, in this review included both types of diabetes.)  In addition, this study identified a 
psychosocial risk factor of depression.    
In concluding this section, it is also necessary to briefly discuss the findings of the 
cross-sectional survey on Men’s Health Issues, the MALES Study, a multinational study that 
included a male cohort, ages 20 to 75 years from Germany, United States, United Kingdom, 
France, Italy and Spain.  The sample was geographically distributed with recruitment in 22 
regions from the United States, 6 from the United Kingdom, 4 from Germany, 16 from Italy, 
11 from France and 7 from Spain.  The survey was completed on males presenting to health 
care professionals (general practitioners) between March and September, 2000.  There were 
two planned phases to the study.  First, while in the physician’s office, a general questionnaire 
was given to the participants eliciting items of sexual health in order to ascertain the overall 
prevalence of ED in the population.  With the first questionnaire, the males were asked to 
provide their names and addresses in order that a second questionnaire could be mailed to them 
to ascertain more detailed information concerning ED.  However, because of the personal 
nature of the subject matter, the males were reluctant to provide follow-up information.  The 
males identifying ED by first questionnaire while in the physician’s office were therefore asked 
to complete a second questionnaire anonymously.  Recruitment also was quite difficult in 4 of 
the 6 countries (Italy, Germany, France and Spain).  Because these countries were having 
recruitment difficulties by using the general practitioner’s office, Germany, Spain and Italy 
recruited from urology offices, while France recruited men from the street.  Collection rates for 
the questionnaires were 51% for phase 1 , while phases 2 and 3 only yielded collection rates of 
18% and 31% respectively.  There were a total of 28, 691 across all 6 countries who provided 
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answers for the first questionnaire.  Overall prevalence for self-reported ED across the 6 
countries was 19%.  Prevalence in the United States was approximately 23 % (6,474 / 28,691) 
while prevalence rates for France, Germany, Italy , United Kingdom and Spain were lower 
ranging from 12% to 19%.  ED was again found to increase with age as previous studies 
reported.  Age specific prevalence rates for males 70 to 75 years of age, ranged from 39 % to 
73%.  There was a 14 fold higher relative risk for this age group as compared to the 20 to 29 
year age group.  Less than 10% of the ED cases were in males younger than 40 years.  
Reported also was a positive correlation between ED and increasing poor health.  Those 
respondents who reported poor health were 5 times more likely to report ED than those 
reporting excellent health.  Also there was significant association between ED and lower 
urinary tract symptoms and ED and hypertension (Rosen et al., 2004).  
The cost and burden of ED are still elusive.  Tan et al (Tan, 2000) used a decision 
analytical model to forecast ED care in a health plan of 100,000 members, in 2000.  The 
estimated cost was $3, 204, 772.00 (Tan, 2000).  Many health plans today do not cover the cost 
of ED care (Sun, Seftel, Swindle, Wenyu, & Pohl, 2005).  From review of the 285, 436 males 
who reported ED in the Sun et al (Sun et al., 2005) medical record review study; $83.91 was 
spent in 1999.  This increased to $95.41 in 2000, and in 2001, $119.26 was spent by each 
patient for ED care.  Review of the 2001 health care expenditures for ED revealed the 
following; 37% of costs were spent on PDE-5 inhibitor therapy, while 14 % of cost was for 
physician office visits, followed by 11% spent on diagnostic procedures, 8.5% on testosterone 
hormone therapy, 4% on penile implants, 4 % on intracaveronous injections, 2.7% on 
alprostadil insertion and 0.8% on vacuum erection devices (Sun et al., 2005). 
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In summary, review of the previous studies noted that there was 1) an underestimation 
of prevalence either due to limitations of study design or reluctance of males to discuss sexual 
function, 2) limited studies on incidence, and 3) the  demographic risk factors associated with 
ED were  increasing age, race, income, marital status, level of edu cation,  biologic risk 
factors of  diabetes mellitus, hypertension, hyperlipidemia,  psychosocial risk factors of 
depression, lifestyle behavioral risk factors of smoking and alcoh ol inta ke and, anti-
hypertensive medications.  There was data for all the variables listed on males enrolled in the 
EDC, therefore all of these were included in the analysis. 
2.1.7 Type 1 Diabetes 
Diabetes mellitus is defined as a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both (MellitusEXpertCommittee, 
2003).  T1D accounts for 5-10% of all diabetes cases diagnosed annually within the United 
States (ADA, 2007).  As previously mentioned, T1D is the most common chronic metabolic 
childhood disease. 
In T1D, formerly known as insulin dependent diabetes or juvenile onset diabetes, there 
are two distinct types identified: immune-mediated diabetes and idiopathic diabetes.  Cellular-
mediated autoimmune destruction of the beta cells of the pancreas is the etiology of immune 
mediated diabetes.  Islet cell antibiodies (ISAs), antibodies to insulin (IAAs), autoantibodies to 
glutamic acid decarboxylase(GAD) and autoantibodies to the tyrosine phosphatase (IA2 and 
IA2 β) are all markers of immune destruction of the β cells.  In 85-90% of all who present with 
hyperglycemia, one or more markers are present (MellitusEXpertCommittee, 2003).  Β cell 
destruction rate is variable.  In mainly infants and children, the rate of destruction is rapid 
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while slow in others.  The later group compromises mostly adults.  Infants and children present 
with ketoacidois as the first sign of the disease while others may have hyperglycemia that when 
challenged by stress or infection converts to ketoacidosis.  Adults in particular may have 
residual β cell function that is sufficient to delay ketoacidosis for many years. Treatment for 
this type of diabetes is insulin and necessary for survival.(MellitusEXpertCommittee, 2003)  
There are multiple genetic predispositions that have been posited as causal for this form of 
diabetes.  There exists an extensive body of knowledge that cites importance to the role played 
by genetics.  In more than 95% of people diagnosed with T1D, the Human Leukocyte Antigen 
(HLA) markers on the short arm of chromosome 6 , DR3 or DR4 are present (Haverkos, 
Battula, Drotman, & Rennert, 2003).  The DR2 haplotypes are associated with lower risk for 
type 1 diabetes (Haverkos et al., 2003).  The genetic component appears to present increased 
disease susceptibility however only one in five children with a first degree relative and only 1 
in 15 children in the general population with identified high risk alleles  will develop 
diabetes(Haverkos et al., 2003) . The DR2 haplotypes are associated with lower risk for type 1 
diabetes.  Therefore, there are additional environmental agents playing key roles in the 
development of diabetes.  Positive linkage has been  attributed to enterovirus infection 
(Haverkos HW, 2003). Other environmental agents investigated as possibilities in the 
development of T1D are chemical toxins, and nutritional and dietary factors. 
The second type of type 1 diabetes is termed idiopathic diabetes and this type has no 
known etiology.  There is no evidence of autoimmunity in this type.  This type affects only a 
minority of the cases and most affected are of Asian or African ancestry (ADA, 2007). 
Idiopathic diabetes is inherited, is lacking in immunological evidence for β cell autoimmunity, 
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and is not associated with HLA.  This form of diabetes requirement for insulin varies (ADA, 
2007).  
Diabetes is a life threatening disorder that requires a complex self-management 
treatment regimen requiring daily insulin, dietary restrictions, exercise and close blood glucose 
monitoring for survival and prevention of complications.  Understanding and regulating blood 
sugar is key for managing this disease. 
Complications: Excess morbidity and mortality in diabetes is due to long term 
complications.  The complications of diabetes are usually categorized as either microvascular 
or macrovascular in origin.  Both are thought to occur as results of long-term dominate effects 
of hyperglycemia.  Previous research however has shown that despite maintaining euglycemia, 
risk of developing complications may only be reduced and not totally eliminated. (Stella, 
Tabak, Zgibor, & Orchard, 2006).  Microvascular complications, which include retinopathy, 
neuropathy and nephropathy, are thought to occur as a result of long term glucose assault on 
the small blood vessels, while macrovascular complications produce large vessel disease 
associated with atherosclerotic lesion development.  Macrovascular complications include 
cardiac, cerebral and peripheral vascular disease.  Brief reviews of these complications follow.  
A more detailed review of diabetic neuropathy is presented since ED, the complication of 
interest in this dissertation, is associated with diabetic autonomic neuropathy.  
Nephropathy: In the United States, this complication is the leading cause of end stage 
renal disease (ESRD) resulting in approximately 28,000 new cases diagnosed per year.     A  
2.2 % cumulative prevalence at 20 years and 7.7% at 30 years following diagnosis of diabetes 
were reported from Finne et al (Finne, Reunanen, Stenman, Groop, & Grönhagen-Riska, 2005) 
(Daneman, 2006).  The stages of progression of diabetic nephropathy include 1) early detection 
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of microalbuminuria defined as urinary albumin excretion rate >20ug <200ug per day to 2) 
overt macroalbuminuria of >200mg per day with renal dysfunction to 3) ESRD.  
Microalbuminuria is predictive of advanced nephropathy in that there is a 50-66% probability 
of progression once detected (Daneman, 2006). 
Retinopathy:  There is a 20-25% prevalence rate of proliferative retinopathy in type 1 
diabetes.  The early stage includes mild non-proliferative diabetic retinopathy defined as 
retinopathy having increased vascular permeability.  This stage clinically is manifested by 
“cotton wool” spots.  The middle stages include 1)moderate non-proliferate diabetic 
retinopathy which is manifested by intraretinal microvascular abnormalities , 2) severe non-
proliferative retinopathy which is retinal capillary loss, and 3) very severe non-proliferative 
diabetic retinopathy evident by retinal ischemia, or extensive intraretinal hemorrhage and 
presence of microaneurisms.  Late stage is proliferative diabetic retinopathy and is the leading 
cause of blindness. Predictors of retinopathy include hyperglycemia, longer duration of 
diabetes, and hypertension.  There is also an association seen between retinopathy and 
nephropathy. 
Macrovascular-Cardiovascular Complication s:  Risk factors for cardiovascular 
disease in type 1 diabetes include diabetic nephropathy, diabetic autonomic neuropathy, 
dyslipedemia, and hypertension.  Exact pathogenesis of this complication is not understood.  
Coronary artery disease pathology may be the result of an interaction from  insulin resistance, 
genetic factors, cytokines and inflammatory biomarkers(white blood cell count) and measures 
of oxidative stress(e-selectin) interrelationships (Costacou et al., 2005). 
Peripheral Vascular Disease:  This complication results from atherosclerotic lesions 
or increased inflammatory activity leading to   lumen narrowing causing either stenosis or 
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thrombus formation (Klabunde, 2007) and is frequently referred to as lower limb arterial 
disease (LEAD).  Increased resistance can lead to reduction in blood flow and hence a decrease 
in distal perfusion pressure.   Vessels most affected include the external iliac and superficial 
femoral arteries (Klabunde et al., 2007). 
Peripheral Neuropathy:  Neuropathies are common complications seen in 
approximately 50% of patients with type 1 diabetes.  They are heterogenous and classed as 
either focal or diffuse.  The most common neuropathies are the autonomic neuropathies and 
chronic sensorimotor distal symmetric polyneuropathy (DPN) (Boulton et al., 2005).  The 
American Diabetes Association (ADA) confers importance to the early recognition and 
treatment of the neuropathies for the following reasons: 1) Nondiabetic neuropathies may be 
present in patients with diabetes, 2) A number of treatment options exist for symptomatic 
diabetic neuropathy, 3) Up to 50% of DPN may be asymptomatic, and patients are at risk of 
insensate injury to their feet, 4) Autonomic neuropathy may involve every system within the 
body , and 5)Autonomic neuropathy causes substantial morbidity and increased mortality, 
particularly if cardiovascular neuropathy (CAN) is present (Boulton et al., 2005).  
Sensory neuropathies can be either acute or chronic.  Acute sensory neuropathies , 
also referred to as “insulin neuritis” are rare and found to follow prolonged periods of poor 
glycemic control or periods where there have been sudden changes to the glycemic control.  In 
contrast chronic sensiomotor DPN  is the most common presentation and is seen in 
approximately 50% of all diabetics.  Clinical symptoms include burning pain, deep aching pain 
and stabbing sensations usually of the lower limbs.  Typically these symptoms are worse at 
night.  There is sensory loss of vibration, pressure, pain and absent ankle reflexes on clinical 
examination.  Screening tests for DPN for advanced abnormality of large nerve fibers includes  
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vibratory perception tests, proprioception testing and light touch, whereas when clinically 
testing for small nerve fiber derangement assessment is completed by pinprick and temperature 
testing  (Maser et al., 1991).  In the Pittsburgh Epidemiology of Diabetes Complications Study 
after standard neurological assessment by a trained internist, distal s ymmetric 
polyneuropathy (DSP) was present in 34% of the cohort, 18% was noted in the 18 to 29 year 
age group while 58% was present in the cohort who were age 30 years or more(Maser et al., 
1990).  Further review, after 30 years of follow-up of the 1950-1980 Pittsburgh Epidemiology 
of Diabetes Complications Study cohort, showed a significant temporal decline for autonomic 
neuropathy at 20 years and a non-significant smaller decline at 25 years (Pambianco et al., 
2006).  On the other hand there was a decline for both time points at 20 and 25 years for 
confirmed distal symetrical polyneuropathy (CDSP).   Independent predictors of DSP were 
hypertension status, macrovascular disease, nephropathy and retinopathy (Maser et al., 1990) 
and glycemic control  and duration (Pambianco et al., 2006).  Focal and multifocal 
neuropathies result  from neuropathic damage to the ulnar, radial, and common peroneal 
nerves and are sudden in onset.  The presence of diabetic autonomic neuropathy (DAN) 
results in significant morbidity.  Subsequent mortality can also be seen as well.  Clinical 
presentations of DAN include orthostatic hypotension, erectile dysfunction, gastroparesis, 
exercise intolerance, resting tachycardia, constipation,  impaired neurovascular function and 
hypoglycemic autonomic failure (Boulton et al., 2005).  Review, after 30 years of follow-up of 
the 1950-1980 Pittsburgh Epidemiology of Diabetes Complications Study cohort, showed a 
significant temporal decline for autonomic neuropathy at 20 years and a non-significant 
smaller decline at 25 years (Pambianco et al., 2006).  Cardiovascular autonomic neuropathy 
(CAN) is probably the most widely researched of the autonomic neuropathies and considered 
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the most important because of associated adverse cardiovascular events.  CAN has been linked 
with a poor prognosis due to sudden cardiac death and nephropathy (Arildsen OM, 2000).  
Arldsen et al   randomly drew a gender and age stratified sample of 120 diabetics between the 
ages of 40 and 75 to test autonomic nervous system function.  E/I ratios were used as 
determining autonomic function.  Values for E/I ratios >1+exp(-1.12-0.0198 x age(years)) 
were  regarded as normal.  CAN prevalence for the type 1 diabetic sample was 38% (95% 
CI=26-50%).  The E/I ratio was found reduced in advanced age, longer duration of diabetes, 
higher fasting glucose, female gender, and higher triglycerides.  There was also a significant 
association found between urinary albumin excretion and CAN, and that significant reduction 
in autonomic function predicted future cardiovascular events (Arildsen, 2000).  Maser et al 
(Maser, Mitchell, Vinik, & Freeman, 2003) support an increased risk between CAN and 
increased risk of mortality (Maser et al., 2003).  Following a meta- analysis of 15 studies, 
results were consistent and strong showing CAN association and increased risk of mortality. 
Associations were stronger if CAN was defined on the basis of two or more abnormalities 
(Maser et al., 2003).  This association confirmed that those diabetics expressing CAN should 
be under close surveillance for development of cardiovascular events.  Maquire et al (Maguire 
et al., 2007) followed adolescents with T1D who were assessed for autonomic neuropathy from 
1990 to 1993.  This study was an attempt to clarify the importance of asymptomatic CAN 
abnormalities using pupil size, a marker of early autonomic neuropathy, and presence of 
microalbuminuria and retinopathy 12 years later.  After adjusting for glycemic control, the 
predictive relationship persisted (Maguire et al., 2007).  Orchard et al (Orchard, Lloyd, Maser, 
& Kuller, 1996) also confirmed that those with T1D  and DAN have a greater increased risk of 
mortality related to a specific cardiac etiology.  DAN was assessed by E/I ratios obtained in a 
  41
two year interval on an incident cohort of type 1 diabetics from the Pittsburgh Epidemiology of 
Diabetes Complications Study.  Duration of  diabetes and glycemic control (HbA1)  was 
found to be the main predictor of DAN.  Clearly DAN was associated with an increase in 
mortality; however this was largely explained by associations with nephropathy and increased 
cardiovascular risk factors, namely hypertension (Orchard et al., 1996). 
Epidemiology of Type 1 Diabetes: Within the United States, the most reliable 
estimates of type 1 diabetes incidence for youth are the result of three registries that include; 
the Allegheny County Registry (1985-1994), the Philadelphia Registry (1985-1999) and the 
Colorado IDDM Study (1978-2004).  From 1965 to 1985, the Allegheny County rate was 
stable.  The rate  increased in the  years 1990-1994,  among non-white adolescents(IM Libman 
et al., 1998).  After review of 257 cases identified for the 1990-1994 period, the standardized 
incidence rate was 16.7/100,000 (95% C.I. 14.7-18.8).  This was  similar to the  incidence rate 
generated for 1985-1989 of 17.1/100,000(IM Libman et al., 1998).  There was a higher rate 
among males (17.2/100,000) than females (14.4/100,000) (Libman IM, 1998) and, for the first 
time the incidence rate was higher in non-whites [17.6/100,000] than whites [16.5/100,000] 
(Libman IM, 1998).  The incidence for the older age group (15-19 years) was higher in non-
whites [30.4/100,000(95% C.I. 18.3-47.4)] than whites for that same age category 
[11.2/100,000(95% C.I. 7.6-15.9)] and accounted for almost a three fold increase (Libman IM, 
1998).   The rate effect was seen in both the males and females. The white population 
maintained a higher incidence in the younger age group (0-14 years) however. Please refer to 
Table 2.2. 
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Table 2.2  Type 1 Diabetes Incidence Rate for Allegheny County by Race/Age Group (Libman IM, 1998) 
Age Group 
(years) 
Incidence in Whites 
Rate/100,000 
(95% C.I). 
Incidence in Blacks 
Rate/100,000 
(95% C.I). 
0-4 9.5(6.6-13.4) 5.2(1.4-13.4) 
5-9 20.7(16.2-26.3) 13.8(6.3-26.1) 
10-14 24.9(19.9-31.3) 23.6(12.9-39.7) 
 
 
Similar findings were reported by the Philadelphia Registry showing a stable rate for 
the non-Hispanic whites and Hispanics from 1985-1999 with an increase in the incidence for 
black children.  The Colorado Study Group found an increasing incidence of type 1 diabetes 
from 1978-2004 in 0-17 year olds (Vehik et al., 2007).  The incidence rate for period 1 (1978-
1988) was 14.8/100,000(95% C.I.14.0-15.6) while period 2 (2002-2004) showed a much 
higher rate of 23.9/100,000(95% C.I 22.2-25.6)(Vehik et al., 2007).   
To monitor incidence patterns of type 1 diabetes in children ≤14 years of age, the 
World Health Organization (WHO) established the Multinational Project for Childhood 
Diabetes (DiaMond) Project in 1990.  This project also, was to determine genetic risk factors 
associated with complications and mortality of diabetes (Podar et al., 2000).  Incidence rates 
were generated from 114 populations in 112 centers in 57 countries.  Of 84 million children, 
43,013 were diagnosed with T1D (DIAMONDProjectGroup, 2006).  Within the various 
populations, the overall age-adjusted incidence rates varied.  The lowest incidence was found 
in China and Venezuela with 0.1/100,000 while the highest reported was for Finland at 
40.9/100,000.  Asian population were for the most part found to have a very low incidence 
(<1/100,000).  The highest incidence rates were found in the North American and European 
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populations, 11-25/100,000 and 4-41/100,000 respectively (DIAMONDProjectGroup, 2006).  
There were no marked age specific incidence differences between genders.  There were 
however found incidence rate differences between age groups, with increasing incidence found 
with increasing age.  Calculated mean annual incidence increase was 2.8% (95% C.I. 2.4-8.6).  
Confirmed from the DIAMOND Project is that the risk of type 1 diabetes has been increasing 
since the 1950’s and there is no current indication that this trend is not continuing 
(DIAMONDProjectGroup, 2006). 
A diagnosis of cardiovascular disease  was reported in approximately 37.2% of all 
persons with diabetes 35 years or older in the year 2000 Ischemic heart disease prevalence for 
those with diabetes was approximately 14 times the rate of those without diabetes for the 18-44 
age group, three times higher in the 45-64 age group and almost twice as high in those 65 years 
or older (Engelau, 2004).  Absolute rates of cardiovascular disease are higher in men than 
women, however the relative risk of cardiovascular disease is higher in women (2-4) than men 
(1.5-2.5) (Engelau, 2004). 
In persons age 20 to 64 years of age, retinopathy is the leading cause of blindness. 
This complication of diabetes accounts for 12,000 to 24,000 new cases of blindness each year 
within the United States.  
Nephropathy attributed to diabetes accounts for 40% of all new cases per year of end-
stage renal disease.  Those with diabetes also account for the largest percentage of patients 
receiving dialysis and transplantation per year. Peripheral arterial disease is diagnosed in 
8.1% of those with diabetes as opposed to 4% in the general population. Peripheral 
neuropathy: Those with diabetes have 2-3 times the prevalence of peripheral neuropathy 
than those without diabetes. Prevalence for Diabetic Autonomic Neuropathy (DAN) can be as 
  44
high as 90% but reported prevalence depends on population examined, clinical tests conducted 
and type and duration of the disease.  Risk factors include age, duration of diabetes, and long 
term glycemic control.  DAN is also seen concurrently with hypertension and dyslipidemias.  
In addition, there is a global geographic variation seen with microvascular and 
macrovascular complications. The DiaComp study, a sub-study of the WHO DiaMond Study, 
was a multinational (17 countries) cross-sectional analysis of complications seen in T1D 
(Walsh MG, 2005).  This group reported more geographic variability than did the EURODIAB 
IDDM Complications Study.  Duration of diabetes for the DiaComp Study was catorgorized 
into one of two groups: 1) short duration of T1D (5-14 years), or 2) long duration of T1D (15-
24 years).  There were high rates of microalbuminuria and renal disease.  Neuropathy was high 
in the eastern European countries as well for the short duration group.  Israel and Finland 
showed high rates of neuropathy for both short and long duration groups. EURODIAB did 
concur with the higher rates seen in eastern Europe for those diabetics with <14 years duration 
however (Walsh, Zgibor, Songer, Borch-Johnsen, & Orchard, 2005).   
Mortality due to diabetes: Diabetes is th e fifth leading cause of death w ithin the 
United States (Association, 2003) .  Deaths due to cardiovascular disease account for 65% of 
all deaths in those persons with diabetes. A population based study in Rochester, Minnesota 
(all types of diabetes) reported a decrease in cardiovascular mortality between 1970 and 1994 
by 13.8%.  However this did not match the decline in cardiovascular deaths in those without 
diabetes which was a decline of 21.4 %(Thomas et al., 2008).  Pambianco et al (Pambianco et 
al., 2006)reported a decreasing trend by diagnoses year for mortality, neuropathy and renal 
failure from the Pittsburgh Epidemiology of Diabetes Complications Study cohort. Less 
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favorable trends for cardiovascular, overt nephropathy and proliferative retionopathy 
complications were seen after 30 years of follow-up (Pambianco et al., 2006). 
It is predicted that by the year 2050 within the United States, there will be 48.3 million 
people with diabetes.  From 2005 to 2050, total prevalence is expected to more than double 
from 5.62 to 12.00% (Narayan, Boyle, Geiss, Saaddine, & Thompson, 2006).  Both sexes are 
projected increases with men up by 174% and women by 220%.  Among non-Hispanic whites, 
diabetes prevalence is expected to increase by 99% and for non-Hispanic blacks 107%.  The 
prevalence increase for Hispanics is expected to increase by 127% and 158% for all other races 
(Narayan et al., 2006).  In 2002, the health care costs for people with diabetes were more than 
double that for those without diabetes (Association, 2003).  It is estimated that more than $1 in 
$10 spent on health care services is the result of diabetes (Association, 2003).  Over $160 
billion was spent in 2002 to provide health care services for those with diabetes.  Estimates for 
health care expenditures for neurological disease care  associated with diabetes totaled $2,748 
million, while those associated with peripheral vascular disease were $1,121 million, 
cardiovascular disease $17,626 million, renal $1,879 million and ophthalmic complications 
$422 million (Association, 2003).  Therefore, the impact of diabetes mellitus is not only to the 
individual but to society as well and because of the increasing prevalence of this disease the 
cost burden to society remains.   
2.1.8 Pathophysiology of Erectile Dysfunction and Diabetes 
There is a multifactorial etiology to ED seen in males with diabetes.  Comorbidities associated 
with diabetes, end-organ damage due to hyperglycemia and side-effects of medications used to 
treat concurrent diseases all contribute to the etiology of ED in diabetes.  In addition, these 
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biochemical mechanisms contribute to the etiology of ED in males with diabetes as well.  They 
are as follows: 1) elevated advanced glycation end-products (AGE’s), 2) impaired nitric oxide 
(NO) synthesis, 3) increased levels of oxygen free radicals, 4) impaired/decreased cyclic 
guanosine monophosphate (cGMP)-dependent kinase-1(PKG-1), 5) increased endothelinB 
(ETB)receptor binding sites and ultrastructual changes,  6) upregulated RhoA/Rhokinase 
pathway and 7) NO dependent selective nitrergic nerve degeneration.  The mediating pathway 
of each of these mechanisms will also be briefly discussed in relation to the development of 
ED. 
Elevated Advanced Glycation End –products :  AGE’s are produced secondary to 
hyperglycemia in people with diabetes.  These are the biochemical end products of non-
enzymatic reactions between glucose and lipids, nucleic acids or proteins that have undergone 
further irreversible chemical modifications.  Vascular thickening, decreased elasticity, 
endothelial dysfunction and atherosclerosis result when AGE’s form covalent bonds with 
vascular collagen.  These accumulate in the aging and diabetic tissue, forming at an accelerated 
rate with glucose elevation. AGE’s can be found in elevated levels in the corpus cavernosal 
tissue of diabetic rats and humans.  These elevations then result in  impaired smooth muscle 
relaxation in the corpus cavernosum.  The pathophysiological pathway has been posited that 
AGE’s contribute to ED by generating oxygen free radicals , which then cause oxidative cell 
damage and impaired  NO synthesis, further causing a decrease in cGMP and in turn resulting 
in impaired smooth muscle relaxation.(Bivalacqua et al., 2005; Cartledge, Eardley, & 
Morrison, 2001; Moore & Wang, 2006; Yamanaka et al., 2003). 
Nitric Oxide(NO): The endothelium of the arteries of the penis produce NO.  NO is 
responsible for mediating relaxation of the corpus cavernosum through the formation of cGMP.  
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Corpus cavernosum relaxation is primarily the result of nNOS (neuronal nitric oxide synthase) 
activity within the nitregenic neurons of the penis.  Reduced amounts of nNOS have been 
shown in diabetic rats.  This decrease in NOS activity has also been shown in human penile 
tissue in those with diabetes and ED (Saenz de Tejada et al., 2005; Tuncayengin et al., 2003; 
Vernet et al., 1995).  It has be hypothesized that diabetes impairs guanylyl cyclase activity 
causing reductions in cGMP production.  Effector cGMP participate in the production of 
diabetic ED.  Thus in summary, NO and the effector molecule  cGMP contribute to the 
development of diabetic induced ED(Moore & Wang, 2006). 
Protein Kinase -1(PKG-1)   Cavernosal smooth muscle relaxation is caused by cGMP 
primarily though PKG-1.  PKG-1 alters intracellular calcium levels and opens the calcium 
dependent potassium channels causing hyperpolarization of the smooth muscle cells.  
Decreased levels of PKG-1 were shown in corporal cavernosal smooth muscle cells of both 
diabetic rat and rabbit animal models.  Decreases in  PKG-1 is thought to augment diabetic ED 
by diminishing  the cGMP intracellular activity pathway(Chang et al., 2004; Moore & Wang, 
2006; Saenz de Tejada et al., 2005). 
Enothelin B Receptor binding sites( ETB) and Ultrastructual Changes:   Endothelin 
(ET) is a known constrictor of non-vascular and vascular smooth muscle.  As a result of ET 
and its receptors, there is evidence to suggest that ED in diabetes is caused by an imbalance 
toward increased penile vasoconstriction.  There are three isopeptides to ET (1, 2, 3) and two G 
protein coupled receptors (ETA and ETB).  .Produced by the vascular endothelium and a 
potent penile vasoconstrictor is ET-1.  It is ET-1 that is elevated in the plasma of diabetics.   
ETA receptors mediate vasoconstriction and cellular proliferation and are located on 
smooth muscle.  ETB receptors are found on the vascular endothelium where their primary 
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function is to mediate vasoconstriction through NO and prostocyclin production (Bivalacqua, 
Usta, Champion, Kadowitz, & Hellstrom, 2003; Moore & Wang, 2006; Saenz de Tejada et al., 
2005; Sullivan et al., 1997).  ETB receptors mediate vasoconstriction in canine coronary 
arteries and human mammary arteries (Teerlink, Breu, Sprecher, Clozel, & Clozel, 1994).  It is 
hypothesized that ETB receptors may cause an imbalance that affects a tendency towards 
penile vasoconstriction.  It is also hypothesized  that ETB receptors are linked to early 
ultrastructual changes of atherosclerotic lesions in diabetics and venous occlusive penile 
function (Sullivan et al., 1997). 
RhoA/Rho-kinase: ET-1 induced vasoconstriction is linked to the RhoA/Rho-kinase 
pathway.  It is through the activation of this pathway that NOS is suppressed and the 
production of NO is decreased.  It is hypothesized that the RhoA/Rho-kinase pathway mediates 
ED by decreasing NO production in penile tissue(Moore & Wang, 2006; Rees, Ziessen, Ralph, 
& Kell, 2002; Saenz de Tejada et al., 2005). 
Neuropathy: Diabetics with ED have abnormal nerve conduction.more frequently than 
diabetics without ED.  It is also noted that diabetics with neuropathic ED also have somatic and 
autonomic neuropathies, hence suggesting that neuropathy contributes to diabetic ED. 
2.1.9 Epidemiology of Erectile Dysfunction and Diabetes  
The prevalence of ED and diabetes has been reported to be anywhere from 20% to 71% 
(Feldman et al., 2000; Klein, Klein, Lee, Moss, & Cruickshanks, 1996; Nathan, Singer, 
Godine, & Perlmuter, 1986).  The large discrepancy reported in the prevalence estimates is 
affected by the sensitivity and specificity of methods used to assess ED.  Several of the studies 
reported statistics based on record reviews while others reported face to face assessments, 
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where ED is under-reported.  Also studies did not control for type of diabetes, severity of ED, 
duration of disease and glycemic control (Penson, Latini et al., 2003).  Unlike the above, our 
EDC study only completed analysis on males with T1D and the analysis of the EDC data for 
males with ED controlled for duration and glycemic control.   
A 20% prevalence rate was reported by Klein et al (Klein et al., 1996) from a 
population based cohort study in southern Wisconsin.  These estimates were self-reported by 
365 males greater than 21 years of age, who were less than 30 years of age at diagnosis, had 10 
or more years of diabetes and were on insulin therapy.  ED was associated with a history of 
peripheral neuropathy, amputation, cardiovascular disease a higher HbA1, higher BMI, use of 
anti-hypertensive medications, severe retinopathy and longer diabetes duration.  Prevalence of 
ED increased from 1.1% in the 21-30 year age group to 47% in those older than 43 years 
(Klein et al., 1996). 
Fedele et al (Fedele et al., 2001) reported a prevalence of 26% in a sample of 1, 383 
T1D males from 178 Italian diabetes centers.  Findings as above were confirmed and an 
additional significant positive association for smoking was found for those with ED (Fedele et 
al., 2001).  Klein et al (Klein et al., 2005) also completed a 10 year incidence of self-reported 
ED in males with long term type 1 diabetes from a study population  from 11 counties in 
southern Wisconsin (Klein et al., 2005).  From a registry, 10, 135 persons with diabetes were 
identified of which 1210 were identified as having diabetes prior to age 30.  Only males who 
participated in the 10, 14 and 21 year examinations and who were 21 years or older were 
eligible to participate because ED was first obtained at the 10 year examination. These totaled 
365. After controlling for age, males with ED at the 10 year examination time were more likely 
to die with a reported hazard ratio of 2.7(95% CI 1.5, 5) than males without ED.  Males with   
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25 or more years duration of diabetes, were 2.4 times (95% CI 1.1, 5.1) more likely to self 
report ED than males with 11-14 years diabetes duration.  This relationship was no longer 
found statistically significant after controlling for age.   
Overall 10 year incidence of ED increased from 10.2% in males between the ages of 21 
and 29 to 48.6% in males older than 40 years (p<.001).  Total serum cholesterol, but not HDL 
was related to incidence of ED.  However, ED was not statistically significantly related to 
higher HbA1’s.   If hypertension was present, the male was three times as likely to have ED.  
Current use of anti-hypertensive medications was not statistically significant in association of 
those with ED and those without.  Age, hypertensive status and smoking were statistically 
associated with incident ED.  Persons married were more likely to report ED but not 
statistically significant after controlling for age.  However, ED was not associated with income, 
education or work status.  Long term complications associated with ED and statistically 
significantly related to ED included neuropathy, lower extremity pain on walking, presence of 
more severe retinopathy at baseline and loss of sensation.  Those with proliferative retinopathy 
were 2.1 times more likely to report incident ED (Klein et al., 2005). 
From our review of the previous prevalence studies, and in summary, prevalence was 
noted to be anywhere from 20% to 71%.  Demographic risk factors identified were increasing 
age, marital status, income, and education (Klein et al., 1996) while the biologic risk factors 
identified were duration of diabetes greater than 10 years, HbA1c, complications (peripheral 
neuropathy, peripheral vascular disease, cardiovascular disease , and retinopathy), 
hypertension,  and total cholesterol (Fedele, 1998; Klein et al., 1996) and  anti-hypertensive 
medication. Lifestyle behavioral risk factors identified were smoking(Fedele, 1998).  
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Demographic risk factors associated with incident studies included demographic ( age, 
marital status ) and biological (  duration of diabetes, complications [neuropathy,  severe 
retinopathy], total serum cholesterol but not High Density Lipoprotein, hypertension.)  and 
lifestyle behavioral risk factors (smoking, alcohol)(Fedele et al., 2001; Klein et al., 2005).  
Demographic risk factors common to both previous prevalence studies and incidence studies 
included age, and marital status.  The biological risk factors included glycemic control, 
duration of diabetes, complications (peripheral neuropathy, cardiovascular disease, severe 
retinopathy, and peripheral vascular disease), blood pressure, weight, and total 
Cholesterol(Fedele et al., 2001; Klein et al., 1996).  These risk factors have all been assessed 
by the EDC Study and were included as variables in this study. In addition our study assessed 
additional biologic factors (E/I ratios) that were not previously reported in the literature.  
In addition to the demographic, biological and lifestyle behavioral risk factors, our 
study assessed depressive symptomatology and quality of life’s association with the 
development of ED.  The following describes what has been reported in the literature. 
2.1.10 Psychosocial Risk Factors 
Quality of Life and Depression 
Risk factors for males with ED include depression, anxiety, and a negative impact on 
relationships.  These compounded with diabetes can have a substantial effect on the quality of 
life (QOL).  The association between poor quality of life and ED has been established, 
however, ED is infrequently addressed by diabetes specialists and primary care physicians 
(DeBerardis et al., 2005; Kalter-Leibovici et al., 2005).  Because of the psychosocial 
implications of ED, males with ED do not actively seek treatment.  In a survey of 500 males 
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over the age of 50 who visited a urologist for urologic issues other than ED, 44% or 218 males 
had ED.  These males with ED did not seek professional help for ED because they were 
embarrassed or viewed ED to be a symptom of aging (Baldwin, Ginsberg & Hawkins, 2003).  
Findings from the National Health and Social Life Survey reported that despite the diminished 
quality of life experienced by males with ED, only 1 in 10 reports and seek medical treatment 
for ED (Laumann et al., 1999).  Findings from the Exploratory Comprehensive Evaluation of 
Erectile Dysfunction( ExCEED) (Penson, Wallace et al., 2003) study not only confirmed this 
disease specific negative quality of life association, but also confirmed that males with ED and 
diabetes report worse erectile dysfunction than males with ED and no diabetes.  This study was 
an observational longitudinal registry study that examined males with ED who sought urologic 
care for sexual dysfunction.  Males with ED and diabetes (cohort definition for diabetes both 
T1D and T2D) reported more severe sexual dysfunction than those males without diabetes, 
and, worse disease specific health related quality of life (HRQOL).  Functional status and 
disease specific HRQOL were measured at 3, 6 and 12 months after baseline in both the non-
diabetic and diabetic male groups.  Males with diabetes and ED responded differently over 
time.  Six months after baseline, the males with diabetes showed marked improvement in 
HRQOL but this trend did not continue as 1 year after baseline the males with diabetes and ED 
reported worse HRQOL than those without diabetes and ED.  In addition, males with ED and 
diabetes initially respond well to treatment, but the treatment effect is not sustained over time 
(Penson, Wallace et al., 2003) which also may have a negative impact on QOL. 
These studies focused on the psychosocial impact of ED, not on analyzing them as 
potential predictors of ED.  Our study analyzed depressive symptomatology and quality of life 
as risk factors for ED.  
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The association with depression and ED has been previously addressed in the preceding 
sections.  For a summary of the above mentioned research studies, please refer to APPENDIX 
A:Summary of ED Studies. 
2.1.11 Behavioral and Cognitive Factors 
Because diabetes mellitus requires self-management behaviors for survival, behavioral and 
cognitive factors were important to examine in this study.  Behavioral theory helps to direct the 
hypothesis and measures.  The Conceptual Framework that guided our analyses was the Social 
Cognitive Theory.  
Social Cognitive Theory (SCT) posits that individuals are governed by their own self 
system.  Within this, there is a self-referent mechanism to provide value and meaning on 
environmental events.  These events then serve a regulation function to shape how the 
individual thinks, feels and acts (Bandura 1990).  Therefore, seen as cognitive self-evaluations, 
these exert influence on such behaviors as goal attainment, the amount of energy expended 
toward attaining these goals, and their likelihood of attaining this level of behavioral 
performance.  SCT has a set core of determinants, a mechanism through which those 
determinants work and the most effective ways of translating knowledge into effective health 
care practice (Bandura, 1988; Bandura & Bussey, 2004).  Through this cognitive self 
evaluation, the individual is able to not only evaluate their experiences but also develop their 
sense of self-belief.  An individual’s behaviors are mediated by their own self-beliefs and, an 
individual is able to attain higher self -performance if functioning within high levels of positive 
self-belief accompanied by a higher sense of control. To understand and intervene in health 
behavior, Mishel and Bandura formulated a number of SCT constructs (Bandura & Bussey, 
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2004).  Two of the SCT constructs used in health behavior intervention models include 
outcome expectancy and self-efficacy.  An individual’s estimate that a given behavior will lead 
to a certain outcome is the definition for outcome expectancy and therefore leads the individual   
to behave in a manner that maximize positive outcomes and minimize negative ones.  Bandura 
identified the most important determinant for behavioral change to be self-efficacy and this is 
the construct most often applied to research of self-management behaviors in chronic disease.  
Self-efficacy is the individual’s belief about ability to organize and execute the course of 
action necessary to attain a given outcome.  Bandura placed more importance to this construct 
because he believed that self-efficacy affects how much effort is invested in and what level of 
performance is attained in a given health related task.   Self- efficacy will influence selection, 
course of action, individual effort, time and perseverance spent despite barriers presented to 
attain the goal. Individuals are more likely to take on a task if they believe they can succeed.  If 
one repeatedly completes a health related task successfully, the success reinforces the behavior 
which in turn promotes a behavioral change (Bandura, 1988; Glanz, Rimer, & Lewis, 2002).  
Self-efficacy affects health behavior directionally and by influencing other determinants.  
Bandura lists four sources that affect self- efficacy.  The first source is mastery and considered 
to be the most important source.  Simply put, success will raise self-efficacy where failure will 
lower it.  The second is modeling.  By this process, a comparison is made between the person 
and a peer.  The third is social persuasion.  Positive persuasions by health care professionals 
increase self-efficacy.  And finally the fourth and last sources are physiologic factors.  A 
person’s perception of normal physiologic responses to stress can alter their level of self-
efficacy.  How an individual cognitively appraises the information, is determined by the impact 
of the efficacy information from these four sources.  Several studies have reported that higher 
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self efficacy is associated with higher levels of self-management (Anderson et al., 1995; 
Glasgow & Anderson, 1995; Hurley & Shea, 1992; Johnson-Brooks, Lewis, & Garg, 2002) in 
people with diabetes.  A conceptualized model with the role of self-efficacy and its relationship 
to self–management behavior and outcome is depicted through the following Figure 2.1 
Figure 2.1 Application of the SCT  
 
 
 
SC 
 
Outcome 
 
 
 
Self-Efficacy 
Perceived Severity 
Self-Management Knowledge 
According to the literature, enhancing diabetes reself-management (diabetes treatment 
regimen) leading to more positive outcomes (metabolic control and prevention of 
complications).  Successful management of diabetes relies on the individual with diabetes’ 
ability to repeatedly and successfully complete tasks to control symptoms and delay or prevent 
long term complications.  An additional self-belief that may contribute to this behavior is 
perceived severity (Health Belief Model) (Becker, 1974; Glanz et al., 2002). Understanding 
self-management behaviors and health beliefs (self-efficacy and perceived severity) may help 
the clinician to recognize potential barriers to adherence.  There have been several studies 
concerning self-efficacy and diabetes adherence (Johnson-Brooks et al., 2002; Kneckt, Syrjala, 
Laukkanen, & Knuuttila, 1999). The gap exists in the research dealing with self-management 
behaviors, health beliefs and knowledge, in males with ED and Diabetes.  
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2.1.12 Treatment of Erectile Dysfunction 
Several treatment options are available to males with ED, prescription of which is based on the 
underlying cause and over–all health of the male.  Non-pharmaceutical effective measures are 
changes in lifestyle that include: 1) regular exercise to decrease weight, relieve stress, 
depression or anxiety, improve muscle tone, increase energy levels and lower blood pressure, 
and, 2) smoking cessation.  There are also vacuum erection devices that can be effective, 
elective penile prosthetic surgery or penile revascularization surgery.  There are 
pharmaceutical agents approved by the FDA for use in ED that are the Phosphodiesterase 
Inhibitors which inhibit PDE5, the primary agent in cavernosal tissue responsible for 
degradation of cGMP.  By inhibiting PDE5, prolonged levels of cGMP can be maintained with 
improved smooth muscle relaxation.(Saenz de Tejada et al., 2005).   
2.1.13 Treatment of Erectile Dysfunction in Diabetes  
Diabetic ED treatment is multimodal.  Medications used to treat comorbidities of diabetes 
should be chosen that have the least adverse effect on erectile function.  Males with diabetes 
with cardiovascular comorbidites need assessment prior to the initiation of therapy to treat ED.  
The Second Princeton Consensus Conference delineated three risk levels based on 
cardiovascular status and risk in the male with diabetes to determine treatment protocols.  
Those in the high risk group need to achieve cardiovascular stabilization prior to receiving 
treatment.  It is recommended that the intermediate risk group receive  assessment by a 
cardiologist prior to the initiation of treatment and the low risk group  considered for all first 
line therapies used in ED treatment (Kostis et al., 2005).  There are presently 5 treatment 
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options available for males with diabetes and ED.  Phosphodiesterase Inhibitors inhibit PDE5 
which is the primary agent in cavernosal tissue responsible for degradation of cGMP. By 
inhibiting PDE5, prolonged levels of cGMP can be maintained with improved smooth muscle 
relaxation (Saenz de Tejada et al., 2005).  Sildenafil is a PDE5 inhibitor and is frequently 
prescribed.  In a study comparing Sildenafil versus placebo in males with type 1 diabetes  and 
ED, those on Sildenafil reported improvement in ability to achieve and  maintain erection 
(Stuckey et al., 2003).  Similar results were obtained in a study by Rendell et al in which 61% 
of the Sildenafil treated versus 22% of the placebo reported at least one successful  intercourse 
attempt (Rendell, Rajfer, Wicker, & Smith, 1999).  Overall the PDE5 inhibitory drugs are well 
tolerated by males with diabetes and ED.  Global efficacy of maximum dose PDE5 inhibitors 
has been reported in the range of 65-72% (Boulton et al., 2005; Saenz de Tejada et al., 2005) .    
Vacuum erection devices are also an option for males with diabetes and ED.  This is a 
cyclindrical chamber device with a pump on one end and an opening on the other end.  After 
lubrication of the penis, the device is placed over the penis, a tight seal is formed at the base of 
the penis,and either manually or by battery the pump is activated.  When the penis has reached 
sufficient engorgement for an erection, a tension ring is placed at the base of the penis thus 
trapping blood in the corporal bodies and an erection is maintained.  There is a 30 minute limit 
to the constriction ring being in place.  This device is contraindicated for those using 
anticoagulants, or having a history of bleeding disorders.  Patient satisfaction is limited with 
the use of this device.(Moore & Wang, 2006; Price et al., 1991; Saenz de Tejada et al., 2005) 
(Sidi, Becher, Zhang, & Lewis, 1990). 
A third option is the use of intraurethral suppositories.  Alprostadil (prostaglandin E) is 
absorbed by the urethra causing vasodilatation and relaxation of the smooth muscle.  Other 
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treatment options available include penile prosthesis, used when oral treatment is 
contraindicated or fails, and intracavernosal injection.  Research for the treatment of ED in 
diabetes continues 1) in the identification of the underlying cause, and, 2) gene therapy with 
neurotrophic factors. 
In summary, this review of the literature has discussed: 1) the pathophysiology of ED, 
2) the pathophysiology of ED as it relates to or is altered by diabetes, 3) T1D, 4) epidemiology 
of T1D, 5) epidemiology of ED, 6) the epidemiology of ED and diabetes and, 7) treatment 
options for males with diabetes and ED.   
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3.0   RESEARCH METHODOLOGY 
The present study involved a secondary data analysis of data collected from male participants of 
the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study (1986-2007). The EDC was 
an NIH (DK34818) funded study designed to address the following three research questions; 1) 
Why do insulin dependent diabetic patients develop complications?    2) What factors relate to the 
type and combination of complications that individual IDDM patients suffer? and, 3) What factors 
relate to the severity of complications? 
There were two major components to this study.  The first was a baseline (prevalence) 
cross sectional analysis of the study cohort designed to determine the prevalence and 
interrelationships of macrovascular and microvascular complications.  The second was a    
prospective longitudinal study that documented the incidence and natural history of new disease 
in participants free from clinical disease at baseline by evaluating interrelationships between risk 
factors in the subsequent development and progression of diabetes complications.  The major 
complications of interest included cardiovascular disease, peripheral vascular disease, 
retinopathy, nephropathy and neuropathy.  
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Erectile Dysfunction (ED) was included as a clinical symptom of symptomatic 
autonomic neuropathy.  However, at the time of the study’s inception, ED was not included 
as a major complication of interest.  Since this type of research plan involves post-hoc 
analysis, a limitation that is sometimes encountered is that there can be no planned measure 
for the variable of interest, and therefore it is sometimes necessary to create a variable within 
the original dataset that matches the variable of interest. Because ED, the present variable of 
interest, was included within the parent study design, this was not seen as a limitation for this 
analysis.  
The proposed analysis of the male participant’s data from the parent study had the 
following primary objectives: 1) to determine both the prevalence and incidence of ED in the 
EDC sample; 2) to identify risk factors for development of ED; and 3) to determine the natural 
history of ED, specifically if ED development occurred at a particular stage of neuropathic 
disease. The secondary objective was to identify longitudinal self-management behaviors of 
males with ED enrolled in the EDC related to their self-efficacy, perceptions of severity of 
complications of diabetes and diabetes knowledge.   
3.1 SAMPLE, SETTING, AND PROCEDURE 
The participant pool for the parent study was obtained through the use of the Children’s 
Hospital of Pittsburgh Registry. This registry consisted of all insulin dependent diabetes 
mellitus patients seen at Children’s Hospital of Pittsburgh from January 1, 1950 to May 31, 
1980 and formed the sampling frame for inclusion in the EDC.  Subjects had to meet the 
following criteria: 1) onset of insulin dependent diabetes mellitus at age 17 years or less; 2) 
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insulin therapy prescribed at discharge; 3) an initial diagnosis, or being seen within one year 
following diagnosis at Children’s Hospital of Pittsburgh; and 4) residence within 100 miles of 
Pittsburgh or 2.5 hours of driving distance from Pittsburgh.  
There were 1124 patients identified from the registry that met the inclusion criteria. Of 
these, 145 had died before recruitment, leaving 979 subjects.  Attempts were made to contact all 
979 by mail and phone.  Of the 979 eligible patients, 788 (80%) agreed to participate.  About 
two thirds (n=658, 67%) provided full participation and 130 (13%) completed only 
questionnaires.  Those who agreed to fully participate were seen for baseline examinations 
between 1986 and 1988.  
Males composed 51% (n=333) of the total sample. Of the 333 males, 331 were 
Caucasian and 2 were African American.  Age range for the males at study entry was from 8.47 
years to 47.43 years with a mean age of 27.53±7.78 years and a median age of 27.27 years.  The 
duration of diabetes varied:  13 % (n=44) had diabetes duration less than 10 years, 40 % (n=136) 
had diabetes duration between 10 and 19 years, 35% (n=117) of the participants had diabetes 
duration between 20 and 29 years and, 11 % (n=36) of the participants had diabetes duration 30 
years or more.  Overall mean and median for duration of diabetes was 19.6 years (± 7.5 years) 
and 18.96 years respectively. Table 3.1 illustrates the distribution of the age of the male 
participants by duration of diabetes.  Hemoglobin A1 mean at baseline was 8.7% ± 1.45%( 
normal range 4.7%-6.8 %).  Twenty-two percent (n=75) of the males actively smoked at 
baseline, while 57 %(n=190) admitted to ever smoking 100 cigarettes in their lifetime.  Fifty-
three percent (n=175) were not married.   Table 3.2 illustrates the overall characteristics of the 
male sample at baseline. 
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Table 3.1 Age by Duration of Diabetes in Male EDC Participants at Baseline (1986-1988) 
 Duration of Diabetes (years)  
 <10 years 0-19 
 
20-29 >30 Total 
Age (years)      
<18 
n=32 
23 9   32 
18 to 25 
n=104 
20 67 17  104 
25 to 30 
n=70 
1 47 22  70 
30 to 35 
n=63 
0 13 43 7 63 
35 to 40 
n=44 
0 0 31 13 44 
>40 
n=20 
0 0 4 16 20 
Total 44 136 117 36 333 
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Table 3.2 Characteristics of Males with T1D Enrolled at Baseline (1986-1988) in the EDC 
Characteristics Total n=333 
Age (m±sd) years 
 
27.53±7.78 
Range: 8.47-47.43 
MARITAL STATUS (n,% total)
never married 
married 
separated 
divorced 
widowed 
not married, living with partner 
 
175 (52.55) 
131 (39.34) 
2 (0.6) 
18 (5.41) 
0 
7 (2.10) 
 
LEVEL OF EDUCATION (n,% total) 
SomeHS/HS  graduate 
Some College 
Graduate 
 
118 (39.46) 
154 (51.51) 
27 (9.03) 
 
 
INCOME (% total) 
<$5,000-$15,000 
$15,000-$30,000 
 >$30,000 
 
 
 
26.12 
38.05 
35.82 
 
HbA1c (m±sd) % 
 
 
8.74 ±1.45 
Range: 5.23-15.16 
 
Age at onset of diabetes (m±sd) years 
 
 
8.34 ± 4.17 
 
 
Duration of diabetes (m±sd) years 
 
 
19.55±7.46 
Range: 7.69-37.40 
Total Complications 1.18 ± 1.35 
Range: 0-5 
Coronary Artery Disease (CAD) 
(n, % total) 
no 
yes 
 
 
 
305 (91.59) 
28 (8.41) 
+Autonomic Neuropathy (AN) ( n, % total)
no 
yes 
92 
 
60 (65.22) 
32 (34.78) 
 
 
+Symptomatic Autonomic Neuropathy 
(SAN) (n, % Total) n=92 
no 
yes 
 
 
 
 
 83 (90.22) 
 9 ( 9.78) 
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Table 3.2 continued 
 
 
Nephropathy (n, % total) 
no 
yes 
 
 
 
 
238 (71.47) 
95 (28.52) 
Lower Extremity Arterial Disease (LEAD)
(n, % total) 
no 
yes 
 
 
 
308( 93.05) 
23 (6.95) 
Retinopathy (n, % total) 
no 
yes 
 
219 (67.18) 
107 (32.82) 
Cerebral vascular Disease(CBVD)  
(n, % total) 
no 
yes 
 
 
331 (99.4) 
1 (0.3) 
Confirmed Distal Symmetrical 
Polyneuropathy (CDSP) 
no 
yes 
 
 
230 (69.27) 
102 (30.73) 
Distal Symmetrical Polyneuropathy (DSP)
no 
yes 
 
 
227 (68.37) 
105 (31.63) 
Systolic Blood Pressure (m±sd) mmHg 
 
117.49±17.14 
Range: 76-234 
Diastolic Blood Pressure (m±sd) mmHg
 
75.52±11.20 
Range: 44-118 
High Density Lipoprotein (HDL) 48.61 ± 9.73 
 
nonHDL Cholesterol 140.60 ± 44.56 
 
Smoking Ever (n,% total) n=322
no 
yes 
 
 
190(59.01) 
132(40.99) 
 
Smoking Now ( n.% total) n=125
 
no 
yes 
 
 
 
50(40) 
75(60) 
 
Total alcohol (Average drinks /wk)
N=192 
6.17 ± 11.1 
Range:0-53 
Hypertensive (n,% total) 
no 
yes 
 
268 (80.72) 
64 (19.28) 
ACE Medication (n, % total) 
no 
yes 
 
 
307 ( 96.54) 
11 (3.46) 
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Table 3.2 continued 
 
Blood Pressure Medication (n,% total) 
no 
yes 
 
 
257 (90.49) 
27 (9.51) 
Quality Of  Life (QOL) (m ± sd) 
 
52.72 ± 12.19 
Range: 33-129 
Impact (m ± sd) 
(Domain within QOL instrument)
 
30.00 ± 6.75 
Range: 19-53 
Worry (m ± sd) 
(Domain within QOL instrument)
 
16.41± 6.42 
Range:1-44 
Satisfaction (m ± sd) 
(Domain within QOL instrument)
 
5.99 ± 1.96 
Range: 3-11 
Sex Question (m ± sd) 
 
 
(Question within Impact 
Domain/QOL Instrument) 
1.72 ± 1.10 
Range: 1-5 
BECK Depression Inventory 
(BDI)(m ± sd) 
6.2±6.20 
Range:0-32 
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 After scheduling the baseline examination and 2 weeks prior to their examination at 
the Diabetes Research Center at the University of Pittsburgh, participants were mailed self- 
report questionnaires that included a medical history, lifestyle questionnaire and containers 
with detailed instructions for 24 hour urine and overnight specimens collection that were to 
be brought to the research center the day of the examination.  If a participant failed to show 
for an appointment, contact was made by the research staff and the participant was asked to 
complete the questionnaires only and return them via the mail (Orchard et al., 1990).   
Procedures completed once the participant arrived at the research center and according to 
protocol included: 1) review and verification of self-report questionnaires with research 
staff; 2) fasting blood draw, insulin and breakfast; 3) clinical examination and procedures 
for retinopathy, cardiovascular and neurological status; and 4) exit interview with the 
research physician.  Total time participants were present within the research center was 
approximately 4 hours.  Participants were given a stipend for their time and travel. Results 
of examination and clinical evaluations were sent to the participant’s physician for review. 
 Data were then collected biennially on this cohort, for a period of 10 years (1986-
1998).  Each cycle (refer to Table 3.3 for actual cycle dates), Cycle 1 through Cycle 6, of 
exams took place over a 10-year period  and included face-to-face clinic visits, physical 
assessments, laboratory testing and self-report.  Collection of data continued after the ten 
year follow-up with annual surveys and a full examination at 18 years (2004-2007) using the 
above methods.  Data was not ascertained on all enrolled participants at Cycle 7(1998-2000) 
or Cycle 8/9 (2000- 2002) as these 2 cycles were EDC-sub studies.    
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 Table 3.3 Dates for Cycles 1 through 10, EDC 
Cycle 1: May,1986-November, 1988 
Cycle 2: November, 1988-November, 1990 
Cycle 3: November, 1990-November, 1992 
Cycle 4: November, 1992-November, 1994 
Cycle 5: November, 1994- November, 1996 
Cycle 6: November, 1996-November, 1998 
Cycle 7: (EDC substudy if T1D Duration 
>30yrs) 
November, 1998-November, 2000 
Cycle 8/9: (EDC substudy for Coronary 
Artery 
Calcification study) 
November, 2000-November, 2004 
Cycle 10: November, 2004-March, 2007 
 
As per EDC protocol, questions concerning sexual maturity were asked by the 
examining physician only if thought appropriate to those older than 16 years of age. Because 
ED is only present in males who have reached an age of sexual maturity, a criterion for 
participation in the present study was age greater than or equal to age 18 years.  Therefore, the 
age of the participant was an additional criterion to the above set of eligibility criteria in the 
present study. At baseline of the 333 males enrolled, 32 of those males were below the age of 
18 years.   In addition to their age, these 32 males statistically differed from the other 301 
males in duration of diabetes, weight, height, total cholesterol, high density lipoproteins, low 
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density lipoproteins, systolic and diastolic blood pressures, waist hip ratios, and BMI.  No 
statistical difference between the samples was found for HbA1, a measure of diabetes control, 
and triglycerides.  In addition, these two samples differed in complications of retinopathy, 
nephropathy, and neuropathy (CDSP).  They did, however, not differ in coronary artery disease 
or lower extremity arterial disease. Refer to Table 3.4.  
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 Table 3.4 Characteristics of Males Older than 18 years of Age at EDC Baseline (1986-1988) as Compared to 
Males Younger than 18 years of Age at EDC Baseline 
Characteristics Males older than 18 years
(n=301) 
Males younger than 18 years 
(n=32) 
p-value 
Age (± sd) (years) 28.96 ± 6.69 
 
14.02 ± 2.60 
 
p<.0001 
Duration of 
Diabetes (years) 
20.62 ± 7.03 
 
9.51 ± 1.41 
 
p<.0001 
Weight (kgms) 
 
71.67 ± 9.81 
 
50.53 ± 14.07 
 
p<.0001 
Height (cms) 172.78 ± 6.51 
 
158.98 ± 14.01 
 
p<.0001 
Total Cholesterol 193.39 ± 44.62 
 
160.65 ± 26.25 
 
p<.0001 
High Density 
lipoprotein 
48.68 ± 9.744 
 
53.84 ± 8.44 
 
p=.0017 
Triglycerides 120.36 ± 93.22 
 
87.20 ± 39.94 
 
p=.0880 
Low Density 
Lipoprotein 
141.08 ± 125.61 
 
90.85 ± 21.13 
 
p<.0001 
Systolic Blood 
Pressure(mmHg) 
118.78 ± 17.41 
 
105.41 ± 6.54 
 
p<.0001 
Diastolic Blood 
Pressure(mmHg) 
76.37 ± 10.97 
 
67.46 ± 10.25 
 
p<.0001 
Waist Hip Ratio 0.87 ± 0.52 
 
0.83 ± 0.03 
 
p<.0001 
BMI 24.02 ± 2.77 
 
19.52 ± 2.90 
 
p<.0001 
HbA1c 10.35 ± 1.74 
 
11.17 ± 2.46 
 
p=.1101 
ACE Medication 
(n, %) 
       Yes 
       No 
 
 
96.17% 
3.83 %  
 
 
    0% 
100% 
 
 
p>.10 
Lipid Lowering 
Med (n, %) 
      Yes 
       No 
 
 
99.31%  
0.69%  
 
 
   0% 
100 % 
 
 
p>.10 
 
  70
Table 3.4 continued 
Proliferative 
Retinopathy 
   Yes 
    No 
  
 
 
64% 
36% 
 
 
    0%                 
100% 
 
 
 
p<.0001 
 Overt 
Nephropathy 
   Yes 
    No 
 
 
68% 
32% 
 
 
    0% 
100% 
 
 
p<.0001 
Lower extremity  
Arterial disease 
    Yes 
     No 
 
 
92.33% 
7.67% 
 
 
    0% 
100% 
 
 
p=.1473 
Confirmed distal 
symmetrical 
polyneuropathy 
    Yes 
     No 
 
 
 
 
 
66.33% 
33.66% 
 
 
 
97% 
3 % 
 
 
 
p<.001 
Coronary arterial 
 Disease 
     Yes 
       No 
 
 
91.36% 
8.64% 
 
 
93.76% 
6.25% 
 
 
p=.2566 
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By Cycle 6, all 32 males had reached 18 years of age.  Participants re-entered into the 
data set for longitudinal analysis at the cycle following their 18th birthday.  Refer to Table 3.5. 
 
Table 3.5 Cycles in which the 32 Males <18 at Baseline Re-Entered 
Cycle Frequency Cumulative Frequency Cumulative Percent 
1 301 301 90.39 
2 6 307 92.19 
3 14 321 96.40 
4 5 326 97.90 
5 3 329 98.80 
6 4 333 100.00 
 
3.1.1 Protection of Human Subjects 
The University of Pittsburgh Institutional Review Board (IRB) approval was obtained prior to 
participant enrollment and maintained as per University protocol for the time of study.  
Informed consents were obtained from the study participants.  Each participant was assigned a 
unique identification number. Data collected for each participant was entered using the 
assigned number.  To assure subject confidentiality, data forms were locked in the 
Epidemiology of Diabetes Complications Center.   
 Renewals and Modifications were completed as per University of Pittsburgh IRB 
protocols yearly.  Author of this manuscript was a Co-Investigator. Refer to Appendix B: IRB .  
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3.1.2 Justification of Sample Size for Parent Study 
Sample size determination for the projected EDC cohort of 800 was completed to assure that 
there would be a sufficient number of participants with specific risk factors and development 
of complications over the course of the study. Associations of various risk factors and 
complications were determined by selection of a sample of affected and a sample of unaffected 
matched on appropriate variables.  Chi -square test statistics was used for dichotomous factors 
and t-test for continuous factors was used to detect statistically significant bivariate association.  
Sample sizes were calculated to detect sufficient power and effect.  
Of the 333 males enrolled in the study at baseline, 298 were 18 years or older.  Thirty-
one (10.4%) males had prevalent ED.  For this resultant prevalence, power was 0.67826, and 
beta was equal to 0.32174.  Power desired for most epidemiological studies is ideally set to be 
.80 or .90 and under-powering a study could result in non-significant findings(Rothman et al., 
2008).  Since this power was below what is usually sought, precision was calculated to 
determine an estimate of the reliability to determine if the results would be generalizable.  A 
sample size of 298 produces a 91% (±0.03072) confidence interval when the estimated 
proportion was 0.10.  The wider the confidence interval, the less likely it will be to generalize 
the results (Rothman et al., 2008). 
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 3.1.3  Measures 
3.1.3.1  Dependent Variable 
ED was used as the outcome measure, or dependent variable, and was defined as a persistent 
inability to attain and maintain an erection adequate to permit satisfactory sexual performance 
not due to any other problem as determined by the examining physician while conducting the 
Diabetes Control and Complications Trial (DCCT) clinical neurological examination protocol.   
ED was to be present for at least 30 days prior to the examination. Trained physician 
investigators inquired about autonomic neuropathy symptoms that included questions relating 
to 1) postural hypotension, 2) gastroparesis, 3) diabetic diarrhea, 4) colonic atony, 5) 
sudomotor abnormality, 6) hypoglycemic unawareness and 7) genitourinary autonomic 
neuropathy symptoms.  ED was a “yes or no” determination after genitourinary system review 
by the examining physician.  Prevalent cases were those males reporting ED at baseline exam 
(1986-1988), while incident cases were those males who were negative for ED at baseline but 
developed ED during a follow-up cycle (1989-2007).  To determine incidence of ED, Cyles 1 
through 6 and Cycle 10 were used. Cycles 7 and Cycles 8 were not used since these were sub-
samples of the EDC participants.  Inclusion of these two cycles could bias the results.  The 
cycle in which the participant first reported ED following baseline examination was considered 
the incident cycle for ED.   
In Cycle 1 thru Cycle 6, there were two measures of ED, one was physician determined 
after face-to-face interview and examination using the DCCT clinical neurological examination 
protocol and documented on the EDC-Medical Examination Form, while the second was self-
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reported by the participant on the EDC-Medical History Questionnaire.  This questionnaire was 
mailed to the participant 2 weeks prior to their EDC scheduled appointment. The participant or 
a participant designee could complete this mailed questionnaire.  It was returned to the EDC at 
the time of the scheduled examination.  The physician review response was used for the ED 
variable since it was thought to a more reliable indicator in determining if the erectile 
dysfunction was due to the diabetes process. However, in the event that the physician 
documentation was not available, consideration was given to whether the participant’s self- 
report of ED could be used.   
To determine if the self-reported ED variable could be used in place of the MD reported 
ED variable, a statistical test of agreement (kappa) was generated.  This statistical 
determination had results indicating poor to good agreement dependent on the cycle and was 
not considered to be a reliable estimate of the ED variable in instances of missing MD reports.  
Refer to Table 3.6 for the cycle specific kappa coefficients.  However, it was noted that despite 
non- statistical significance of the kappa statistic, the male participants reporting ED were 3 
times [OR= 3.00,(0.6861-13.1184)] more likely to report ED if the physician examiner were 
male.  This led to a further inquiry into whether this was the result of physician-gender bias.  
Sixty-two percent of the exams were completed by female physicians and 38% were completed 
by male physicians.  There were 7 female and 6 male physicians who completed examinations 
throughout the 21 years of the EDC.  All physicians were equally trained in completing the 
DCCT protocol examination.  After a repeated measures analysis for within subject difference 
of self-report using participant self-reported response, the MD gender was not significant 
(p=0.4624); however, cycle 6 (p=.0023), cycle 3 (p=0.0392) and duration (p=.0191) were 
which suggests that the self-report was not affected by the gender of the examining physician. 
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but rather by participant response variability.   Since the self-report variable was present for 
only the first six cycles, ED physician assessment was chosen as the ED measure. 
 
Table 3.6:Kappa Statistic and 95% Confidence Interval for Physician Reported vs. Participant Self-
Reported ED Cycles 1 thru Cycle 6 
Cycle Kappa Score 95% Confidence Interval 
Cycle 1 0.4418 0.2515-0.6320 
Cycle 2 0.6482 0.4361-0.8603 
Cycle 3 0.4045 0.1427-0.6662 
Cycle 4 0.5134 0.3066-0.7203 
Cycle 5 0.6538 0.4681-0.8395 
Cycle 6 0.5541 0.3968-0.7114 
 
 
3.1.3.2 Independent Variables: 
Demographic, psychosocial and behavioral variables were collected by self-report. Male 
participants completed the EDC- General Medical History Questionnaire and EDC-Lifestyles 
Questionnaires.  (For a copy of this measure, please contact the PI of the Pittsburgh EDC).   
These questionnaires were mailed to the participant approximately two weeks before each 
scheduled appointment at the EDC Research Center.  These questionnaires were completed by 
the participant and reviewed by the research staff prior to each biennial (cycle) visit. Cycles 
were approximately two years apart (refer to Table 3.2 for actual cycle dates).  Variables of 
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interest were collected at baseline as well as Cycles 2 through 10 unless otherwise noted in the 
following descriptions. 
Demographic Measures 
Age was verified and recorded as age in complete years calculated from the 
participant’s self-reported date of birth in month, day, and year at Cycle 1.  Income, marital 
status and level of education were all self-reported by the participant on the EDC Lifestyles 
Questionnaire.  
Income   was adjusted accordingly over the course of the study.  Cycle 1-2 entered  as 
1= <$5,000/yr, 2=$5,000-$10,000/yr, 3=$10,000-$15,000/yr, 4=$15,000-$20,000/yr, 
5=$20,000-$30,000/yr, 6=$30,000-$40,000/yr, 7=>$40,000/yr; Cycle 3: 1=<$10,000/yr, 
2=$10,000-$20,000/yr, 3=$20,000-$30,000/yr, 4=$30,000-$40,000/yr, 5=>$40,000/yr, Cycles 
4-10: 1=<$10,000/yr, 2=$10,000-$20,000, 3=$20,000-$30,000/yr, 4=$30,000-$40,000, 
5=$40,000-$50,000, 6=$50,000-$60,000, 7=$60,000-$70,000, 8=>$70,000. These categories 
were then further collapsed based on the distribution of the income data to 1 of 3 income 
categories from; 1) $5,000/year to < $15,000, 2) $15,000 to <$30,000 and 3) >$30,000/year.  
Marital Status was measured categorically as follows: 1) never married,    
2) married, 3) separated, 4) divorced, 5) widowed, or, 6) not married, living with parent. 
Highest Level of Education: Participant’s answered as to their highest level of formal 
education and responses were coded as follows; 1=some high school, 2=high school graduate, 
3=some college, 4= received bachelor’s degree, and 5= graduate education beyond bachelor’s 
degree.  Due to the distribution of the data these then were recategorized into the following: 1) 
some high school/high school graduate, 2) some college, 3) college graduate/graduate degree. 
Biologic Factors 
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Clinical samples and procedures were obtained and or performed by trained research 
physician/ personnel as per protocol. (See Appendix B  Clinical Samples and Procedures)    
HbA1: Glycosylated Hemoglobin (HbA1) is a measure of diabetes control.  The value 
reflects the level of circulating glycosylated hemoglobin for the past 120 days.  A person 
without diabetes has a level below 7.3%.  Levels above the normal (7.3%) are reflective of 
poor control and associated with the development of long term complications in those with 
existing diabetes.  Laboratory values are continuous and were entered into the participant’s 
data set and checked for accuracy.  For the first 18 months of the EDC, HbA1 was determined 
by using saline-incubated blood and microcolumn cation exchange chromatography (Iso-Lab).  
Following the remainder of the 10 year follow-up, HbA1 was measured by an automated high 
performance liquid chromatography method (BioRad, Diamat).  These two methods were 
found to be almost identical and highly correlated (r=.95).  For Cycles beyond the 10th year, 
HbA1c was measured using the DCA 2000 analyser (Bayer, Tarrytown, NY).  The DCA and 
Diamat were also highly correlated (r=.95).  HbA1 and HbA1c were converted to DCCT 
standard HbA1c values.  The following conversion formula was applied to the first 10 years of 
HbA1 samples; DCCT HbA1=(0.83*EDC HbA1) + 0.14, while to the second 10 year EDC 
HbA1c samples the following conversion formula was applied; DCCT HbA1c=(EDC HbA1c-
1.13)/0.81(Prince, Becker, Costacou, Miller, & Orchard, 2007).  
Duration of diabetes, a continuous variable, was calculated, at each biennial visit, from 
the month, day and year of diabetes diagnosis recorded at baseline.  This was entered into the 
participant’s data file in complete years.  
Expiration/Inspiration (E/I) Ratio: This measure was collected in Cycles 2 through 
Cycle 10. A sub-study was completed in Cycle 1 measuring the E/I ratios of a sub-set of the 
  78
participant population. There were 92 males assessed (84 without ED and 8 with ED).  
Selected and trained research study staff completed the measurement procedure for the 
Expiration/Inspiration (E/I) ratio test.  The E/I ratio, an autonomic nervous system function 
test, was measured with the participant in a supine position, limb EKG leads were attached and 
a lead II rhythm tracing recorded.  The participant was then instructed to inhale deeply for 5 
seconds followed by a forced expiration for 5 seconds and to continue this process of deep 
inspiration and forced expiration every 5 seconds for a total of 2 minutes.  The participant was 
prompted by the examiner for determination of the 5 second intervals.  The EKG was then 
marked to indicate an inspiration or expiration every 5 seconds during the recording for the 
total 2 minute testing time.  After a one minute rest, the maneuver was repeated.  Both the 
shortest R-R interval of each inspiration segment and the longest R-R interval of each 
expiration segment were measured in milliseconds.  The E/I ratio was then calculated using the 
sum of six of the expiration (EXP) and inspiration (INP) R-R intervals using the following 
formula; sum of (R-R) EXP/  sum of (R-R) INP.  Values < 1.1 were considered indicative of 
autonomic neuropathy (Stella, Ellis, Maser, & Orchard, 2000).  Sensitivity of the E/I 
measurement is 0.93, specificity is 0.93, positive predictive value is 0.93 and negative 
predictive value is 0.94 (A  Vinik et al., 2003).  This variable was entered into the data set as a 
continuous variable. 
Type and Number of Complications: There were 10 complications assessed for this 
analysis.  Type and number of complications were measured as follows;1) autonomic 
neuropathy (AN) (confirmatory was an E/I ratio < 1.1 while an E/I ratio > 1.1 was considered 
negative for AN), 2) Confirmed Symptomatic Autonomic Neuropathy (SAN) was defined as 
having an average E/I Ratio of <1.1 and 2 or more of the other autonomic symptoms as 
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determined by the examining physician using the DCCT neuropathy protocol previously 
described, 3) Distal Symmetrical Polyneuropathy (DSP) was measured using the DCCT 
protocol and defined as clinically evident diabetic peripheral neuropathy confirmed by 
physician's exam (defined as at least 2 of the following symptoms consistent with DSP; 
confirmatory symptoms included either an abnormal sensory exam consistent with DSP, or 
decreased or absent deep tendon reflexes), 4)  Confirmed distal symmetrical polyneuropathy 
(CDSP) was clinically evident diabetic peripheral neuropathy consistent with DSP confirmed 
by physician’s exam and vibratory threshold of >2.39 for ages <36 years, > 2.56 for ages 36-50 
years, and >2.89 for ages > 50 years.  EDC protocol for measurement of the vibratory 
threshold procedure included the following:  The participant was instructed to use the index 
finger of his or her dominant hand and press against each rod in sequence for approximately 
one second.  During each trial the participant was allowed to touch the rods only once.  Only 
one of the rods would be vibrating and the participant had to decide whether it was the right or 
left rod.  The task became increasingly more difficult with each of the trials. For this 
procedure, threshold determination was as follows; a number of vibration intensities were set 
and sampled by the participant.  This was done to determine the appropriate voltage level at 
which to begin testing.  After each correct choice, the intensity was decreased by 10 %.  When 
the participant made an error, the same intensity was repeated for two additional trials.  If two 
of the three trials were correct, the intensity was decreased.  If two of the three trials were 
incorrect, the intensity was increased.  Testing was continued until a total of five errors were 
made.  The procedure was repeated using the participant’s great toe of his/her dominant side.  
The threshold was determined by recording the vibratory values of the five errors and the five 
lowest correct scores.  The highest and lowest of these ten scores were eliminated.  The mean 
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of the remaining eight scores was used to determine the absolute vibratory threshold.  Data 
were coded as none (0), DSP (as defined above) and vibtoe negative (1),  DSP and vibtoe not 
available (2), and, DSP and confirmed with vibtoe (3), 5)  Resting ankle and arm blood 
pressure readings, using a Doppler Flow Detector, and the participant in the supine position, 
were used to determine the presence of lower extremity arterial disease (LEAD).  Ankle- 
brachial pressures were calculated using the arm pressure taken closest in time to the ankle 
pressure.  Any participant with an ankle-brachial index (AB) of <0.8 for any of the four vessels 
or a history of claudication or of amputation for vascular reasons was considered positive for 
LEAD.  Data were coded as none (0), or AB<.8, amputation or claudication (1), 6) Overt 
nephropathy (ON) was measured as an albumin excretion rate >200micrograms/min in 
multiple timed urine specimens, renal dialysis or a kidney transplant.  Data for ON were coded 
none (0), or overt or renal failure (1), 7) Coronary artery disease (CAD) was measured as a 
history of MI ( confirmed by ECG Q-waves or hospital records, using standardized criteria), 
coronary arterial occlusion (>=50 % by angiography, myocardial infarction (Minnesota codes 
1.1, 1.2), ischemic ECG (Minnesota codes 1.3, 4.1-4.3, 5.1-5.3 or 7.1) or revascularization at 
the 10 year-examination, or diagnosis of angina by the EDC study physician during any cycle 
(Prince et al., 2007), 8) Cerebral Vascular Disease (CBVD) was ascertained by history by the 
examining physician and  measured as none (0), or definite stroke (2), 9) Proliferative 
retinopathy was determined from fundus photography and measured  as none (0), retinopathy 
and/or  laser treatment of retinopathy (1), and 10)  Hypertension was defined as a blood 
pressure greater than 140/90 mmHg or on anti-hypertensive medication. 
Total number of complications: Using the following: CAD, CDSP, LEAD, overt 
nephropathy and proliferative retinopathy, a summation score was calculated.  Score range was 
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from 0-5 with the higher number indicating more complications.  Hypertension was assessed 
separately.  AN and SAN were not included in the total number of complications because 
measurement at baseline was available for only 27% of the male participants (84 without ED 
and 8 with ED). 
Systolic and Diastolic blood pressure: Trained EDC research staff measured blood 
pressure per Hypertension Detection and Follow-up Protocol using a random zero 
sphygmomanometer. Mean of the second and third blood pressure readings were used and 
entered as a continuous variable for systolic and diastolic pressures separately.  
Lipid Profile: High density lipoprotein (HDL) was determined by means of precipitation 
(heparin-manganese chloride method)(Warnick & Albers, 1978).  This lipid sub-particle is 
believed to be protective for cardiovascular disease.  Triglycerides (Bucolo & David, 1973) as 
well as plasma cholesterol were measured enzymatically (Allain, Poon, Chan , Richmond, & 
Fu, 1974).  Low density lipoprotein (LDL) is the cholesterol sub-fraction associated with the 
development of plaque within the arteries that contributes to the development of 
atherosclerosis.  Levels below 100mg/dL are clinically associated with lower risk for 
development of cardiovascular disease.  LDL was measured by using the Friedwald equation 
(LDL Cholesterol=Total Cholesterol.- High Density Lipoprotein cholesterol - Triglycerides/5) 
(Friedewald, Levy, & Fredrickson, 1972).  For this analysis, non-High Density Lipoprotein 
(HDL) cholesterol was calculated as total cholesterol minus HDL.  
Lifestyle Behavior 
Smoking status: Smoking status was coded as “ever smoked 100 cigarettes” 0=no, 
1=yes.  Ever smokers were then directed to answer “current smoker” 0=no, 1=yes. 
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Alcohol Intake: In addition to the average number of alcoholic beverages consumed 
per week, data were also collected for type of alcohol consumed, i.e., beer (12 oz), wine (4 oz), 
or liquor (shots). Average number of alcoholic beverages was entered into the database as well 
as type of alcohol consumed. In addition to the continuous alcohol variable (to reflect mean of 
alcohol consumed per week), a categorical variable was created; 0=no alcohol, 1=1 to 3 drinks 
per day, 2=>3 drinks/day.  This variable was created to show the difference in group 
membership by ED status.   
Anti-hypertensive medication: 
Participants were asked to self-report medication used for hypertension. To qualify as a 
blood pressure medication (ant-hypertensive medication) the medication had to be used to treat 
hypertension in the participant.   
Psychosocial Measures 
Quality of Life:  This was measured by a modified version of the Diabetes Control and 
Complications Trial (DCCT)-Quality Of Life (QOL) instrument, and, referred to as modified 
DCCT-QOL (mDCCT-QOL:  By self-report, on the EDC Lifestyle Questionnaire, quality of 
life was assessed by a modified version of Diabetes Control and Complications Trial Quality 
Of Life (DCCT-QOL) instrument.  The DCCT-QOL was developed for use in the Diabetes 
Control and Complications Trial (DCCT) to compare the relative personal burden for 
participation in either the intense treatment group or standard care group for insulin therapy.  
There were 46 questions divided into four domains that included the following; impact (20 
questions), worry-social/vocational (7 questions), worry-diabetes related (4 questions) and 
satisfaction (15 questions) (Group, 1988). Cronbach’s alpha for this measuresment used in the 
DCCT was 0.92.(DCCT, 1988).  The modified DCCT-QOL (mDCCT-QOL) measure 
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contained 14 of the original 20 item questions in the impact domain, all of the 7 questions from 
the worry-social/vocational domain, and 3 of the original questions from the worry-diabetes 
related domain. Responses to questions within each of these domains were made on a 5-point 
Likert scale.  Impact and worry scales were from 1 (no impact and never worried) to 5 (always 
impacted and always worried). Impact total scores ranged from 14-70. Worry total score 
ranged from 11-66.  The higher scores indicating more impact and worry.  Satisfaction was 
surveyed using 3 general questions: one question responses were “very satisfied, fairly 
satisfied, or, not very satisfied”.  Scores for this question ranged from “very satisfied"(1) to 
"not very satisfied"(3).  The other 2 questions, questions of comparison for general health 
compared to other persons their age with and without diabetes, were scored using a Likert scale 
from 1 (excellent health) to 4 (poor health).  Total score range for satisfaction was from 3-11, 
the higher score indicating less satisfaction.  Total mDCCT-QOL scores ranged from 28-147, 
higher scores indicating more impact and worry from diabetes and less satisfaction with the 
quality of life.  In addition to the total mDCCT-QOL score and the domain scores there was 
one question within the impact domain that was reviewed separately for this study.  This 
question (#9impact domain), “How often does your diabetes interfere with your sex life” was 
answered on a Likert scale from 1-5, 1 being “never” to 5 being “all the time”.  Scores for this 
question ranged from 1-5, higher score indicating more interference.  Cronbach’s alpha for the 
total mDCCT-QOL for this EDC population was 0.8348.  Cronbach’s alpha scores for each of 
the three domains were as follows; impact (Cronbach’s alpha=0.784), worry (Cronbach’s alpha 
=0.714), and satisfaction (Cronbach’s alpha=0.710).  
Depression: The Beck Depression Inventory (BDI-II) is an instrument used to measure 
self-reported depressive symptoms.  This measure was part of the Epidemiology of Diabetes 
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Complications Lifestyle Questionnaire. (For a copy of this questionnaire, please contact the 
PI).  It was included in the packet of questionnaires that was sent to the participants two weeks 
prior to their scheduled research clinic appointments and was collected at baseline as well as 
each biennial visit.  The BDI was developed by Dr. Aaron Beck in the early 1960’s.  The BDI 
contains 21 items and two dimensions.  The first domain is the Somatic-Affective domain 
measuring somatic symptoms such as fatigue and loss of energy.  The second domain, the 
Cognitive domain, is associated with such psychological symptoms as pessimism and 
worthiness.  There are 4 ordered responses in intensity and are coded from “0” to “3”   Scores 
can range from 0 to 63, and are calculated by summing the number that corresponds to the 
symptom level  self-reported by the participant (Beck, 1961).  Participants were instructed to 
answer the questions based on the way they were feeling during the past week.  High scores 
(ranging from 29 to 63) indicate severe depressive symptoms.  Scores ranging from 20 to 28 
indicate moderate depressive symptoms, whereas, scores ranging from 14 to 19 indicate mild 
depressive symptoms.  Those with total scores between 0 and 13 were considered not to have 
any depressive symptomatology.  Cronbach’s alpha for internal consistency for the total score 
is 0.88.  The BDI –II was positively correlated with the revised Hamilton Psychiatric Rating 
Scale for Depression (r=.71) for construct validity (Beck, 1961).  There were 2 previous 
versions of the BDI which have been revised for clinical use.  The latest version was derived to 
reflect the diagnostic criteria for major depressive disorders that are described in the American 
Psychiatric Association’s Manual of Mental  Disorders, Fourth Edition (DSM-IV).  At baseline 
there were 39 missing BDI scores.  Since these missing represented 13.1% of the male 
participants, an analysis of the missing was completed to assure that these were indeed missing 
by random.  Thirty-five of these males were ED negative, while 4 were ED positive.  
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Characteristics of the participants with missing BDI scores were not significantly different in 
age (p=.051), systolic blood pressure (p=.3690), diastolic blood pressure (p=.136), duration of 
diabetes (p=.725), or DCCT corrected Hba1 (p=.682) than those participants with BDI scores.   
Behavioral and Cognitive Measures 
Self- Management Behavior: For this study, there were 3 questions that were to be 
combined to form the self management behavior variable of interest for this secondary data 
analysis. Unfortunately, the self-efficacy, knowledge and perception of severity variables were 
only measured at baseline.  Therefore, the analysis was only completed to compare those with 
prevalent ED to those without ED.  These questions were part of the more inclusive Diabetes 
Measure for Attitudes, Behavior and Self Care which was also included for participants’ 
response and contained within the Epidemiology of Diabetes Complications General Medical 
History Questionnaire.  The Diabetes Measure for Attitudes, Behavior, and Self Care (Rand) 
was a brief, valid and reliable self-report of diabetes management that contained assessment of 
diet, exercise, blood glucose monitoring, and beliefs and attitudes toward diabetes.  There were 
3 questions of interest used to define self-management behavior and were as follows, response 
choices were yes or no; 1) Have you tested your urine or blood for glucose or sugar at least 
once a week during the last 12 months?  2) If your urine sugar is running high, do you make 
any changes in the following? Diet: yes, no, Exercise: yes, no, Insulin usage: yes, no, 3) If your 
blood sugar levels are running high, do you make any changes in the following?  Diet: yes, no, 
Exercise: yes, no, Insulin usage: yes, no.  Questions #2 and #3 were combined and recoded as 
0=no and 1=yes if the participant changed diet, exercise or insulin usage according to either 
blood or urine tests.  
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Self Efficacy: For this measure, the following question was chosen from the EDC-
Lifestyles Questionnaire as an indicator of self-efficacy and coded as follows; “Do you believe 
that you can do something to prevent or delay the occurrence of these long term 
complications?”  0=no, 1=yes, 2=don’t know.  
Perception of Severity: This variable was assessed by the following 2 questions; 1) Do 
you believe the controlling of your blood sugar would prevent or delay the development of 
these long term complications? 0=no, 1= yes, 2=don’t know and, 2) Do you believe that 
controlling your blood sugar would make the complications less severe if they developed? 
0=no, 1=yes, 2=don’t know.  Each question was assessed separately.  
Knowledge:   This variable was assessed by the following question: How would you 
rate your overall knowledge of diabetes?  0=poor to fair, 1= good to excellent. 
For the above variables of self management, knowledge, perceptions of severity, and 
self efficacy, content validity was established through behavioral experts. 
3.2 ANALYSIS PLAN 
3.2.1 Data Accuracy and Appraisal of Missing Data  
The EDC had an established data quality control procedure.  Data forms were reviewed and 
coded by the data manager in the EDC.  Questions about the validity of values were forwarded 
to the study coordinator and/or the principle investigator.  One individual performed the data 
entry then all forms were subsequently double keyed by an additional staff member or student 
researcher.  Should discrepancies between the two entries exist, the two entries were reviewed 
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and resolved by the data manager.  Data cleaning consisted of checking the accuracy and 
validity of the data, including checking the range of values for each item and comparing 
responses among related items.  Data cleaning occurred on an ongoing basis, to give timely 
feedback.  When appropriate, missing values were substituted with answers provided on other 
surveys or imputed from prior data.  Values that remained missing were assigned classification 
codes for missing values.  
For this analysis: The accuracy of the data was checked by comparing the range of the 
values, minimum and maximum values, missing data, and patterns of missing data.  Of the 
baseline data, adjusting for age greater than 18 years, missing baseline data for ED status and 
one multivariate outlier (n=297), there were 8 variables identified with missing values.  They 
were BDI total score (n missing=39, 13%), income (n missing=57, 19%), hypertension status 
(n missing=1), retinopathy status (n missing=3), ACE medication (n missing=13), lipid 
medication (n missing=12), and smoking ever status (n missing=9).  The values with greater 
than 5% missing were evaluated further.  BDI score was previously presented in this chapter 
and determined that those with missing BDI scores g were not statistically different from those 
participants with recorded BDI scores.  The variable income was evaluated.  This variable 
differed from the non-missing in age, BDI score, and duration of diabetes.  This variable did 
not differ by education, complication status, ACE medication, lipid medication or diabetes 
control.  When describing the sample, this was noted.   
3.2.2 Exploratory Data Analysis: 
Two statistical software programs were used; SPSS (Statistaical Software Package for the 
Social Sciences, Versions 15 and 16, 2007 and 2008) and SAS (version 9.1 and 9.2, Cary, NC 
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2007 and 2008).  SPSS was used to generate preliminary statistics to characterize the sample, 
explore missing values of the variables, detect outliers and evaluate the underlying assumptions 
of linearity, normality and homoscedasticity.  The planned analysis (logistic regression) uses a 
binomial distribution, and therefore the assumption of normality was relaxed. However, there 
was still a necessity to determine normality of the variables to choose the appropriate 
parametric or non-parametric comparison test.  Using the exploratory data generated, there 
were appropriate numeric summaries, visual displays and graphs that further investigated these 
relationships between the independent and dependent variables of interest.  For the descriptive 
statistics, SAS was used to generate means and standard deviations   calculated as measures of 
location and spread for all continuous variables, while contingency tables were generated to 
test the categorical variables. Continuous variables were assessed for skewness and kurtosis 
and through graphical representation using a histogram. Correlations were determined through 
Pearson’s correlation coefficient and Spearman’s rank correlation coefficient where 
appropriate.   Data were checked for multicollinearity within the covariance matrix.  
Correlations, variance inflation factors (VIF), tolerance and condition indices were used to 
identify inter-correlations and redundancies among the variables.  All correlations with the 
exception of age and duration, confirmed distal symmetrical polyneuropathy (CDSP) and distal 
symmetrical polyneuropathy (DSP) were below 0.8, VIFs’ <10, tolerance values >0.10 and 
condition indices <30.  Age and duration of diabetes were highly correlated (r=.89, p <.0001). 
Adjusting for both age and duration when modeling could not occur simultaneously.  Duration 
was therefore chosen.  However, separate analyses were conducted using age in place of 
duration and similar results were obtained.   CDSP and DSP (r=.94, p<.0001) were also highly 
correlated.  CDSP was chosen as the variable for the analysis.  
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3.2.2.1 Outlier assessment (univariate/multivariate) 
An outlier is a case of an extreme value on one variable, termed a univariate outlier, while 
multivariate outliers have unusual combinations of scores of two or more variables 
(Tabachnick & Fidell, 2001).  Outliers may impact the regression coefficients.  Categorical 
variables were investigated by determining the splits over categories while the continuous 
variables employed descriptive statistics for determination of range, minimum and maximum.  
Also for the continuous variables, stem and leaf plots, histograms, box plots, and normal 
probability plots were used to assess extreme values.  Z-scores were computed to assess how 
extreme the identified univariate outliers were.  If a z-score was greater than the critical value 
of 3.29, or less than the critical value of 3.29,  the data point was considered an outlier (Rosner, 
2000; Tabachnick & Fidell, 2001).  Assessment of multivariate outliers was completed by 
computing Mahalonobis distance.  Mahalonobis distance, the distance of the case from the 
centroid of the remaining cases where the centroid is the point created at the intersection of the 
means of all the variables (Rosner, 2000; Tabachnick BG, 2001), has a chi-square distribution 
with degrees of freedom based on the number of variables being assessed.  Conservative 
estimate cut points are p<0.001 for the chi square value.  There were several univariate outliers 
that impacted the distribution, with z-scores greater than/less than 3.29.  These were then 
further evaluated by deleting them from the analysis, i.e. sensitivity analysis.  However, after 
deletion, since no change resulted, these values were allowed to remain in the analysis.  There 
was one multivariate outlier identified.  This multivariate outlier was also identified as a 
univariate outlier as well, with extreme values for duration of diabetes, systolic blood pressure 
and HbA1.  Since this participant was identified as an incident ED case, a decision was made 
to retain the observation.  Separate analyses were then conducted, with this multivariate outlier 
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in the dataset and a second time with this multivariate outlier deleted from the dataset.  Since 
there was a  significant difference after conducting this exploratory analysis (Rosner, 2000; 
Tabachnick BG, 2001), the decision was made to delete this data point.  . 
3.2.3 Data Analysis Procedures 
The following were the data analysis procedures used according to each specific aim. 
Specific Aim #1:  Determine both the age specific prevalence and incidence of ED as 
measured by self-report during physician interview 
Question #1a: What was age-specific prevalence of ED for males enrolled at baseline as 
compared to age specific normative data? 
Prevalence was defined as the number of cases per population at risk(Jewell NP, 2004). 
It was important to calculate the prevalence of a given disease because not only does this rate 
measure the amount of illness within a certain population at a specific period of time but the 
rate can theoretically help determine the health care needs of the population at risk(Jewell NP, 
2004). Age-specific rates were calculated for particular age groups at baseline.  The numerator 
and the denominator refer to the same age group, or in other words both have the same age 
distribution.  These age specific rates were calculated to display certain aspects of the ED 
health experience, i.e., by generating these rates it was possible to determine if ED occurred 
more frequently in the younger age groups.  Since there were no   normative data for 
comparative purposes, this could not be determined.  Had this step in the analysis been able to 
be completed, it would have shown if the ED experience in this EDC population was different 
from that of the general population.  In the ED literature, the age specific categories were 
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usually in 10 year increments.  Age categories for this analysis were within the 18 to 47 year 
range.  
Overall prevalence rate per 1000 was calculated for ED using the following formula:  
(Number of cases of ED present at baseline / Number of eligible males at baseline) x 1,000. 
Age specific prevalence rates were computed for the ED cases present at baseline. Age 
categories were chosen because of the age range of the enrolled males in the EDC study:  
Ninety-five percent confidence intervals were generated for these rates to determine if the 
number of cases were significant for that particular age group.  The age groups were as 
follows: 18-29 years, 30-39 years, and 40-49 years. 
As previously stated, there were no normative data found to compare this sample.  The 
age specific rates reported in the literature that were appropriate, either due to definition of ED 
used or research methodology, were age specific rates for age groups starting at ages 40 years 
and older.  There was no NHANES data to compare as ED only became a variable of interest 
for this national survey starting in 2000. 
Question #1b: What was the age-specific incidence of ED?  
The incidence rate directly estimates the probability of developing a disease within a 
specific period of time and is defined as the number of “new cases” per population at risk.  
These rates are used not only to determine the probability of developing a specific disease but 
also to determine /detect etiological factors.  
Calculation for Incidence rate per 1,000 was as follows: 
(Number of new cases of a disease occurring in a population during a specified period of time / 
Number of persons exposed to risk of developing the disease during that period of time ) x 
1,000. 
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The age-specific rates were computed by limiting the population at risk to a certain age 
category.  Ninety-five percent confidence intervals were calculated for these rates to determine 
if the number of cases were significant for that particular age group.  
The Kaplan-Meier survival analysis method was used to generate a table and plot of 
survival or hazard functions for ED history data (time to ED data) . This model was not used to 
assess the effects of the covariates on ED event.  It was used to provide descriptives for the 
time-to-ED event using the cycle time as the salient variable.  Since there were censored 
observations (e.g., participants who were lost to follow-up) within the EDC dataset, the Kaplan 
Meier estimation estimated survival functions when censoring occurred. .  The Kaplan-Meier 
curve is estimated by calculating the number of participants who do not have an ED event 
divided by the number of participants at risk.  Participants who have not reached that time 
point or who were censored were not counted in the at risk group.  The probability of surviving 
(not having ED) to any time point was then estimated from the cumulative probability of 
surviving (not developing ED) at each of the preceding cycle time points.  It should be noted 
that the precision of the Kaplan –Meier estimate was dependent on the number of total 
observations.     
Specific Aim #2: Determine baseline predictive risk factors for the development of ED  
Question #2a:Which baseline demographic factors (age,  income, marital status, level 
of education, smoking, alcohol intake), biologic factors [HbA1c,  age at diagnosis, duration of 
diabetes, E/I ratios, type and number of complications, systolic and diastolic blood pressure, 
lipid profile (HDL and nonHDL cholesterol ] lifestyle behaviors (smoking, alcohol intake), 
and, anti-hypertensive medication use predict prevalent and incident cases of ED? 
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Question #2b: Do baseline psychosocial factors [quality of life (modified DCCT-QOL 
Questionnaire)], and depression (Beck Depression Inventory)] predict ED? 
For both research questions, binary logistic regression analysis was used to investigate 
the relationship between the binary dependent variable, ED, and the independent explanatory 
variables or covariates.  As with, and in common with, standard linear regression, logistic 
regressions’ primary objective is to relate the probability of a response to a set of covariates 
(Rosner, 2000).  Since the outcome of interest, ED, was binary and the predictors tested for 
associations were both discrete and continuous it was necessary to use a modified regression 
technique to assess the probability of the male experiencing the ED outcome.  The outcome 
was expressed as a proportion, and the predictor variables were expressed as log-odd ratios.  A 
link was necessary to make the outcome linear.  Link is defined as a non-linear transformation 
applied to μ to enable the transformed probabilities to be related linearly to Xi,..  All continuous 
variables were evaluated to assure that they were linear in the logit.  This was completed by 
multiplying the natural log of the variable by the variable and then regressing this product on 
the outcome variable.  The variable was considered linear in the logit if the regression co-
efficient had a p-value >.05.   Statistically this was explained as the raw outcome, which is 
expressed as a proportion, was converted to a linear function with the logit link function of the 
form of:  
Logit(x) =ln [p(x)/1+p(x)] = β0 +β1x1+β2x2+… +βkxk 
Whereby, x is the vector of k predictor variables from the i-th participant.  The set of predictor 
variables for this analysis included; baseline demographic factors (age, income, marital status, 
level of education), biologic factors [HbA1c, age at diagnosis, duration of diabetes, E/I ratios, 
type and number of complications, systolic and diastolic blood pressure, lipid profile (HDL, 
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nonHDL)],  lifestyle behaviors (smoking and alcohol use) and antihypertensive medication use 
as well as the psychosocial variables (QOL, depression) given the predictors equals p(x) is the 
following: 
p(x)=exp(β0 + β1x1+ β2x2+… βkxk) / 1+ exp(β0 1 2 k)  + β1x + β2x …+ βkx
Calculation of the odds ratio for the outcome associated with the individual predictor 
variables was calculated by exponentiation of the regression co-efficients. Maximum likelihood 
estimation (MLE) was used to find the regression coefficients.  This was an iterative process 
that starts with arbitrary values of the co-efficients and  determines direction and size of change 
in the coefficients that maximize the likelihood of obtaining the observed 
frequencies(Tabachnick & Fidell, 2001).  It was necessary to use MLE in order to estimate the 
parameters associated with the predictor variables to make inferences about the parameters in 
the model.  The most parsimonious model was constructed to determine the predictor variables.  
A selection model with variable entry set at 0.15 and determination of the predictor variables 
set at 0.05 was used to determine the best fitting model.  Predictor variables were assessed for 
model fit by using the Wald Chi square statistic set at p-value less than or equal to 0.05.  Model 
improvement was determined by using the -2log likelihood (p-value less than or equal to 0.05).  
Goodness of fit of the model was assessed using the Hosmer-Lemeshow Test with a p-value 
greater than 0.05.  SAS (PROC LOGISTIC) was used as the statistical software for the logistic 
regression procedures with exact options since some of the predictor variables had SPARSE 
cells <5 (Hosmer & Lemeshow, 2000).  All models for SA #2a were adjusted for duration of 
diabetes whereas the models for SA#2b were adjusted for duration of diabetes and total 
complications.    
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Cox proportional hazards modeling, a method that describes how the hazard or risk 
changes over time, was used to show the prospective relationship of predictive variables to 
incident ED outcome.  All variables that were significant univariately, p-value set at less than 
or equal to 0.15, were then evaluated for their independent relationship to ED development in 
the multivariate model. 
Specific Aim #3: Determine the sequence of the development of ED to other markers 
of neuropathy, i.e., Cardiac Autonomic Neuropathy (CAN defined as an E/I ratio <1.1), 
Confirmed Distal Symmetrical Polyneuropathy (CDSP), and Symptomatic Autonomic 
Neuropathy (SAN) (excluding ED) using longitudinal data. 
Question# 3a: What was the sequence to the development of ED in relation to other 
markers of neuropathy, i.e., CAN, CDSP, and SAN? 
 Cox proportional hazards model was constructed for the longitudinal data with time 
dependent covariates.  The primary goal of this analysis was to determine if predictor variables 
the cycle preceding the ED event were independent predictors for incident ED.  
 Secondary Specific Aim: Determine behavioral and cognitive risk factors, as 
represented by self-management behavior, self-efficacy, perception of severity and knowledge 
associated with the development of ED using EDC longitudinal data.    
Question #1.: Did self-management behavior, self-efficacy, perceptions of severity and 
knowledge of diabetes predict ED? 
For this analysis, the longitudinal predictor covariates of self management, self-
efficacy, knowledge and perceptions of severity in their relationship to the outcome variable of 
ED and their time dependent manner were to be used; however the variables, knowledge, 
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perception of severity and self-efficacy were only collected at baseline.  The longitudinal 
assessement of these variables therefore  could not be completed.    
Question #2: Is self-management a mediator between cognitive variables (self-efficacy, 
perceptions of severity and knowledge) and ED? 
Path Analysis, an extension of multiple regression, was to be used for this longitudinal 
analysis.  However, the data was not available beyond baseline.  
Explanation of Path Analysis:  This analysis form would have been used to test the fit 
of the correlation matrix against two or more casual models which are used in the comparison.  
A regression would have been done for each variable in the model as dependent on others 
which the model indicates as causal.  The regression weights predicted by the model are 
compared with the observed correlation matrix for the variables and a goodness-of-fit statistic 
is calculated.  Path coefficients were used to assess the relative importance of various direct 
and indirect causal paths to the dependent variable.   There are several assumptions that need to 
be met for path analysis: 1) relationships among variables must be  linear , 2) there are no 
interaction effects, 3) Interval level data are needed for all variables, if regression is used to 
estimate the path parameters, 4) Residual variables, or unmeasured variables, are uncorrelated 
with any of the variables in the model other than the one they cause, 5) Disturbance terms are 
uncorrelated with the endogenous variables, 6) Low multicollinearity, 7) appropriate 
correlational input, i.e., Pearson correlation for two variable intervals, polychoric correlation 
for two ordinal variables, tetracholoric for two dichotomies and polyserial for an interval and 
an ordinal variable. To test for mediation, it is necessary to test the following three regression 
equations.  First, it is necessary to regress the mediator on the independent variable. Second, 
the dependent variable is regressed on the independent variable, and third, regression of the 
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dependent variable on both the independent variable and on the mediator. Path diagrams are 
used to show the models considered.  In this study, ED is the dependent variable, and self 
management behavior is the mediator variable.  Self-efficacy is the independent variable, as are 
knowledge and perceptions of severity.  The hypothesized path is a follows in Figure 3.1: 
 
 
 
            Figure 3.1: Mediation Model Path Diagram of Self-Management Behavior and  ED Outcome 
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Mediation variables account for the relation between the predictor and the criterion. 
The above Figure depicts the causal pathways to the outcome of ED, 1) the direct impact of the 
independent variable or path c, the impact of the mediator, path b and finally the impact of the 
independent variable to the mediator, path a.  A variable functions as mediator after meeting 
the following three conditions; 1) variation in levels of the independent variable significantly 
account for the variations in the presumed mediator ( path c), 2) variations in the mediator 
significantly account for variations in the dependent variable (path b) and 3) when paths a and 
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b are controlled, a previously significant relation between the independent and dependent 
variables is no longer significant  with the strongest demonstration of mediation occurring 
when path c is zero (Baron, 1986). 
Exploratory path analysis could not be completed  to examine the relationship between 
knowledge, perceptions of severity, self-efficacy, self management behaviors and ED. 
Criterion for examining the goodness of fit of the model would have  included a chi square 
probability greater than or equal to 0.05, with a Comparative Fit Index (CFI) or at least 0.90. 
(Norris, 2005: Steele, 2005). SPSS would have been used to run the analysis. 
Correlation statistics were generated for these behavioral and cognitive risk factors.  
Descriptive statistics were also generated for the baseline variables (self-management behavior, 
self-efficacy, perception of severity, and knowledge associated with prevalent ED. 
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4.0  MANUSCRIPT ONE 
4.1 ABSTRACT 
Objective: The purpose of this study was to examine the overall prevalence and incidence of 
ED self-reported in males with T1D during physician exams enrolled in the Pittsburgh 
Epidemiology of Diabetes Complication (EDC) study from 1986 to 2007 and determine 
significant baseline demographic, biologic, behavior lifestyle, anti-hypertensive medication 
usage, and, psychosocial risk factors for the prevalent and incident cases of ED. 
Methods: In a large population-based cohort study of type 1 diabetes, 333 males enrolled at 
baseline were followed biennally for a period of 21 years for ED development.  Two separate 
multivariate models, using logistic regression for the prevalence (Model 1) and Cox 
proportional hazard regression (Model 2) for the incidence, were constructed.  After 
controlling for duration of diabetes, Model 1 identified associated demographic, biologic, 
lifestyle behavior, use of anti-hypertensive medication use as risk factors, while Model 2 
identified only psychosocial risk factors.    
Results:  Mean age of the males at baseline with ED was 35.8 ± 5.3 years and mean duration 
of diabetes was 26.9±5.9years.  Prevalence rate was 10.4 %, with 31 males having ED at 
baseline. Males at baseline, with ED, had higher systolic and diastolic blood pressures, and had 
3.21 (95% C.I. 1.4-6.6, p=0.0021) and 3.8 (95% CI 1.45-9.96, p=0.0106) times the odds to 
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have hypertension and CAD, respectively, than those males without ED.  Males with prevalent 
ED did not statistically differ from males without ED in the baseline characteristics of 
metabolic control (HBA1), level of education, income, or the current use of ACE or lipid 
lowering medication.  However, males with prevalent ED had 6.27 (95% CI 2.12-10.18, 
p=.0210) times and 4.65 (95% CI 2.12-10.18, p=.0053) times the odds to have proliferative 
retinopathy and overt nephropathy respectively than those males without ED.  For the baseline 
logistic regression model, multivariate risk factors identified for Model 1 were CDSP and 
HDL.  There were no demographic or lifestyle behavior risk factors that remained in the 
model.  Use of anti-hypertensive medication was not a significant predictor.  The significant 
logistic regression independent predictor for Model 2 was the BDI depressive symptomatology 
score.  Fifty-four new cases of ED were reported.   Incidence was 17.78 % , with person time at 
risk equal to 2034 person years during the 18 years of follow-up.  Thus, the incident rate was 
2.60/ 100/year.  Mean age for the incident cases was 40.6 ± 5.9 (range 26.7-60.8) years while 
the mean duration of diabetes  was 32.54 ± 5.88 (range 20.9-51-9) years at diagnosis.  Mean 
systolic and diastolic blood pressures were 125. 2 ± 20.5 (range 88.0-191.0) mmHg and 75.57 
± 11.36 (range 49.0-108.0) mmHg respectively.  Mean HbA1 was 10.68 ± 2.19% for cases.  
The mean E/I ratio for these incident males was 1.14 ± 0.122 (range 1.0-1.55) and mean BDI 
depressive symptomatology total score was 9.5 ± 6.9 (range 0-32).  Ninety percent of the 
incidence cases were between 30 and 49 years of age. Multivariate predictors for Model 1 (Cox 
Proportional Hazard Regression) included CDSP, nonHDL cholesterol while significant Model 
2 (Cox proportional Hazard Regresssion) predictor was total BDI depressive symptomatology 
score.  
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4.2 INTRODUCTION 
An estimated 12.0 million (11.2%) men aged 20 years or older in the United States have 
diabetes (NIH, 2007).  Among the most prevalent long-term complications that may result 
from diabetes is erectile dysfunction (ED).  Males with type 1 diabetes (T1D) are twice as 
likely to develop ED than males without diabetes (Bacon et al., 2002; Bacon et al., 2003; 
http://www.diabetes.org/diabetes-statistics/complications.jsp, 2007; A  Vinik et al., 2003). 
The etiology of ED in men with T1D is multifactoral.  Once thought to be purely 
psychogenic in origin, it is now recognized that approximately 80% of all ED results from  
vascular, neuropathic , and /or endocrinological etiologies in males with diabetes (Blumentals 
et al., 2003; Dean & Lue, 2005; Garban et al., 1995; Saenz de Tejada et al., 2005). Biological 
risk factors of increasing age, longer duration of diabetes, poor metabolic control, associated 
chronic complications of diabetes including hypertension, dyslipidemia, cardiovascular 
disease, neuropathic disease, and depression have been confirmed by numerous studies 
(Burnett, 2006; Fedele, 1998; Klein et al., 2005).  Also previously reported  associated  risk 
factors for  ED development  include; demographic  factors of age, income, marital status, and 
level of education, psychosocial factors affecting quality of life (Burnett, 2006; DeBeradis et 
al., 2002) and lifestyle behavioral risk factors include smoking and alcohol ingestion ,(Burnett, 
2006; Close & Ryder, 1995; Enzlin, 2003; Fedele, 1998; Klein et al., 2005). 
Many of the same risk factors are shared by ED and cardiac disease development and 
progression in males with T1D.  Like ED, males with diabetes have a 2-fold increase in 
developing cardiac disease.  ED may be considered an important marker in the development 
and progression of cardiac and vascular disease (Kloner, 2008b).  Although it is known that 
males with diabetes have a higher incidence of coronary artery disease (CAD) than those 
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without diabetes, the risk is even greater for males with diabetes who have ED.  In a recently 
published study (Gazzaruso et al., 2008), males with type 2 diabetes were more likely to report 
ED four years before the development of a major adverse cardiac event (Gazzaruso et al., 
2008; Kloner, 2008b)  Moreover,  males with ED and T1D have an increase in the severity of 
coronary heart disease, as well as neuropathic disease (A Vinik & Erbas, 2001).  Thus an 
association between the onset of ED, CAD and neuropathy is well established.  
Those with ED and diabetes experience an earlier mortality than males in the general 
population without diabetes which may be isolated or coexist with other diabetic complications 
or peripheral neuropathies (A Vinik & Erbas, 2001). Since it is estimated that in the year 2025, 
there will be more than 322 million men worldwide with ED, it is necessary to develop 
preventive strategies in males likely to develop ED (DeBerardis  et al., 2007).  
Therefore, the purpose of this study was to examine ED self-reported in males during 
physician exams enrolled in the Pittsburgh Epidemiology of Diabetes Complication (EDC) 
study (1986-2007), a large population-based cohort study of type 1 diabetes.  The specific aims 
of this study were to: 1) determine both the age-specific prevalence and incidence of ED in the 
EDC population; and 2) determine significant baseline demographic, biologic, lifestyle 
behavior risk factors, anti-hypertensive medication and psychosocial risk factors associated 
with prevalent and incident ED.  Baseline demographic factors include: age, income, marital 
status, and level of education.  The baseline biologic factors include: HbA1c, age at diagnosis, 
duration of diabetes, E/I ratios, type and number of complications, systolic and diastolic blood 
pressure, lipid profile [High Density Lipoprotein (HDL) and non-HDL cholesterol]. Baseline 
lifestyle behavior risk factors include: smoking and alcohol intake.  Baseline Anti-hypertensive 
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medication use and baseline psychosocial risk factors include: quality of life and depressive 
symptomatology.   
4.3 RESEARCH DESIGN AND METHODS 
All insulin dependent diabetes mellitus patients seen at Children’s Hospital of Pittsburgh from 
January 1, 1950 to May 31, 1980 formed the sampling frame for inclusion in the EDC. 
Participants had to meet the following criteria: 1) onset of insulin dependent diabetes mellitus 
at age 17 years or less; 2) insulin therapy prescribed at discharge; 3) an initial diagnosis, or 
being seen within one year following diagnosis at Children’s Hospital of Pittsburgh; and 4) 
residence within 100 miles of Pittsburgh or 2.5 hours of driving distance from Pittsburgh.  
Recruitment and response rates for the EDC study have been detailed extensively in previous 
publications (Orchard et al., 1990).  Six hundred and fifty eight participants completed baseline 
examinations between 1986 and 1988.  
Of the 658 participants enrolled at baseline (1986) for participation in the Pittsburgh 
Epidemiology of Diabetes Complications Study, 643 were Caucasian and 15 were African 
American.  Thirteen of the African Americans were female participants and 2 were African 
American males.  This sample was epidemiologically representative of the Allegheny County 
population and the incidence of T1D for that time frame (LaPorte et al., 1986; Orchard et al., 
1990; Wagener, Sacks , LaPorte, & Macgregor 1982). 
Males composed 51% (n=333) of the total sample.  Age range for the males at baseline 
was from 8.5 years to 47.4 years.  The duration of diabetes varied: 13 % (n=44) had diabetes 
for less than 10 years, 40 %(n=136) had diabetes between 10 and 19 years, 35% (n=117) of the 
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participants had diabetes between 20 and 29 years and, 11 % (n=36) of the participants had 
diabetes for 30 years or more.  Overall mean for duration of diabetes for all males was 19.5 
years (s.d.± 7.6 years). 
Because ED is only present in males who have reached an age of sexual maturity, an 
additional inclusion criterion for the ED study was age greater than or equal to an age of 18 
years.  Thirty-two of the 333 males were less than 18 years of age and baseline ED status was 
missing for three participants, therefore, the assessment of prevalent ED was based on a sample 
size of 298 males.  As the 32 males reached 18 years of age they were entered into the risk set 
for the incidence analysis.  
At baseline and all subsequent biennial examinations, participants completed 
questionnaires and were assessed for potential risk factors and diabetes complication 
development.  Two weeks prior to their examination at the Diabetes Research Center at the 
University of Pittsburgh, participants were mailed self- report questionnaires that included a 
medical history, lifestyle questionnaire, assessment of depressive symptoms and containers 
with detailed instructions for 24 hour urine and overnight specimen collections that were to be 
brought to the research center the day of the examination (Orchard et al., 1990). Follow-up 
examinations were conducted every two years and were similar to the baseline examination. 
Data were then collected biennially, for a period of 10 years (1986-1998).  Cycle 1 through 
Cycle 6 exams took place over a 10-year period and included face-to-face clinic visits, physical 
assessments, laboratory testing and self report.  Collection of data continued after the ten year 
follow-up with annual surveys, and a full examination at 18 years (Cycle 10:2006-2008) using 
the above methods.   
  105
4.3.1 Measures 
ED was used as the outcome measure and was defined as a persistent inability to attain and 
maintain an erection adequate to permit satisfactory sexual performance not due to any other 
problem as measured by the examining physician while conducting the Diabetes Control and 
Complications Trial (DCCT) clinical neurological examination protocol.  ED was to be present 
for at least 30 days prior to the examination.  Trained physician investigators inquired about 
autonomic neuropathy symptoms that included questions relating to 1) postural hypotension, 2) 
gastroparesis, 3) diabetic diarrhea, 4) colonic atony, 5) sudomotor abnormality, 6) 
hypoglycemic unawareness, and 7) genitourinary autonomic neuropathy symptoms.  ED was a 
“yes or no” determination after genitourinary system review by the examining physician.  
Prevalent cases of ED were those males reporting ED at baseline exam (1986-1988) while 
incident cases of ED were those males who were negative for ED at baseline but developed ED 
during a follow-up cycle (1989-2007).  The cycle in which the participant first reported ED 
following baseline examination was considered the incident cycle for ED. 
4.3.1.1  Demographic Measures 
Age was verified and recorded as age in complete years calculated from the participant’s self-
reported date of birth in month, day, and year. Income, marital status and level of education 
were all self-reported by the participant on the EDC Lifestyles Questionnaire.  Income was 
chosen from 1 of 3 income categories from; 1) $5,000/year to < $15,000, 2) $15,000 to 
<$30,000 and 3) >$30,000/year.  Marital Status was measured categorically as follows:  1) 
never married, 2) married, 3) separated, 4) divorced, 5) widowed, 6) not married, or living with 
parent.  Highest level of formal education response was chosen from a list of categorical 
  106
response list that included: 1) some high school or high school graduate, 2) some college or 
received bachelor’s degree, or 3) graduate education beyond bachelor’s degree. 
 
4.3.1.2  Biologic Measures 
Fasting blood samples were used to measure lipids, and HbA1/HbA1c.  For the first 18 months 
of the EDC, HbA1 was determined by using saline-incubated blood and microcolumn cation 
exchange chromatography (Iso-Lab).  Following the remainder of the 10-year follow-up 
period, HbA1 was measured by an automated high performance liquid chromatography method 
(BioRad, Diamat).  These two methods were found to be almost identical (r=.95). HbA1’s were 
converted to DCCT aligned HbA1c’s for data analysis.  The following conversion formula was 
applied to the first 10 years of HbA1 samples; DCCT HbA1=(0.83xEDC HbA1) + 0.14, while 
to the second 10 year EDC HbA1c samples the following conversion formula was applied; 
DCCT HbA1c=(EDC HbA1c-1.13)/0.81)(Prince et al., 2007).  Normal range for Hba1 was 
considered to be <7.3. %.  Duration of diabetes was calculated from age at diagnosis recorded 
at baseline and at each biennial visit.  Selected and trained research study staff completed the 
measurement procedure for the Expiration/Inspiration (E/I) ratio test.  The E/I ratio, an 
autonomic nervous system function test, was measured with the participant in a supine 
position, limb ECG leads were attached and a lead II rhythm tracing recorded.  The participant 
was then instructed to inhale deeply for 5 seconds followed by a forced expiration for 5 
seconds and to continue this process of deep inspiration and forced expiration every 5 seconds 
for a total of 2 minutes.  The participant was prompted by the examiner for determination of 
the 5 second intervals and at each prompt the ECG was marked.  Both the shortest R-R interval 
of each inspiration segment and the longest R-R interval of each expiration segment were 
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measured in milliseconds.  The E/I ratio was then calculated using the sum of six of the 
expiration (EXP) and inspiration (INP) R-R intervals using the following formula; sum of (R-
R) EXP/ sum of (R-R) INP.  Values < 1.1 were considered indicative of autonomic neuropathy  
(Stella et al., 2000).  There were 10 complications assessed for this analysis. Number of 
complications was a summation score calculated using the following: CAD, CDSP, LEAD, 
nephropathy and retinopathy.  Score range was from 0-5 with the higher number indicating 
more complications. Hypertension was assessed separately.  AN and SAN were not included in 
the total number of complications because measurement at baseline was available for only 27% 
of the male participants (84 without ED and 8 with ED).   Type of complications were 
measured as follows; 1) autonomic neuropathy (AN) (confirmatory was an E/I ratio < 1.1 while 
an E/I ratio > 1.1 was considered negative for AN), 2) Confirmed Symptomatic Autonomic 
Neuropathy (SAN), an average E/I Ratio of <1.1 and 2 or more of the other autonomic 
symptoms as determined by the examining physician using the DCCT neuropathy protocol, 3) 
Distal Symmetrical Polyneuropathy (DSP) using the DCCT protocol  the examining physician 
documented clinically evident diabetic peripheral neuropathy  with  at least 2 of the following 
symptoms consistent with DSP; abnormal sensory exam consistent with DSP, or decreased or 
absent deep tendon reflexes,  4)  Confirmed distal symmetrical polyneuropathy (CDSP) was 
clinically evident diabetic peripheral neuropathy  consistent with DSP confirmed by 
physician’s exam  and vibratory threshold of >2.39 for ages < 36 years, >2.56 for ages 35-50 
years, or >2.89 for ages > 50 years  5)  Resting ankle and arm blood pressure readings, using a 
Doppler Flow Detector, and the participant in the supine position, were used to determine the 
presence of lower extremity arterial disease (LEAD).  Ankle-brachial pressures were calculated 
using the arm pressure taken closest in time to the ankle pressure.  Any participant with an 
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ankle-brachial index (AB) of <0.8 for any of the four vessels or a history of claudication or of 
amputation for vascular reasons was considered positive for LEAD, 6) Overt nephropathy 
(ON) was an albumin excretion rate >200micrograms/min in multiple timed urine specimens, 
renal dialysis or a kidney transplant.  Data for ON were coded none (0), or  overt or renal 
failure (1), 7) Coronary artery disease (CAD) documented as positive if  the participant had a 
history of MI (confirmed by ECG-Q-waves or hospital records, using standardized criteria), 
coronary arterial occlusion (>=50% occlusion by angiography, myocardial infarction 
(Minnesota codes 1.1, 1.2), ischemic ECG (Minnesota codes 1.3, 4.1-4.3, 5.1-5.3 or 7.1) or 
revascularization at the 10 year-examination, or diagnosis of angina by the EDC study 
physician during any cycle (Prince et al., 2007) ), 8) Cerebral Vascular Disease (CBVD) was 
positive if there was a history of a stroke, 9) retinopathy was determined from fundus 
photography and measured as none (0), retinopathy and/or laser treatment of retinopathy (1), 
10).  Hypertension was defined as a blood pressure greater than 140/90 mmHg or on anti-
hypertensive medication. Systolic and Diastolic blood pressure was measured per 
Hypertension Detection and Follow-up Protocol using a random zero sphygmomanometer.  
Mean of the second and third blood pressure readings were used and entered as a continuous 
variable for systolic and diastolic pressures separately.  Participants were asked to self-report 
medication used for hypertension.  To qualify as a anti-hypertensive medication the medication 
had to be used to treat hypertension in the participant   Use of Angiotensin II receptor blockers 
(ACE-MED) as well as lipid lowering medication  were also separately self-reported by the 
participant using the EDC Medical History Form.  The lipid profiles were measurements for 
HDL and nonHDL cholesterol.  HDL was determined by means of precipitation (heparin-
manganese chloride method) (Warnick & Albers, 1978). Triglycerides (Bucolo & David, 1973) 
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as well as plasma cholesterol were measured enzymatically (Allain et al., 1974).  Low density 
lipoproteins (LDL) were determined from measurements of the total cholesterol, triglycerides, 
and HDL measurements using the Friedewald formula (Friedewald et al., 1972).  For this 
analysis, non-HDL cholesterol was calculated as Total cholesterol minus HDL. 
4.3.1.3  Lifestyle Behavioral Factors 
Smoking status was in response to “Have you ever smoked at least 100 cigarettes in your 
lifetime?”  Total alcohol was self-reported by the participant.  The following question was 
asked “How often do you drink the following beverages (Beer-12oz, wine-4oz, mixed 
drinks/liquor )? and how much of each beverage do you usually drink on a weekly basis?”  
Both of these measures were part of the self-reported survey questions from the EDC General 
Medical History Questionnaire.  This questionnaire was also mailed two weeks prior to the 
scheduled EDC for review at the time of the scheduled visit.  In addition to the total number of 
alcoholic beverages per week, total alcohol was categorized into the following; no average 
weekly intake of alcoholic beverages (0), 1-3 drinks per day (1), or greater than 3 drinks per 
day (2). 
4.3.1.4 Psychosocial Measures 
Depressive symptomatology was measured by the Beck Depression Inventory (BDI-II).  High 
scores (ranging from 29 to 63) were suggestive of severe depressive symptomatology. Scores 
ranging from 20 to 28 indicated moderate depressive symptomatology whereas scores ranging 
from 14 to 19 indicated mild depressive symptomatology.  Those with total scores between 0 
and 13 were considered to be without clinical depressive symptomatology (Beck, 1961).  The 
BDI-II was part of the EDC Lifestyle Questionnaire.  Participants were mailed this 
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questionnaire two weeks prior to their EDC visit and returned the survey at the time of their 
EDC clinical examination.    
Also by self-report, on the EDC Lifestyle Questionnaire quality of life was assessed by 
a modified version of Diabetes Control and Complications Trial Quality Of Life (DCCT-QOL) 
instrument.  The DCCT-QOL was developed for use in the Diabetes Control and 
Complications Trial (DCCT) to compare the relative personal burden for participation in either 
the intense treatment group or standard care group for diabetes management.  It was divided 
into four domains that included the following domains; impact (20 questions), worry: 
social/vocational (7 questions), worry: diabetes related (4 questions) and satisfaction (15 
questions) (Group, 1988).  Responses to questions within each of these domains were made 
with a 5- point Likert scale. Impact and worry scales were from 1 (no impact and never 
worried) to 5 (always impacted and always worried). Impact total scores ranged from 14-70. 
Worry total score ranged from 11-66. The higher scores indicating more impact and worry.    
Satisfaction was surveyed using 3 general questions: one question responses were very 
satisfied, fairly satisfied, or, not very satisfied.  Scores for this question ranged from “very 
satisfied "(1) to "not very satisfied"(3).  The other 2 questions, questions of comparison for 
general health compared to other persons their age with and without diabetes, were scored 
using a Likert scale from 1 (excellent health) to 4 (poor health).  Total score range for 
satisfaction was from 3-11, the higher score indicating less satisfaction. Total m DCCT-QOL 
scores ranged from 28-147, higher scores indicating more impact and worry from diabetes and 
less satisfaction with the quality of life.  In addition to the total mDCCT-QOL score and the 
domain scores there was one question within the impact domain that was reviewed separately 
for this study.  This question “How often does your diabetes interfere with your sex life” was 
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answered on a Likert scale from 1-5, 1 being never to 5 being all the time.  Scores for this 
question ranged from 1-5, higher score indicating more interference. 
 
 
4.3.2 Statistical Analysis 
Analysis was performed using SAS (Version 9.1.3 SAS Institute Inc., Cary, NC).  All data 
were verified after an extensive detailed exploratory analysis to assess missing values and 
outliers.  Descriptive statistics were generated for the continuous variables and normality was 
determined for each of these variables.  For normally distributed variables the Student’s t-test 
was used to assess case and control differences while for those non-normally distributed 
variables the Kruskal-Wallis Test were used.  Chi-square test for binomial proportions was 
used to test differences for the categorical variables.  Tests for trend were completed using the 
Cochran Armitage test for trend. P-value was set at 0.05 to indicate statistical significance.  
Logistic regression was used to determine prevalent predictor variables for the prevalent model 
controlling for duration of diabetes, while Cox proportional hazards regression was used to 
examine the independent association between time to ED incidence and the baseline predictor 
variables. The logistic regression model for the psychosocial variables was adjusted by 
duration of diabetes and total number of complications.  Stepwise selection was used for Model 
determination.  The Wald chi-square test statistic was used to test each of the predictor 
variables and variables were selected if p< 0.05.   Age-specific prevalence rates were 
calculated from total sample of males within the specific age category and confidence intervals 
were calculated for each age-specific group.  Incident cases were defined as a case when first 
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documented by the examining physician.  Cumulative Incidence Rates were calculated by 
Kaplan-Meier method.  Incidence density was calculated by dividing the number of 
participants developing a first event by the person years of observation for those at risk during 
the study. One multivariate outlier was identified in the dataset and was subsequently deleted 
from the analysis; therefore, the total number of males enrolled at baseline and used for this 
analysis totaled 332.    
4.4 RESULTS 
4.4.1 Baseline Characteristics of Males Enrolled in the EDC 
One multivariate outlier was identified in the dataset and was subsequently deleted from the 
analysis; therefore, the total number of males enrolled at baseline and used for this analysis 
was 332.  The following characteristics of all males enrolled in the EDC at baseline (N=332) 
included: mean age 27.53 ± 7.78 years (range 8.47-47.43 years), duration of diabetes 
19.55±7.46 years, systolic blood pressure 117.49 ± 17.14 mmHg, diastolic blood pressure 
75.52 ± 11.20 mmHg, mean glycosylated hemoglobin 8.74 ± 1.45%, BMI 23.59 ± 3.1 kg/m2 , 
high density lipoprotein 48.61 ± 9.73 mg/dl, and  non-HDL cholesterol 140.69 ± 44.56 mg/dl.  
(Refer to Table 4.1). 
Prevalence: Of the 332 male participants enrolled in the EDC, 32 (9. 6%) were 
eliminated from the baseline analysis due to age less than 18 years, and 3 (0.9%) had missing 
ED status data.  Thirty-one male participants (10.4%) were identified as prevalent ED cases. 
The prevalence of ED rose from 2% in those 18-29 years of age to 42% in those 40-45 years of 
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age (test of trend p < .05) and this relationship is graphically shown in Figure 1. Sixty-one 
percent of the total ED cases (19/31) occurred in the males with ages between 30 and 39 years.  
Refer to Table 4.1 and Figure 4.1 
 
 
 
             Table 4.1  Age specific Prevalence Rates for Males Enrolled in the EDC at Baseline (1986-1988) 
Age ED+ Number of males withi
age-group 
% within age 
group with ED 
95% Confidence 
Interval 
18-29 years 4 172 2 (0.08-4.58) 
30-39 years 19 107 18 (10.52-25.00) 
40-45 years 8 19 42 (19.9-64.31) 
Total 31 298 10.4 (6.93-13.87) 
 
 
 
With increasing duration of diabetes, the prevalence of ED also rose.  Nineteen percent 
of the cases (n=6) occurred with a diabetes duration between 10 and 20 years, with the first 
case being reported after 10.7 years diabetes duration.  Sixteen percent of the ED cases (n=5) 
occurred after 21-25 years of diabetes duration, 35% (n=11) occurred after 26-30 years 
duration while 29% (n=9) of the cases occurred after 31-37 years duration.  
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Figure 4.1:The relationship of age to ED prevalence by baseline EDC exam (1986-1988) 
 
Mean age of the males with ED was 35.8 ± 5.3 years and mean duration of diabetes was 
26.9±5.9years. Cases were significantly different from those without ED for baseline 
characteristics of age, duration of diabetes, systolic blood pressure, diastolic blood pressure, 
BDI score, BMI, marital status, CAD and hypertensive status.  Males with ED were older, had 
a longer duration of diabetes, had higher systolic and diastolic blood pressures, and had 3.21 
(95% C.I. 1.4-6.6, p=0.0021) and 3.8 (95% CI 1.45-9.96, p=0.0106) times the odds to have 
hypertension and CAD respectively, than those males without ED.  Males with ED did not 
significantly differ from males without ED in the baseline characteristics of metabolic control 
(HBA1), level of education, income, or the current use of ace or lipid lowering medication.  
(Refer to Table 4.2.  However, males with ED had 6.27 (95% CI 2.12-10.18) times and 4.65 
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(95% CI 2.12-10.18,) times the odds to have proliferative retinopathy and overt nephropathy 
respectively than those males without ED.  
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Table 4.2 Baseline Characteristics of the all EDC male participants (N=332) 
 Total  
(N=332) 
Without ED  
(n=266) 
With ED(+) 
(n=31) 
*p value 
 
Age (m±sd) years 
27.53±7.78 
Range: 8.47-47.43 
28.2 (± 6.4 ) 
Range: 18.01-47.43
35.8 (±5.3) 
Range: 22.9-44.88 
* p<0.0001 
 
Duration(m±sd) 
years 
19.55±7.46 
Range: 7.69-37.40 
19.9  (± 6.8) 
Range: 8.1-37.4  
26.9 (±5.9) 
Range:10.07-35.91 
*p<0.0001 
 
Age at onset of 
diabetes (m±sd) 
years 
8.34 ± 4.17 
 
8.27 ± 8.3 
Range:0.79-15.56 
 
8.92 ± 3.7 
Range: 1.63-15.58 
 
p>0.05 
 
DCCT 
HbA1c(m±sd) % 
 
  
8.74 ±1.45 
 
 
8.72 (±1.41) 
Range:6.19-13.58 
n=265 
 
8.94 (±1.77) 
Range:5.28-12.09 
n=30 
 
p=0.427 
 
SBP(m±sd) mmHg 
117.49±17.14 
Range: 76-234 
117.9 (±16.7) 
Range: 92-234 
126.4 (± 22.2) 
Range:76-188 
 
*p=0.007 
 
DBP(m±sd) mmHg 
 
75.52±11.20 
Range: 44-118 
77.9 (± 10.8) 
Range:45-118 
79.8 (± 12.2) 
Range:49-102 
*p =0.033 
 
BMI(m±sd) 
23.59±3.1 
Range: 13.87-33.12 
24.1 (± 2.8) 
Range: 17.32-33.12
n=265 
22.9 (± 2.2) 
Range: 19.4-26.4 
*p=0.03 
 
WHR(m±sd) 
0.87±0.053 
Range: 0.75-1.1 
0.88 (± 0.05) 
Range: 0.75-1.10 
0.89 (±0.04) 
Range: 0.81-0.99 
 
*p=0.011 
MARITAL 
STATUS (n,% total) 
1=never married 
2=married 
3=separated  
4=divorced 
5=widowed 
6=not married, 
living with partner 
 
 
175 (52.55) 
131 (39.34) 
2 (0.6) 
18 (5.41) 
0 
7 (2.10) 
 
 
 
138 (46.3%) 
109 (36.6%)= 
1 (0.34%) 
13 (4.4%) 
0 
6 (2.01%) 
 
 
5 (16.13) 
20 (64.52) 
1 (3.23) 
0 (0.00) 
5 (16.13) 
0 (0.00) 
 
 
 
*p<.0.0001 
 
LEVEL OF 
EDUCATION (n,% 
total) 
1= SomeHS/HS  
graduate 
2=Some College 
3=Graduate 
 
 
 
118 (39.46) 
154 (51.51) 
27 (9.03) 
 
 
 
 
100 (38.03%) 
139 (52.85) 
24 (9.13) 
 
 
 
 
 
13 (43.33) 
14 (46.66) 
3 (10) 
 
 
 
 
 
p=0.37 
 
 
INCOME (% total) 
1=<$5,000-$15,000 
2=$15,000-$30,000 
3= >$30,000 
 
 
 
1=26.12 
2=38.05 
3=35.82 
 
 
57 (23.7%) 
80 (33.3%) 
77 (32%) 
 
 
 
 
6 (2.5%) 
11 (4.6%) 
10 (4.2%) 
 
 
 
 
p=0.59 
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Table 4.2 continued 
Smoking 
Ever(n,% total) 
no 
yes 
 
 
190(59.01) 
132(40.99) 
 
 
 
152 (58.91) 
106 (41.09). 
 
 
10 (32.26) 
21 (67.74 
 
 
p=.007 
Smoking Now( 
n.% total) 
no 
1es 
 
 
 
50(40) 
75(60) 
 
 
 
41 (40.59) 
1=60 (59.41) 
 
 
 
6 (30 ) 
14 (70) 
 
 
p=.46 
Total alcohol 
(Average /wk) 
6.17 ± 11.1 
Range:0-53 
5.66 ± 8.04 
Range: 0-42 
10.55 ± 25. 6 
Range: 0-53 
 
p=0.33 
HDL 48.61 ± 9.73 
 
49 ± 9.7 
n=263 
44 ± 9.6 
n=30 
 
*p=0.006 
Non-HDL 
Cholesterol 
 
 
 
140. 69 ± 44.56 
 
142 ± 25 
n=263 
 
166.67 ± 47.39 
n=30 
 
*p=0.028 
CAD (n, % total) 
no 
 yes 
 
 
305 (91.59) 
28 (8.41) 
 
248 (92.88) 
19 (7.12) 
 
 
24 (77.42) 
7 (22.58) 
 
*p=.0106 (Fisher 
Exact) 
+AN ( n, % total) 
no 
yes 
 
60(65.22) 
32(34.78) 
n=92 
 
57 (67.86) 
27 (32.14) 
n=84 
 
3 (37.5) 
5 (62.5) 
n=8 
 
p=.12 (Fisher 
Exact) 
+Symptomatic 
Autonomic 
Neuropathy (n, % 
Total) 
no 
yes 
 
 
 
 
83 (90.22) 
9 ( 9.78) 
 
 
 
 
79 (94.04) 
5 (5.95) 
 
 
 
 
4 (50) 
4 (50) 
 
 
 
p=.0026(Fisher 
Exact) 
Hypertensive 
(n,% total) 
no 
yes 
 
 
268(80.72) 
 64(19.28) 
 
 
215 (80.83) 
51 (19.17) 
n=266 
 
 
18 (58.06) 
13 (41.94) 
n=31 
 
 
*p=.0092 
Overt 
Nephropathy (n, 
% total) 
no 
yes 
 
 
 
238 (71.47) 
95 (28.52 
 
 
192 (71.91) 
75 (28.09) 
 
11 (35.46) 
20 (64.52) 
 
 
p< .0001 
Lower Extremity 
Arterial Disease 
(n, % total) 
no 
yes 
 
 
 
 
308( 93.05) 
23 (6.95) 
 
 
 
250 (93.63) 
17 (6.37) 
 
 
 
25 (80.65) 
6 (19.35.) 
 
 
p=0.0217 
Proliferative 
Retinopathy 
no 
yes 
 
 
219 (67.18) 
107 (32.82) 
 
 
181 (68.56) 
 83 (31.44) 
 
 
8 (25.81) 
23 (74.19) 
 
 
p<.0001 
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 Table 4.2 continued 
Cerebral vascular 
Disease (n, % total) 
no 
es 
 
 
331 (99.4) 
1 (0.3) 
 
 
265 (99.62) 
1 (0.38) 
 
 
31(100) 
0 (0) 
 
 
p=1 (Fisher 
exact) 
Confirmed Distal 
Symmetrical 
Polyneuropathy 
no 
yes 
 
 
 
230 (69.27) 
102 (30.73) 
 
 
 
 
192 (71.91) 
75 (28.09) 
 
 
 
 
5 (16.13) 
26 (83.87) 
 
 
 
p<.0001 
(Fisher Exact) 
Distal Symmetrical 
Polyneuropathy 
no 
yes 
 
 
 
227 (68.37) 
105 (31.63) 
 
 
189 (70.79) 
78 (29.21) 
 
 
5 (16.13) 
26 (83.87) 
 
 
p<.0001 
(Fisher Exact) 
Total Complications 1.18 ± 1.35 
 
1.01(14.64 have 3 
or more 
complications) 
2.56(  58% with 3 or 
more complications) 
p<.0001(test for 
trend) 
Ace Medication (n, 
% total) 
no 
yes 
 
 
 
307 ( 96.54) 
11 (3.46) 
 
 
247 (96.86) 
8 (3.14) 
n=255 
 
 
27 (90.) 
3 (10) 
n=30 
 
 
p=0.0972 (Fisher 
Exact) 
Lipid Medication (n, 
% total) 
no 
yes 
 
 
 
317 (99.37) 
2 ( 0.63) 
 
 
255 (99.61) 
1 (0.39) 
 
 
 
29 (96.67) 
1 (3.33) 
 
 
p=.1991(Fisher 
Exact) 
Blood Pressure 
Medication 
no 
yes 
 
 
257 (90.49) 
27 (9.51) 
 
 
233 (91.73) 
21 (8.27) 
 
 
24 (80) 
6 (20) 
 
 
p=.0496 (Fisher 
Exact) 
QOL(m ± sd) 
 
52.72 ± 12.19 
Range: 33-129 
52.2 ± 12.1 
Range:33-129 
57.4 ± 11.5 
Range: 36-81 
*p=0.007 
Impact (m ± sd) 
 
30.00 ± 6.75 
Range: 19-53 
29.44 ± 6.1 
Range: 19-52 
34.72 ± 7.94 
Range:23-53 
*p=0.0003 
Worry(m ± sd) 16.41± 6.42 
Range:1-44 
16.55 ± 6.5 
Range: 1-44 
15.3 ± 5.78 
Range:6-25 
 
p=0.44 
Satisfaction(m ± sd) 5.99 ± 1.96 
Range: 3-11 
5.83 ± 1.93 
Range: 3-11 
7.37 ± 1.65 
Range: 4-10 
 
*p<0.0001 
Sex Question (m ± 
sd) 
1.72 ± 1.10 
Range: 1-5 
1.54 ± 0.78 
Range: 1-5 
3.3 ± 1.4 
Range: 1-5 
 
*p<0.0001 
BECK(mean±standard 
deviation) 
6.2±6.20 
Range:0-32 
5.8 (± 5.7) 
Range: 0-30 
n=232 
10.6 (± 8.4) 
Range: 0-32 
n=27 
*p=0.003 
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Men with ED had 3.15 times the odds to report ever smoking (95% CI 1.43-6.95, 
p=.007), 1.6 times to report current smoking (95% CI 0.57-4.51, p=.46) and consume more 
alcoholic drinks per week than those males without ED.  Mean BDI score (10.6 (± 8.4) 
p=.0003), although not suggestive of depressive symptomatology, and total QOL score (57.4 
± 11.5 p=.007) were higher in males with ED.  More impact (p=.0003) from diabetes and 
more interference as a result of diabetes on their sex life (p<.0001) were also reported in the 
males with ED.  HDL and nonHDL cholesterol was significantly different between those 
with ED and those without ED.  Males with ED had lower mean HDL (44 ± 9.6, p=.006) and 
higher nonHDL (166.67 ± 47.39, p=.028) cholesterol.  
Those factors found to be related to ED univariately included: duration of diabetes, 
systolic and diastolic blood pressure, BMI, HDL, nonHDL cholesterol, HbA1 (DCCT 
adjusted), hypertension, CDSP, LEAD, CAD, retinopathy, nephropathy, smoking ever, 
marital status, ace medication, lipid medication and blood pressure medication.  Those 
variables not showing univariate significance included level of income, age of onset of 
diabetes, level of education, and total alcohol.  After controlling for duration of diabetes, 
Model 1[ED (-) n=246, ED (+) n=29] had CDSP and HDL cholesterol as the predictor 
variables for ED (Hosmer and Lemeshow Goodness of Fit Chi-Square= 10.2868, df=8, 
p=.2455). Model 2[ED(-) n=231, ED(+) n = 27), adjusted for duration of diabetes and total 
complications, resulted in the model with  total BDI score as the predictor variable( Hosmer 
and Lemeshow goodness of fit Chi-Square=5.9491, df=8, p=.6529).  By Cycle 10 (2004), 70 
males had died; 15 (21.4%) were prevalent cases.  Log-rank test for equality (15 males with 
prevalent ED vs. 55 males without ED of all males who died) over the strata, shows that 
these two curves were different, log-rank Chi square=15.0830, df=1, p=.0001. 
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4.4.2 Incident Characteristics of Males with ED  
In Cycles 2 through 6 and Cycle 10 there were 54 new cases identified for ED (refer to Table 
4.3).  The incidence analysis was based on 53 cases.  There were no incident cases identified 
in Cycle 7 and 2 cases identified in Cycle 8.  Because these two cycles were sub-studies 
within the EDC and did not include all participants enrolled, they were not included in this 
analysis.    Mean follow-up time in years for the 181 males who never developed ED was 9.8 
years whereas mean follow up time for the males with incident ED was 10.9 years.  Follow-
up time was calculated by summing only those years in which ED data was documented, 
thereby accounting for missing cycles not seen.  After bivariate analysis,for time of the ED 
event  mean age for the incident cases was 40.61± 5.9 (range 26.7-60.8) years (Refer to Table 
4.4) while the  mean duration of diabetes was 32.54 ± 5.88 (range 20.9-51-9) years (Refer to 
Table 4.5).  Mean systolic and diastolic blood pressures were 125.29 ± 20.56 (range 88.0-
191.0) mmHg and 75.57 ± 11.36 (range 49.0-108.0) mmHg, respectively.  Mean HbA1 was 
10.68 ± 2.19%.  The mean E/I ratio for these incident males was 1.14 ± 0.122 (range 1.0-
1.55) and mean BDI total score was 9.5 ± 6.9 (range 0-32).  Refer to Table 4.6.  Crude 
incidence rate for this cohort was 17.78% [53 (number of new cases developing ED over 16 
years follow-up)/298 (number at risk from baseline without ED)] and person time at risk was 
2034 person years.  The incident rate was 2.60/ 100/year.  By Cycle 10, cumulative hazard 
was 0.561 (Refer to Table 4.7).  Ninety percent of the incidence cases were between 30 and 
49 years of age.  Refer to Table 4.4 and Figure 4.2. 
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Table 4.3 New ED Cases by Cycle 2 thru 6(1988-1998) and Cycle 10 (2004-2007) 
cycle 2 
 
3 
 
4 
 
5 
 
6 
 
10 
 
 1988-1990 
n=251 
1990-1992
n=225 
1992-1994
n=205 
1994-1996
n=176 
1996-1998 
n=205 
2004-2007 
n=67 
Number
of new 
ED 
cases 
 
6 (11%) 
 
6 (11%) 
 
10 (19%)(
 
9 (17%) 
 
14 (27%) 
  
  8 (15%) 
 
 
            Table 4.4 Age distribution of the 53 Incidence Cases at time of ED event 
 n % total 
 
20-29 years of age 
2 3.7 
30-39 years of age 21 38.9 
40-49 years of age 27 51.8 
50-59 years of age 2 3.7 
60 + years of age 1 1.9 
total 53 100 
 
The males were 2 times more likely to have developed ED after duration of diabetes 
longer than 30.1 years. (Refer to Table 4.5)  
 
                              Table 4.5 Duration Distribution of the Incident Cases 
Duration 
(Years) 
n % of total 
20-25 8 14.8 
25.1-30 10 18.5 
30.1-35 18 33.3 
35.1-40 14 25.9 
40 + 4 7.5 
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 At the time of the ED event, only 38 % of the incident cases documented taking an 
ACE medication while 4.4 % noted taking a lipid lowering medication.  Males who were 
married were more likely to report ED (67.92%, n= 36) than those males who were never 
married (20.75%, n=11).  Seventy three percent had some college through a professional 
degree (n=38) while almost half of the males reported a yearly income greater than $30,000.  
Incident ED was associated with positive history of confirmed distal symmetrical 
polyneuropathy (64.10%, n=25), and proliferative retinopathy (73.58%, n=39). (Refer to 
Table4.6)  Approximately 50% (n=23) were hypertensive.  In the multivariate analysis, 
controlling for duration of diabetes, the significant variables of the  demographic, biologic 
and lifestyle behavior variables entered  associated with ED incidence were confirmed distal 
symmetrical polyneuropathy and nonHDL cholesterol.  From the multivariate model with the 
psychosocial variables, after controlling for duration of diabetes and for number of 
complications was the total BDI score. Refer to Tables 4.6 and Table 4.8 and Table 4.9).  
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    Table 4.6 Characteristics of the 53 Incident Cases  at time of ED event (1988-2007) 
Age (m±sd) years 40 ± 5.96 Range: 26.27-60.90 
 
Duration of Diabetes (m±sd) 
       years 
32.54 ± 5.94 Range: 20.9-51.90 
Marital Status:  
 
69.23 % n=36  married  
Level of Education 74.5% n=38 college/ graduate / 
professional) 
Income  38% (n=19) annual income < $30,000 
HbA1 10.68 (m±sd) 2.19 Range:7.4-17 
Systolic Blood Pressure 125 (m±sd) 20.71 Range: 88-191 
Diastolic Blood Pressure 76.10 (m±sd) 10.82 Range: 52-108 
E/I Ratio 1.138 (m±sd) .123 Range: 1-1.545 
CDSP 63.16% n=24 
Proliferative Retinopathy 73.08% n=38 
Overt Nephropathy 45.28% n=24 
Hypertension 48.89% n=22 
Taking Ace Medication 38.46% n=20 
Taking Lipid Medication 4.55% n=2 
BECK 9.34 (m±sd) 6.95 Range: 0-32 
Age Categories (years) <30 years    n=2 (4%) 
31-40 years n=21 (40%) 
41-50 years n=27 (50%) 
51-61 years  n=3 (6%) 
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 Figure 4.2 Kaplan Meier  53 Incident Cases by Cycle 
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                            Table 4.7 Kaplan-Meier Table 53 Incident cases by Cycle 
Cycle # at Risk #of Events Survival 
Probability 
Standard 
Error 
95% CI 
(Survival 
probabilit
y) 
2     263       6        .977      .0092 .959-.995
3    232       6        .952      .0136 .926-.979
4    210      10        .907      .0190 .87-.945 
5    185       9        .862      .0231 .818-.909
6    165      14        .789      .0282 .736-.847
          10    18        8        .439      .0938 .288-.667
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          Table 4.8 Cox proportional Hazards (Relative Risk) for all baseline risk factors 
Variable Parameter 
Estimate 
Standard 
Error 
p-value Hazard Ratio 95% CI 
HbA1 % .1675 .0987 .0897 1.182 .974-1.435 
Duration of 
Diabetes years 
.1039 .0185 <.0001 1.109 1.07-1.150 
Age years 
 
.1138 .0203 <.001 1.121 1.077-1.166 
Systolic  Blood  
Pressure mmHg 
.1078 .0091 .0513 1.018 1-1.036 
Diastolic 
 Blood  
Pressure mmHg 
.0362 .01349 .0073 1.037 1.01-1.065 
BMI -.0014 .0042 .7391 .999 .99-1.007 
BDI -.01738 .00701 .0131 .983 .969-.996 
Height (cm) .01032 .01768 .5595 1.01 .976-1.041 
Weight (kgms) .02471 .01165 .0338 1.025 1.002-1.049 
Total Alcohol -.02390 .02601 .3581 .976 .928-1.027 
Total Insulin 
Units 
-.00282 .00247 .2529 .997 .992-1.002 
Total Cholesterol .01247 .0028 <.001 1.03 1.007-1.008 
Triglycerides 
<130 
>130 
 
 
.47636 
 
.2963 
 
.1079 
 
1.610 
 
.901-2.878 
HDL 
>45 
<45 
.52734 .38653 .125 1.694 .79-3.694 
HDL -.02294 .01599 .1594 .977 .947-1.008 
Triglycerides .00373 .00161 .0207 1.004 1.001-1.007 
nonHDL .01349 .00275 .<.0001 1.014 1.008-1.019 
LDL .01724 .00346 <.001 1.017 1.00-1.024 
impact .05235 .02156 .0135 1.055 1.011-1.1 
worry .01551 .02240 .4885 1.016 .972-1.061 
Satisfaction .23418 .07803 .0027 1.264 1.085-1.473 
Sex Question  .2767 .1569 .0777 1.319 .970-1.793 
QOL .02413 .0124 .0468 1.024 1-1.049 
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       Table 4.8 continue- 
Ever smoked -.0475 .10099 .6383 .954 .782-1.62 
Level of 
Education 
.0986 .1882 .6006 1.104 .763-1.596 
Income -.12653 .03637 .0451 .881 .77-.998 
Marital Status .9686 .2776 .0005 2.634 1.529-4.538 
Age of Onset 
of Diabetes 
-.0285 .03325 .3906 972 .919-1.037 
Lipid Med .3988 1.029 .6982 1.49 .998-11.188 
Ace Med .3372 .17042 .0478 1.401 1.003-1.957 
CDSP 1.1639 .28014 <.001 3.202 1.849-5.545 
Overt 
Nephropathy 
1.0169 .28210 .0003 2.765 1.59-4.806 
Proliferative 
Retinopathy 
1.0409 .2758 .0002 2.832 1.649-4.861 
CAD .82603 .43412 .0571 2.284 .975-5.349 
LEAD .14152 .5217 .7862 1.152 .414-3.203 
SAN -.00582 .36329 .9872 .994 .488-2.026 
             Table 4.9 Multivariate Final Cox Model with Independent Predictors for ED (53 Incident Cases) 
Variable Parameter 
Estimate 
Standard 
Error 
p-value Hazard Ratio 95% CI 
Hazard Ratio 
Duration of 
Diabetes 
0.09066 0.02294 <0.001 1.095 1.047-1.145 
CDSP 0.82875 0.30352 0.0063 2.290 1.263-4.152 
nonHDL 0.01344 0.00322 <0.001 1.014 1.007-1.020 
Weight 0.02855 0.0124 0.0450 1.029 1.001-1.058 
4.5 DISCUSSION 
Prevalent ED as ascertained by physician exam in the Pittsburgh-EDC population was 
10.4%.  As age increased, the prevalence of ED also increased.  The prevalence of ED rose 
from 2% in those 18-29 years of age to 42% in those 40-45 years of age.  Sixty-one percent 
of the total ED cases (19/31) occurred in the males with ages between 30 and 39 years.  After 
entering all of the demographic, biologic, lifestyle behavior and use of antihypertensive 
medication variables into a multivariate logistic regression model, controlling for duration of 
diabetes, only biologic variables of CDSP and HDL were identified as independent 
associated risk factors  for ED.  In the multivariate logistic regression model with the 
psychosocial variables entered, after controlling for duration of diabetes and total number of 
complications, the mean BDI symptomatology score was the significant independent 
associated risk factor of ED identified.  
Incidence was 17.78 % from 1989 to 2007 and reflects 53 new cases of ED.  Person 
time at risk was 2034 person years over 18 years; the incident rate per year was estimated 
at 2.6/100 /year.  Ninety-five percent of the incident cases were between 30 and 49 years of 
age.  After entering all of the demographic, biologic, lifestyle behavior and use of anti-
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hypertensive medication variables into a multivariate Cox model (n=53), controlling for 
duration of diabetes, only the biologic variables of CDSP, nonHDL and weight were 
identified as the independent predictors for ED.  In the multivariate Cox model with the 
psychosocial variables entered for the incident cases (n=53), after controlling for duration 
of diabetes and total number of complications, the mean BDI symptomatology score was 
the significant independent predictor of ED identified.  
Both the prevalent and incident cases of ED had CDSP, lipid sub-fractions and BDI 
score as independent predictors of ED. The multivariate Cox (incidence) model also 
identified weight as an independent predictor.  
This prevalence rate was somewhat lower than previously reported (20%-90%) in the 
literature for ED and all types of diabetes(Bacon et al., 2002; Bacon et al., 2003; 
http://www.diabetes.org/diabetes-statistics/complications.jsp, 2007; A  Vinik et al., 2003).  
Our reported incidence rate of 17.78 % was also lower than previously reported  for studies 
of males with T1D by Klein (Klein et al., 2005) at 25.6% and McCulloch (McCulloch, 
Young, Prescott, & Campbell, 1984) at 28%.  Differences found in rates reported across 
studies may be due to differences in definitions used for ED as well as ascertainment 
measures.  Choice of the measure can affect the sensitivity and specificity.  For example, 
Klein et al (Klein et al., 1996), used particpant self-report to ascertain cases. Males were 
asked to self- report ED by answering the following question “Has diabetes caused 
impotence that is an inability to achieve a normal erection(Klein et al., 1996)?”   
Participants in this study might have over-reported impotence in that in replying yes to the 
question posed, they did not rule out other potential interactions between diabetes and/or 
other comorbidity treatment regimes.  Several studies also have reported rates from specialty 
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clinics (urology) and this higher representation may be the result of males with T1D 
presenting with more illness and hence are they are more sick than those represented in 
follow-up for  a longitudinal cohort  such as the EDC. Our studied used the DCCT neurology 
criteria and the physician ruled out whether the ED was caused by diabetes. Also the 
definition and measure used to determine ED varied across studies.  Some of the studies have 
used measures specific for ED such as the International  Index (Fedele, 1998) or structured 
interviews detailing prescence, and severity of the ED, while others have used more objective 
measures such as  nocturnal penile tumescence and rigidity testing.  Therefore the research 
methodology can not be ruled out as a factor affecting these rates.  
Several studies have confirmed the association of duration of diabetes and ED (Bacon 
et al., 2003; Klein et al., 1996; Kloner, 2008a).  Longer duration of diabetes was related to 
ED and found to be an independent predictor in this EDC population.  The first case for the 
prevalent ED cases was after 10.7 years whereas the first case for the incident cases was 20.4 
years.  This confers with similar findings previously reported (Burnett, 2006; Fedele, 1998; 
Fedele et al., 2001; Klein et al., 2005).  Diabetes is thought to be an age accelerating disease 
due to the effects of the diabetes disease process on endothelial function at the cellular level.   
The longer therefore someone has diabetes the faster they are aging.  For those with diabetes 
this may be the reason ED is seen 10 to 15 years earlier than in the general population.  
After adjusting by duration of diabetes, HDL cholesterol, in the prevalent cases, and 
nonHDL cholesterol for the incident cases were significant predictors.  Although ED has 
causal neuropathic pathways , there are also most probably vascular pathologies associated 
with its development (A. D. Seftel et al., 2004) as well.  Higher levels of non-HDL have been 
associated with endothelial dysfunction and vascular aging (Thomas et al., 2008).  
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Hypercholesterolemia has been associated with impairment of endoththieum dependent 
relaxation in smooth muscle cells of the corpus cavernosum (DeBerardis  et al., 2007).  
Impaired  endothelial dysfunction   results  from the modification of the nonHDL cholesterol 
by glycation, as in those with diabetes, oxidation or incorporation into immune complexes 
which contribute to vascular smooth muscle and endothelial dysfunction (Ross, 1999).  In the 
prevalent cases HDL cholesterol was a predictor and was noted to be significantly lower than 
the males without ED.  This association may be the resultant effect from vascular stiffness and 
atherosclerosis development.  These abnormal lipid levels may be the common pathway for ED 
as well as the other macrovascular complications frequently seen in diabetes.   
In both the prevalent and incident cases, confirmed distal symmetrical polyneuropathy 
was found to be a significant predictor of ED.  This has been previously reported (Fedele, 
1998; Klein et al., 2005; Saigal, Wessels, Pace, Schonlau, & Wilt 2006).  Klein et al (Klein et 
al., 1996)  found a relationship between lower extremity pain on ambulation and incident 
ererctile dysfunction in a 1996 prevalence study from Southern Wisconsin in a group of youth-
onset diabets males.  The effect of repeated hyperglycemia causes endoneuronal 
microangipathic change within all sensory nerves which then proceeds to the loss of nerve 
fibers, especially in the lower extremities and trunk (Yagihashi, 2007).  Further, this then 
causes a decrease in the small skin fibers affecting skin sensativity to stimuli.  All of the above 
therefore contribute to the development of ED in males with T1D. 
Finally, the psychosocial predictor variable, BDI total score, found in this analysis for 
both prevalence and incidence has previously been reported as well.  It is unknown however, if 
ED was caused by the depression or whether the depression was concurrently present as a 
result of another disease process. 
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4.5.1 Limitations  
There are several limitations to this study.  First, the methodology utilized the physician self-
reported ED on physical examination.  There were no objective findings to concur with this 
diagnosis and hence it is not known if this was under/over reported.  This population was 
almost all Caucasian, so it is unknown if this statistics hold true for other racial populations.  
The prevalence analysis was on all males that were enrolled at baseline; however, the incidence 
data was affected by censoring which further limits the generalizability of these results. 
4.5.2 Implications for Future Research 
Prospective studies should evaluate the effect of early treatment and intervention to prevent 
sensory polyneuropathy, control of blood lipids, and depression using standardized objective 
measures specific to ED.  Quality of life should be evaluated using a sexual function specific 
evaluation tool.  Since glycemic control has been shown previously to delay ED from 
occurring, the self-management and risk perceptions of males with respect to ED should be 
explored with respect to their knowledge of diabetes, self-efficacy and perceptions of 
severity for complication development.   
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5.0   MANUSCRIPT TWO 
5.1 ABSTRACT 
OBJECTIVE:  The purpose of this study was to identify the sequence to the development of 
ED in relation to other markers of neuropathy, i.e., E/I Ratio, Confirmed Distal Symmetrical 
Polyneuropathy (CDSP), and Symptomatic Autonomic Neuropathy (SAN). 
RESEARCH DESIGN AND ME THODS:  From 1989 to 2007, male participants (n=333) 
enrolled in the Pittsburgh Epidemiology of Diabetes Complication Study (EDC), received 
biennial examinations in the EDC center and were assessed for potential risk factors and 
diabetes complication development.  In addition to the physical assessment that included 
autonomic neuropathy review, and distal symmetrical polyneuropathy reviews, E/I ratios 
were completed on all participants.  Fifty-four incident cases of ED were identified during 
the 18 year follow-up.  ED incident cases were identified for E/I Ratio, CDSP and SAN, the 
cycle in which the ED case was reported and the cycle preceding the incident cycle.  
Inclusion in this study also included an age greater than or equal to 18 years. Cox 
proportional Hazard modeling and repeated measure assessment were used to determine 
independent predictors of ED at the time of reported incident ED and the cycle preceding this 
report. 
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RESULTS: Fifty-three incident cases were identified for ED.  In the Cox proportional 
hazards regression model, E/I Ratio [hazard ratio=0.008 (95% CI: 0.001-.0101) , p=0.0002] 
was significant at the time of the event, but not in the preceding event cycle [hazard 
ratio=0.312 (95% CI: 0.056-1.75), p=0.1836] ;  CDSP [hazard ratio=3.60 (95% CI: 2.01-
6.47), p<0.001] was significant in the preceding cycle to ED development and at the time of 
the event [hazard ratio=4.28 (95% CI: 2.41-7.6), p<.001].  For the repeated measure analysis, 
CDSP was significant in the preceding cycle to the ED development but not at the time of the 
event. 
CONCLUSION: Since it appears that CDSP is a significant independent predictor 
for ED, at both time points, males with diabetes should be assessed frequently for early 
warning signs and symptoms of sensory polyneuropathies.  Further investigation of this area 
is warranted to determine if by preventing and/or delaying the polyneuropathies, ED can be 
delayed or even prevented. 
5.2 INTRODUCTION 
Neuropathies are common complications of type 1 diabetes (T1D) seen in approximately 
50% of patients (Boulton et al., 2005).  The most common neuropathies are the chronic 
sensorimotor distal symmetric polyneuropathies (DSP) and diabetic autonomic neuropathies 
(DAN).  DSP is clinically evident with either an abnormal peripheral sensory exam and/or 
with decreased or absent deep tendon reflexes.  However, when one of these signs is present 
along with an objective measure of decreased sensation it is considered to be Confirmed 
Distal Symetrical Polyneuropathy (CDSP) (Boulton et al., 2005; Orchard et al., 1990).   
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The presence of DAN significantly impacts morbidity and subsequently affects 
mortality.  The markers for DAN include autonomic symptoms and measures of autonomic 
function such as Expiration/Inspiration Ratio (E/I ratio).  Autonomic symptoms of DAN are 
1) postural hypotension, 2) gastroparesis, 3) diabetic diarrhea, 4) colonic atony, 5) sudomotor 
abnormality, 6) hypoglycemic unawareness and 7) genitourinary autonomic neuropathy 
symptoms [including Erectile Dysfunction (ED) in males].  In addition, Symptomatic 
Autonomic Neuropathy (SAN) is defined as an average E/I Ratio of <1.1 and 2 or more of 
the other DAN autonomic symptoms.   
One of the earliest markers of DAN in males with T1D is erectile dysfunction (ED).  
ED is defined as a persistent inability to attain and maintain an erection adequate enough to 
permit satisfactory sexual performance not due to any other problem and present for at least 
30 days.  ED is not viewed as a life threatening disorder; however, ED may be considered an 
important marker in the development and progression of cardiac and vascular disease 
(Kloner, 2008b).  Males with diabetes have a 2-fold or greater increase in developing both 
ED and cardiac disease.  ED shares many of the same risk factors with cardiac disease 
development and progression in males with T1D.  These risk factors include increasing age, 
hypertension, hyperlipidemia, weight, depression, and certain medications.  Given that ED is 
a significant marker for life-threatening disorders, understanding the sequence of its 
development vis-à-vis other complications is important.  However, the pathological 
development of ED in relation to other neuropathies is not well defined.   
Therefore, the purpose of this study was to identify the sequence to the development 
of ED in relation to other markers of neuropathy, i.e., E/I Ratio, Confirmed Distal 
Symmetrical Polyneuropathy (CDSP), and Symptomatic Autonomic Neuropathy (SAN).  For 
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this analysis the hypothesis was that an E/I Ratio less than 1.1 would precede the 
development of ED. 
5.3 RESEARCH DESIGN AND METHODS 
All insulin dependent diabetes mellitus patients seen at Children’s Hospital of Pittsburgh 
from January 1, 1950 to May 31, 1980 formed the sampling frame for inclusion in the 
Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Participants had to meet 
the following criteria: 1) onset of insulin dependent diabetes mellitus at age 17 years or less; 
2) insulin therapy prescribed at discharge; 3) an initial diagnosis, or being seen within one 
year following diagnosis at Children’s Hospital of Pittsburgh; and 4) residence within 100 
miles of Pittsburgh or 2.5 hours of driving distance from Pittsburgh.  Recruitment and 
response rates for the EDC study have been detailed extensively in previous publications 
(Orchard et al., 1990).  Six hundred and fifty-eight participants completed baseline 
examinations between 1986 and 1988.  
Of the 658 participants enrolled at baseline (1986) for participation in the Pittsburgh 
Epidemiology of Diabetes Complications Study, 643 were Caucasian and 15 were African 
American.  Thirteen of the African Americans were female participants and 2 were African 
American males.  This sample was epidemiologically representative of the Allegheny County 
population and the incidence of T1D for that time frame.(Orchard et al., 1990; Wagener et 
al., 1982). 
Males composed 51% (n=333) of the total sample.  Age range for the males at baseline 
was from 8.5 years to 47.4 years.  The duration of diabetes varied: 13% (n=44) had diabetes 
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for less than 10 years, 40% ( n=136) had diabetes between 10 and 19 years, 35% (n=117) of 
the participants had diabetes between 20 and 29 years and, 11% (n=36) of the participants 
had diabetes for 30 years or more.  Overall mean for duration of diabetes for all males was 
19.5 years (sd ± 7.6 years).  Ninety-nine percent of the males were Caucasian, 52% had never  
married, and, 36 % reported an income over $30,000 while 64% had incomes less than 
$30,000/year. 
Because ED is only present in males who have reached an age of sexual maturity, an 
additional inclusion criterion for the ED study was age greater than or equal to an age of 18 
years.  Thirty-two of the 333 males were less than 18 years of age and baseline ED status was 
missing for three participants. However, as the 32 males reached 18 years of age they were 
entered into the risk set for the incidence analysis.  
Participants received biennial examinations in the EDC center, by trained physician 
investigators, and were assessed for potential risk factors and diabetes complication 
development (Orchard et al., 1990).  Follow-up examinations were conducted every two 
years and were similar to the baseline examination. Data were then collected biennially, for a 
period of 10 years (1986-1998).  Cycle 1 through Cycle 6 exams took place over a 10 year 
period and included face-to-face clinic visits, physical assessments, laboratory testing and 
self report.  Collection of data continued after the ten year follow-up with  annual surveys , 
and a full examination at 18 years (Cycle 10:2006-2008) using the above methods.  For this 
analysis, Cycles 2 through 6 and Cycle 10 were used. 
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5.3.1 Measures 
   5.3.1.1   Measure of Neuropathy 
Physician investigators also inquired about diabetic autonomic neuropathy symptom while 
conducting the Diabetes Control and Complications Trial (DCCT) clinical neurological 
examination protocol that included questions relating to: 1) postural hypotension, 2) 
gastroparesis, 3) diabetic diarrhea, 4) colonic atony, 5) sudomotor abnormality, 6) 
hypoglycemic unawareness and 7) genitourinary autonomic neuropathy symptoms (i.e., ED 
in males). 
5.3.1.2  Erectile Dysfunction (ED) 
ED was to be present for at least 30 days prior to the examination. ED was a “yes or no” 
determination after genitourinary (GU) system review of 3 items by the examining physician.  
GU items included: 1) impotence, 2) retrograde ejaculation and, 3) lower urinary tract 
symptoms. Prevalent cases were those males reporting ED at baseline exam (1986-1988) 
while incident cases were those males who were negative for ED at baseline but developed 
ED during a follow-up cycle (1989-2007).  The cycle in which the participant first reported 
ED following baseline examination was considered the incident cycle for ED.  The incident 
ED cases were used for these analyses.   
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5.3.1.3  Expiration / Inspiration Ratio (E/I ratio) 
Selected and trained research study staff completed the measurement procedure for the E/I 
ratio test.  The E/I ratio, an autonomic nervous system function test, was measured with the 
participant in a supine position, limb EKG leads were attached and a lead II rhythm tracing 
recorded.  The participant was then instructed to inhale deeply for 5 seconds followed by a 
forced expiration for 5 seconds and to continue this process of deep inspiration and forced 
expiration every 5 seconds for a total of 2 minutes.  The participant was prompted by the 
examiner for determination of the 5 second intervals.  The ECG was then marked to indicate 
an inspiration or expiration every 5 seconds during the recording for the total 2 minute 
testing time.  Both the shortest R-R interval of each inspiration segment and the longest R-R 
interval of each expiration segment were measured in milliseconds.  The E/I ratio was then 
calculated using the sum of six of the expiration (EXP) and inspiration (INP) R-R intervals 
using the following formula; sum of (R-R) EXP/  sum of (R-R) INP.   Values < 1.1 were 
considered  
5.3.1.4  Symptomatic Autonomic Neuropathy (SAN) 
SAN was defined as having an average E/I Ratio of <1.1 and 2 or more of the other 
autonomic symptoms as determined by the examining physician using the DCCT neuropathy 
protocol previously described.   
  140
5.3.1.5  Confirmed Distal Symmetrical Polyneuropathy (CDSP) 
CDSP was clinically evident DSP confirmed by physician’s exam and a vibratory 
threshold of >2.39 for ages < 36 years, > 2.59 for ages 35-50 years, or > 2.89 for ages >50 
years. . Data were coded as none (0), DSP (as defined above) and vibtoe negative DSP and 
vibtoe not available and, (1) DSP and confirmed with vibtoe. 
5.3.1.6 Other Covariates 
Hypertension was defined as a blood pressure greater than 140/90 mmHg or on anti-
hypertensive medication.  Blood pressure was measured per Hypertension Detection and 
Follow-up Protocol using a random zero sphygmomanometer.  Mean of the second and third 
blood pressure readings were used and entered as a continuous variable for systolic and 
diastolic pressures separately.  
Overt nephropathy (ON) was measured as an albumin excretion rate 
>200micrograms/min in multiple timed urine specimens, renal dialysis or a kidney 
transplant.  Data for ON were coded none (0), or overt or renal failure (1).  
Proliferative Retinopathy was determined from fundus photography and measured as 
none (0), or retinopathy and/or laser treatment for proliferative retinopathy (1). 
Demographic Variables include continuous variables:  age (years), duration of 
diabetes (years), HbA1, systolic and diastolic blood pressure, and depression (BDI); and 
categorical variables include: marital status, level of education, income, and usage of ACE or 
lipid –lowering medications. 
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5.3.2 Statistical Analysis 
Analysis was performed using SAS (Version 9.1.3, SAS Institute Inc., Cary, NC).  All data 
were verified after an extensive detailed exploratory analysis. Descriptive statistics were 
used to describe the sample.   As mentioned, incident ED cases were used for these 
analyses.  There was one multivariate outlier identified among the 54 incident cases.  This 
data was verified and checked for accuracy.   Since this outlier impacted the multivariate 
analysis, the decision was made to delete this case.  SAN was not used for this analysis 
because one of the confirmatory autonomic symptoms was ED, which was considered a 
confounder and not used. 
Cox proportional hazards modeling was used for the longitudinal data with time 
dependent covariates, controlling for duration.   The cycle in which the ED event occurred 
was investigated for CDSP and E/I Ratio.   Since the Cox proportional hazard model 
utilizes data points until the time of the event, a more robust model utilizing repeated 
measures to assess within and between differences was employed.  
Also, lag variables (the variable for the preceding cycle) for CDSP and E/I Ratio 
were created to identify potential predictor variables in the cycle preceding the ED event.  
In developing the lag variables, in order to account for missing values, it was necessary to 
impute some of the missing values.  In creating the lag variable for the E/I ratio there were 
33 missing data points.  In review of the E/I data, the imputed value was based on the 
Principle Investigator’s expert opinion.  The  lag E/I variable  for Cycle 2 incident cases  
was considered negative if the cycle 1 E/I variable was missing and the cycle 2 E/I value 
was negative.    
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5.4 RESULTS 
Fifty-three males were identified as incident ED cases between 1988 and 2007.   The 53 
males that had ED were characterized by having a mean age of 40.61± 5.9 (range 26.7-
60.8) years; a mean duration of diabetes 32.54 ± 5.88 (range 20.9-51-9) years; 69% (n=36) 
were married at the time of the reported ED; 74.5% (n=38) were college prepared, graduate 
or had professional degrees; 62% (n=32) had an annual income of  > $30,000; mean HbA1 
of 10.68 ± 2.19 %, range 7.4-17;  mean systolic and diastolic blood pressures 125. 29 ± 
20.56 (range 88.0-191.0) mmHg and 75.57 ± 11.36 (range 49.0-108.0) mmHg, 
respectively; Sixty three percent (n=24) of the incident cases also had CDSP while 49 % 
were hypertensive. Average BECK score for depression was 9.34 ± 6.95 (range 0-32). Two 
thirds of the sample had diabetes duration for greater than 30 years while approximately 
one half of the sample was older than 40 years.   Refer to Tables 5.1 and Table 5.2. 
 
      Table 5.1 Duration Distribution of the Incident Cases at Time of ED Event 
Duration 
(Years) 
n % of total
20-25 8 14.8 
25.1-30 10 18.5 
30.1-35 18 33.3 
35.1-40 14 25.9 
40 + 4 7.5 
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 Table 5.2 Characteristics of the 53 Incident Cases At Time of ED Event (1988-2007) 
Age (m±sd) years 40 ± 5.96 Range: 26.27-60.90 
Duration of Diabetes (m±sd) years 32.54 ± 5.94 Range: 20.9-51.90 
Marital Stataus:  69.23 % n=36 ( married at time of ED 
incident) 
Level of Education 74.5% n=38( college/ graduate / 
professional ) 
Income  38% (n=19) annual income < $30,000 
HbA1 10.68 (m±sd) 2.19 Range:7.4-17 
Systolic Blood Pressure 125 (m±sd) 20.71 Range: 88-191 
Diastolic Blood Pressure 76.10 (m±sd) 10.82 Range: 52-108 
E/I Ratio 1.138 (m±sd) .123 Range: 1-1.545 
CDSP 63.16% n=24 
Retinopathy 73.08% n=38 
Nephropathy 45.28% n=24 
Hypertension 48.89% n=22 
 Taking Ace Medication 38.46% n=20  
Taking Lipid Medication 4.55% n=2 
Depression  9.34 (m±sd) 6.95 Range: 0-32 
Age Categories (years) <30 years     =  2 (4%);      
 31-40 years = 21 (40%) 
41-50 years = 27 (50%)    
51-61 years = 3 (6%) 
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Univariate significant hazard ratios for the time of the reported ED event included: E/I 
Ratio, CDSP, and the controlled variables of hypertension, retinopathy, HbA1, and 
depression.  When all variables were placed in the Cox regression model, only CDSP (3.70, 
95% C.I: 1.99-6.72, p<0.001) was a significant independent predictor. 
Preceding the ED event (the cycle before the incident cycle, with an average spacing of 
two years), univariate significant hazard ratios were CDSP, hypertension, proliferative 
retinopathy, nephropathy and HbA1.  When all the lag variables were placed in a Cox model, 
only CDSP (3.14, 95% CI: 1.715-5.761, p=.002) again was the significant lagged 
independent predictor.  
Taking into account variability, the significant variables from the repeated measures 
analysis at the time of the event included E/I ratio, time (cycle), duration of diabetes, 
HbA1, and depression.  Whereby, the cycle before the reported incident ED, significant 
findings were for CDSP, time (cycle), duration of diabetes, and HbA1.   
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 Table 5.3 Hazard Ratios of Variables at Time of Reported ED and at Cycle before the ED Event 
Time of ED Event Cycle Before ED Event 
Variable Paramete
r 
estimate 
se p-value Hazard Ratio 95%CI Parameter 
estimate 
se p-value Hazard 
Ratio 
95%CI 
E/I Ratio -4.7899 1.27 .0002 .008 .001- 
.101 
-1.16528 .88 .1836 .312 .056- 
1.75 
CDSP 1.4537 0.29 <.001 4.28 2.41- 
7.6 
1.2815 .30 <.001 3.60 2.01- 
6.47 
Hypertensio
n 
0.8912 0.28 .0012 2.44 1.42- 
4.18 
.7632 .28 .0062 2.15 1.24- 
3.77 
Retinopathy 0.7817 0.31 .0120 2.19 1.18- 
4.02 
.6885 .31 .0243 1.99 1.09- 
3.06 
Nephropath
y 
0.7790 0.28 .0053 2.18 1.26- 
3.77 
1.0708 .30 .0003 2.92 1.63- 
5.24 
HbA1 0.1722 0.08 .0297 1.19 1.02- 
1.39 
.2169 .08 .0075 1.24 1.06- 
1.46 
Depression 0.0198 0.008 .0170 1.02 1.00- 
1.04 
.0146 .02 .3154 1.02 .987- 
1.04 
5.5 DISCUSSION 
The sequence in the development of ED was examined in relation to other indicators of 
neuropathy namely E/I Ratio and CDSP, as well as other co-variates (hypertension, 
retinopathy, nephropathy, HbA1, and depression).  The majority of men in this report were 
between the ages of 31-50 years with greater than 30 years duration of diabetes.   
Current incident ED was univariately associated with E/I Ratio, CDSP, hypertension, 
retinopathy, nephropathy, HbA1 and depression, which all, except for E/I Ratio, have been 
previously reported in the literature (Fedele et al., 2001; Klein et al., 2005). Multivariate 
analysis resulted in only CDSP as being a significant independent predictor for incident ED.  
  146
This, too, has previously been reported in the literature (Klein et al., 2005).  The repeated 
measures analysis at the time of the event included significant associations with E/I ratio, time 
(cycle), duration of diabetes, HbA1, and depression. 
The cycle prior to the development of incident ED had lag variables that were 
univariately associated with incident ED were CDSP, hypertension, retinopathy, nephropathy 
and HbA1. The lag variables of E/I Ratio and depression were not associated with incident ED.  
In the multivariate analysis, CDSP, was the only significant independent predictor of incident 
ED in the preceding cycle.  However, in the repeated measures analysis in the preceding cycle 
significant variables were CDSP, time (cycle), duration of diabetes, and HbA1.  It appears then 
that CDSP may precede the development of ED.  Unfortunately, we could not confirm that E/I 
Ratio also preceded the development of ED.  To the best of our knowledge the sequence of 
these events has not been previously reported in the literature. 
To our knowledge, lag variables have not been previously reported in the literature 
because ED has been used as a predictor of life-threatening events as opposed to being 
examined as the outcome variable. 
There are several limitations, however, to this research and therefore the results of this 
analysis should be viewed with caution.  The E/I ratio was missing for the analysis in the cycle 
preceding the event in 21 (39.6%) of the 53 cases.  Imputed values were used for the missing 
values.  These results were generated with imputed values and may not reflect the true clinical 
picture at the events times.  This EDC longitudinal study is the gold standard of research.  
Following this EDC cohort provided the benefit of prospectively tracking the development of 
complications associated with diabetes over 21 years.  However, problems following a cohort 
over this period of time include loss of patients to follow-up and mortality.  It is difficult to 
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generalize these findings to the larger population of men with diabetes and ED due to the 
interval censoring.  
It appears that CDSP is a significant independent predictor for ED 2 yrs before the 
occurrence of ED in males with diabetes.  The E/I ratio was not a significant predictor for ED 
but based on the limitations of this study should not be discounted.  Males with diabetes should 
be assessed frequently for early warnings of sensory polyneuropathies and early concurrent 
signs of ED.   Further investigation of this area is warranted to determine if by preventing/or 
delaying the polyneuropathies, ED can be delayed/prevented as well, therby 
delaying/preventing some of the more life-threatening comorbidities. 
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6.0  OTHER RESULTS 
6.1 GENERAL RESULTS 
In addition to those demographic, biologic, lifestyle behavior, anti-hypertension use and 
psychosocial factors identified in Chapter 1, additional descriptives were generated to 
characterize the male cohort at baseline enrollment for the EDC.   Please refer to Table 6.1. 
 
  149
Table 6.1  Characteristics for all Males at Baseline 
  
 
 
Total 
( N=333) 
 
Age (m±sd) years 
 
27.53±7.78 
Range: 8.47-47.43 
 
Duration of diabetes (m±sd) years 
 
19.55±7.46 
Range: 7.69-37.40 
Age at onset of diabetes (m±sd) years 
 
8.34 ± 4.17 
 
 
HbA1c(m±sd) % 
 
 
8.74 ±1.45 
Range: 5.23-15.16 
 
Systolic Blood Pressure (m±sd) mmHg 
 
117.49±17.14 
Range: 76-234 
 
Diastolic Blood Pressure (m±sd) mmHg 
 
75.52±11.20 
Range: 44-118 
 
BMI (m±sd) 
23.59±3.1 
Range: 13.87-33.12 
 
Waist Hip Ratio (m±sd) 
 
0.87±0.053 
Range: 0.75-1.1 
MARITAL STATUS (n,% total) 
never married 
married 
separated 
divorced 
widowed 
not married, living with partner 
 
175 (52.55) 
 131 (39.34) 
2 (0.6) 
18 (5.41) 
0 
7 (2.10) 
 
LEVEL OF EDUCATION (n,% total) 
SomeHS/HS  graduate 
Some College 
Graduate 
 
118 (39.46) 
154 (51.51) 
27 (9.03) 
 
 
INCOME (% total) 
<$5,000-$15,000 
$15,000-$30,000 
 >$30,000 
 
 
 
26.12 
38.05 
35.82 
Smoking Ever(n,% total) 
no 
yes 
n=322 
 
190(59.01) 
132(40.99) 
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Table 6.1 continued 
Smoking Now( n.% total) 
no 
yes 
n=125 
 
50(40) 
75(60) 
 
Total alcohol (Average drinks /wk) 
N=192 
6.17 ± 11.1 
Range:0-53 
High Density Lipoprotein (HDL) 48.61 ± 9.73 
 
nonHDL Cholesterol 140.60 ± 44.56 
 
Coronary Artery Disease (CAD) (n, % total) 
no 
 yes 
 
 
305 (91.59) 
28 (8.41) 
+Autonomic Neuropathy (AN)  ( n, % total) 
no 
yes 
n=92 
 
60 (65.22) 
32 (34.78) 
 
+Symptomatic Autonomic Neuropathy (SAN) (n, % 
Total) 
no 
yes 
n=92 
 
83 (90.22) 
 9 ( 9.78) 
Hypertensive (n,% total) 
no 
yes 
 
 268 (80.72) 
 64 (19.28) 
Nephropathy (n, % total) 
no 
yes 
 
 
238 (71.47) 
95 (28.52) 
 
Lower Extremity Arterial Disease (LEAD) (n, % total) 
no 
yes 
 
 
 
308( 93.05) 
23 (6.95) 
 
Retinopathy (n, % total) 
no 
yes 
 
219 (67.18) 
107 (32.82) 
Cerebral vascular Disease(CBVD)(n, % total) 
no 
yes 
 
331 (99.4) 
 1 (0.3) 
Confirmed Distal Symmetrical Polyneuropathy (CDSP) 
no 
yes 
 
230 (69.27) 
 102 (30.73) 
 
Distal Symmetrical Polyneuropathy (DSP) 
no 
yes 
 
 
 227 (68.37) 
 105 (31.63) 
Total Complications 1.18 ± 1.35 
Range: 0-5 
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Table 6.1 continued 
 
 
Ace Medication (n, % total) 
no 
yes 
 
 
307 ( 96.54) 
 11 (3.46) 
 
Lipid Medication (n, % total) 
no 
yes 
 
 
 
317 (99.37) 
2 ( 0.63) 
Blood Pressure Medication (n,% total) 
no 
yes 
 
257 (90.49) 
27 (9.51) 
Quality Of  Life (QOL) (m ± sd) 
 
52.72 ± 12.19 
Range: 33-129 
Impact (m ± sd) 
(Domain within QOL instrument) 
 
30.00 ± 6.75 
Range: 19-53 
Worry(m ± sd) 
(Domain within QOL instrument) 
 
16.41± 6.42 
Range:1-44 
Satisfaction(m ± sd) 
(Domain within QOL instrument) 
 
5.99 ± 1.96 
Range: 3-11 
Sex Question (m ± sd) 
(Question within Impact Domain/QOL Instrument) 
1.72 ± 1.10 
Range: 1-5 
BECK Depression Inventory (BDI)(m ± sd) 6.2±6.20 
Range:0-32 
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6.2 SPECIFIC AIMS 
6.2.1 Secondary Specific Aim 
Determine behavioral and cognitive risk factors, as represented by self-management 
behavior, self-effica cy, perceptio n of severity  and knowledge associated with the 
development of ED using EDC self- reported longitudinal data.   
Question #1.: Does self-management behavior, self-efficacy, perceptions of severity 
and knowledge of diabetes predict ED?   
             Question #2: Is self-management a mediator between cognitive variables (self-
efficacy, perceptions of severity and knowledge) and ED? 
Complete data for the behavioral and cognitive risk factors were only found at 
baseline.  Metabolic control (HbA1), self-management behaviors, knowledge, self-efficacy 
and beliefs were examined in 98 males without ED and 31 males with ED (matched for age 
and duration of diabetes).  A significant, positive, difference (p=.04) was found between 
those with ED and those without ED for knowledge of diabetes.  Borderline positive 
significance was found for self-management (p=.10) and perception of severity  (p=.08) 
between those with ED and those without ED.  However no significant difference was found 
between the two groups for self-efficacy.  Non-significant correlations between ED and self-
management behavior, self-efficacy, perception of severity and knowledge were found.  See 
Tables 6.2 and 6.3 for presentation of findings. 
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 Table 6.2 Biological, Behavioral and Cognitive Risk Factors in men with ED matched for Age and Duration 
to 98 males without ED at EDC baseline (1986-1988) 
 ED(n=31) No ED(n=98) p-value 
Age (years) 
 
35.8 ±5.3 
 
35.2 ±3.7 
 
 
 
 
Duration (years) 
 
26.9 ±5.9 
 
36.3 ±4.9 
 
 
HbA1 8.94 ±2.1 
 
8.52 ±1.7 
 
p>.05 
Self-Management 
Behavior: 
1. Tested 
Weekly                      
2. Based on 
Blood Glucose made 
changes to insulin 
 
 
58% 
 
100% 
 
 
 
55% 
 
98% 
 
 
p>.10 
 
p=.10 
Self-Efficacy: 
Can do something to control 
my diabetes and 
prevent/delay complications 
 
 
85% 
 
87% 
 
p>.5 
Perception of Severity: 
1. Perceive 
controlling glucose 
prevents/delays 
complications 
2. Perceive that 
by controlling 
glucose, 
complications are 
less severe 
 
81% 
 
 
 
76% 
 
91% 
 
 
 
90% 
 
p=.18 
 
 
 
p=.08 
Knowledge (good to 
excellent) 
90% 73% p=.04 
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 Table 6.3 Association between ED and Self-management Behavior, Self-Efficacy, Perception of 
Severity, Knowledge and ED 
 N=131 95% Confidence Limits 
Self-Management Behavior* 
 
 Tested glucose 
 
 Based on glucose changed 
insulin 
 
 
.022 
 
.069 
 
 
 
-.1730        .2175 
 
-.0015        .1404 
Self-Efficacy* 
 
-.1163 -.3440        .1113 
Perception of Severity* 
 Perceive 
controlling glucose will 
prevent/delay 
complications 
 Perceive 
controlling glucose will 
lessen severity of 
complications 
 
-.1939 
 
 
 
-.1990 
 
-.4308        .0430 
 
 
 
-.4260        .0281 
Knowledge* 
 
.08499 -.0901         .2601 
*Spearman Corrrelation p>0.05 
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7.0  CONCLUSIONS 
7.1 SPECIFIC AIM #1 
Determine both the ag e specific prevalence and  incidence of ED obtained by s elf-report 
during physician interview. 
The prevalence of ED in males with T1D enrolled at baseline in the Pittsburgh-EDC study was 
10.4%.  As age increased, the prevalence of ED also increased.  The prevalence of ED rose 
from 2% in those 18-29 years of age to 42% in those 40-45 years of age.  Sixty-one percent of 
the total ED cases (19/31) occurred in the males with ages between 30 and 39 years.  With 
increasing duration of diabetes, the prevalence of ED also rose.  Nineteen percent of the cases 
(n=6) occurred with a diabetes duration between 10 and 20 years, with the first case being 
reported after 10.7 years diabetes duration.  Sixteen percent of the ED cases (n=5) occurred 
after 21-25 years of diabetes duration, 35% (n=11) occurred after 26-30 years duration while 
29% (n=9) of the cases occurred after 31-37 years duration.  This prevalence rate is somewhat 
lower than previously  reported (20-60%)  in the literature (Bacon et al., 2002; Bacon et al., 
2003; http://www.diabetes.org/diabetes-statistics/prevalence.jsp, 2007; A  Vinik et al., 2003). 
Incidence was 17.78 % from 1989 to 2007 and reflects 53 new cases of ED.  Person 
time at risk was 2034 person years, over 18 years, and, the incident rate per year was estimated 
at 2.6/100 /year.  Ninety-five percent of the incident cases were between 30 and 49 years of 
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age.  As seen with the prevalent cases, with increasing duration of diabetes, the incidence also 
rose.   Our reported incidence rate was also lower than previously reported by Klein (Klein et 
al., 1996; Klein et al., 2005) at 25.6% and McCulloch (McCulloch et al., 1984) at 28%. 
Different rates across studies may be due to varying definitions or measures used to 
assess ED.  These differences can affect the sensitivity and specificity.  For example, Klein et 
al (Klein et al., 1996) used participant self-report to ascertain cases.  Males were asked to self-
report ED by answering the following question “Has diabetes caused impotence, that is an 
inability to achieve a normal erection?”(Klein et al., 1996).  Participants in this study might 
have over-reported impotence in that in replying yes to the question posed, they did not rule 
out other potential interactions between diabetes and/or other comorbidity treatment regiems.    
De Berardis et al (DeBerardis et al., 2005) used a self-report question , “How often have you 
experienced problems in achieving and maintaining an erection during the past six months? A 
Likert scale was presented for the patient to then make a selection from “never to more than 
once per week” and only those patients who selected more than once /week were then 
considered to have ED.  A criterion then not only became a positive response to the occurrence 
of ED but a frequency in the occurrence as well.   Several studies also have reported rates from 
specialty urology clinics and this higher representation may be the result of males with T1D 
presenting with more severe ED than those represented in a follow-up cohort such as the EDC, 
adding a severity factor to reporting ED as well..  Our study used the DCCT neurology criteria 
and the physician ruled out whether the ED was caused by diabetes.  Some of the studies have 
used measures specific for ED such as the International Index of Erectile Function (Fedele, 
1998) or structured interviews detailing presence, and severity of ED while others have used 
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more objective measures such as nocturnal penile tumescence and rigidity testing. Therefore 
the research methodology can not be ruled out as a factor affecting these rates. 
There was no normative data to assess if the prevalence rates in males with T1D differ 
from the rates within the general population for the EDC.  Additionally, studies completed 
within the early time frame of the EDC measured ED in males older than 40 and did not 
include the younger age groups.  ED became a variable of interest in 2000 and was 
documented in a large national survey (NHANES) dataset; however, collection of this data did 
not coincide with the same time frame as our data.  Therefore, no conclusion could be drawn as 
to whether the rates generated from our study were different.   
7.2 SPECIFIC AIM #2 
Determine baseline predictive risk factors for the development of ED.   
From the multivariate analysis of the prevalent cases, only the biologic factors of duration of 
diabetes, CDSP and HDL were identified as independent predictors for ED while for the 
psychosocial model, the mean BDI symptomatology score was the significant independent 
predictor of ED identified.  
The independent predictors for the 53 incident cases with ED were duration of diabetes, 
CDSP, nonHDL and weight.  As found in the prevalence analysis, with the psychosocial 
variables for the incident cases, the mean BDI symptomatology score was the significant 
independent predictor of ED identified.  
Both the prevalent and incident cases of ED had duration of diabetes, CDSP, lipid sub-
fractions and BDI symptomatology as independent predictors of ED identified.  In addition, the 
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additional independent predictor, weight, was identified for the incidence cases.  Weight was 
not however identified in the EDC prevalence analysis. 
Several studies have confirmed the association of duration of diabetes and ED (Klein, 
1996; Bacon,2006; Kloner RA,2008).  The first case for the prevalent ED cases was after 
10.7 years whereas the first case for the incident cases was 20.4 years.  This confers with 
similar findings previously reported (Burnett, 2006; Fedele, 1998; Fedele et al., 2001; Klein 
et al., 2005) . The most probable hypothesis for the increased association between ED and 
diabetes duration may in part be due to the effects of sustained and variable levels of glucose 
on the cavernosal tissue.  The accumulation of advanced glycolsalated end products (AGEs), 
the consequence of long term hyperglycemia, most probably mediate many of the 
complications of diabetes to include cardiovascular disease, neuropathy and nephropathy.  
The role of the accumulating AGEs in the pathology of ED is its association with the 
impairment of the endothelial dependent reduction in endothelial nitric oxide synthatase 
expression (A. Seftel et al., 1997)  Effects of diabetes on the protein kinase C-beta 
expression/activation in cavernosal smooth muscle can lead to exaggerated contractile penile 
responses and thereby impair erectile function (Gantz & Seftel, 2002).  Diabetes is thought to 
be an age accelerating disease due to the effects of the diabetes disease process on 
endothelial function at the cellular level with a resultant acceleration in atherosclerosis 
development.  The longer someone has diabetes, the faster the effects of this accelerating 
aging effect are seen, especially in the absence of tight metabolic control.  For those with 
diabetes this may be the reason ED is seen 10 to 15 years earlier than in the general 
population.  
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HDL cholesterol, in the prevalent cases, and nonHDL cholesterol for the incident 
cases were significant predictors.  Although ED has causal  neuopathic pathways , there  are 
also most probably vascular pathologies associated with its development (A. D. Seftel et al., 
2004) as well.  Higher levels of non-HDL has been associated with endothelial dysfunction 
and vascular aging (Thomas et al., 2008).  Hypercholesterolemia has been associated with 
impairment of endoththieum dependent relaxation in smooth muscle cells of the corpus 
cavernosum (DeBerardis  et al., 2007).  Impaired  endothelial dysfunction results from the 
modification of the nonHDL cholesterol by glycation, as in those with diabetes, oxidation or 
incorporation into immune complexes which contribute to vascular smooth muscle and 
endothelial dysfunction (Ross, 1999).  In the prevalent cases HDL cholesterol was a predictor 
and was noted to be significantly lower than in the males without ED.  This association may 
be the resultant effect from vascular stiffness and atherosclerosis development.  These 
abnormal lipid levels may be the common pathway for ED as well as the other macrovascular 
complications frequently seen in diabetes.  The association of lipid abnormalities with ED 
have been previously reported in the literature (Fedele et al., 2001; Klein et al., 2005). 
In both the prevalent and incident cases, confirmed distal symmetrical 
polyneuropathy was found to be a significant predictor of ED.  This has been previously 
reported (Fedele, 1998; Klein et al., 2005; Saigal et al., 2006).  Klein (Klein et al., 1996)  
found a relationship between lower extremity pain on ambulation and incident erectile 
dysfunction in a 1996 prevalence study from Southern Wisconsin in a group of youth-onset 
diabetes males.  It is hypothesized that the effect of repeated hyperglycemia causes 
endoneuronal microangipathic change within all sensory nerves which then proceeds to the 
loss of nerve fibers, especially in the lower extremities and trunk (Yagihashi, 2007)..  
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Further, this then causes a decrease in the small skin fibers affecting skin sensitivity to 
stimuli.  All of the above therefore contribute to the development of ED in males with T1D. 
Weight was identified as an independent predictor for the incidence cases but not in 
the prevelant cases.  Weight has been previously reported in the literature as well for its 
association to ED development, diabetes and cardiovascular disease.  The association with 
the effect of weight may be organic but the effect may also have a   psychogenic origin.  
Increased weight affects body-image which may affect self-esteem.  This may then lead to a 
decline in quality of life and expression of depressive symptomatology which has been 
linked with ED (Shiri et al., 220). 
Finally, the psychosocial predictor variable, BDI symptomatology score, found in this 
analysis for both prevalence and incidence has previously been reported as well.  From this 
study, we concluded that the BDI score was an independent predictor of ED in both the 
prevalent and incident cohort.  Although this score for both those males with ED and without 
ED was not in the moderate or severe depressive symptomatology range, there was a 
statistically significant difference between the two groups.  It is unknown however, if ED 
was caused by the depressive symptomatology or whether the depressive symptomatology 
(higher BDI score) was concurrently present as a result of another disease process.  The 
effect of this expression of depressive symptomatology  can result from organic causes, 
mainly an  inhibition of the parasympathetic nervous system which affects the blood flow to 
the penis causing inhibition of penile smooth muscle relaxation (Shiri et al., 220).  The effect 
on erectile function may be psychological as well.  Psychosocial explanations have been 
given as reactive depression effect, i.e., the male’s partner negatively reacts to the depression 
as a result of the males loss of sexual functioning (Shiri et al., 220). 
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7.3 SECIFIC AIM #3 
Determine the sequen ce of the d evelopment of ED in relation to  other markers  of 
neuropathy, i.e., Autonomic Neu ropathy (AN)( E/I ratio <1.1), Confirmed  Distal 
Symmetrical Polyneuropathy (CDSP), and Symptomatic Autonomic Neuropathy (SAN)  
(excluding ED) using longitudinal data. 
The sequence in the development of ED was examined in relation to other indicators of 
neuropathy namely E/I Ratio and CDSP as well as hypertension, retinopathy, nephropathy, 
HbA1, and BDI score.  Multivariate analysis resulted in only CDSP as being a significant 
independent predictor for incident ED.  This, too, has previously been reported in the 
literature (Klein et al., 2005) and has been previously discussed for Specific Aim #2.  The 
repeated measures analysis at the time of the event included significant associations with E/I 
ratio, time (cycle), duration of diabetes, HbA1, and BDI score.      
Two years prior to the development of incident ED the lag variables that were 
univariately associated with incident ED were CDSP, hypertension, retinopathy, nephropathy 
and HbA1.  The lag variables of E/I Ratio and BDI score were not associated with incident ED.  
In the multivariate analysis, CDSP, again, was the only significant independent predictor of 
incident ED in the preceding cycle.  However, in the repeated measures analysis in the 
preceding cycle significant variables were CDSP, time (cycle), duration of diabetes, and HbA1.  
  162
To our knowledge, lag variables have not been previously reported in the literature because ED 
has been used as a predictor of life-threatening events as opposed to being examined as the 
outcome variable. 
It appears then that CDSP may precede the development of ED.   We could not 
confirm that E/I Ratio also preceded the development of ED.   For CDSP to be positive, in 
addition to the clinically evaluated physical signs, an age-specific vibratron score was also 
necessary to delineate the neuropathy.  This may be a very sensitive marker for neuropathy.  
The E/I ratio may not have been as sensitive in determining sub-clinical neuropathy in this 
cohort, and hence, non-confirmation as a marker for ED.  Although the exact pathway was not 
determined, the association with CDSP preceding the development of ED may share a common 
pathway with metabolic control, hypertension and duration of diabetes.  To the best of our 
knowledge the sequence of these events has not been previously reported in the literature. 
7.4 SECONDARY SPECIFIC AIM 
Determine behavioral and cognitive risk factors, as represented by self-management 
behavior, self-effica cy, perceptio n of seve rity and know ledge associated w ith the 
development of ED using EDC self- reported longitudinal data. 
Complete data for the behavioral and cognitive risk factors were only found at baseline.  
Metabolic control (HbA1), self-management behaviors, knowledge, self-efficacy and beliefs 
were examined in 98 males without ED and 31 males with ED (matched for age and duration 
of diabetes).  A significant positive association (p=.04) was found between those with ED and 
those without ED for knowledge of diabetes.  Borderline significance was found for self-
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management (p=.10) and perception of severity (p=.08) between those with ED and those 
without ED.  However no significant difference was found between the two groups for self-
efficacy.  Non-significant correlations between ED and self-management behavior, self-
efficacy, perception of severity and knowledge were found.  This was a retrospective analysis 
of self-management behaviors, knowledge, self-efficacy and perceived susceptibility to 
diabetes complications.  The Social Cognitive umbrella of theories was chosen as the 
conceptual framework to fit the data that was present at baseline, and hence was not theory 
generating in the EDC’s original design.   Specific questions were chosen from the baseline 
Questionnaires to fit the behaviors, attitudes, knowledge and awareness.  Although the self-
management data was present longitudinally, some of the baseline questions for the remaining 
were deleted over time of the study.   
7.5 OVERALL SUMMARY 
In conclusion, results of this study were confirmatory of what has been previously reported in 
the literature for the demographic, biologic, behavioral lifestyle and psychosocial risk factors 
for predicting prevalent and incident ED.  Although both the prevalence and incidence rates 
were lower than previously reported, this study’s uniqueness was in the physician’s assessment 
of ED based on the DCCT neuropathy examination protocol.  As a result of this physician 
assessment then, this study may have therefore provided a more accurate description in males 
with T1D and ED.  CDSP was identified as significant factor proceeding in time to ED 
development.  This to our knowledge has not been previously reported and further 
investigation is warranted.  Confirmation that males with diabetes and ED engaged in self-
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management behaviors for diabetes control occurred.  However we were unable to describe the 
longitudinal relationship of these behaviors to self-efficacy, level of diabetes knowledge, and, 
the male perception of the severity as they related to ED development over time.  These 
variables of interest were retrospectively designed for this analysis from baseline questionnaire 
data, and other than the self-management behavior variable were not maintained longitudinally. 
. Therefore no conclusion could be drawn concerning the variables of self-efficacy, knowledge 
of diabetes, and, perceived susceptibility of complications..  It is imperative to have a better 
understanding though of this to affectively change, if necessary adherence to diabetes treatment 
regimes. 
7.6 LIMITATIONS 
There are several limitations to this study, the first of which lies in the methodology.  This 
study started in 1986, fourteen years before ED became an interest in the general population 
and before validated questionnaires for ED, ie, the International Index for Erectile Function, 
and the DMS-QOL were available.  Although ED was based on the DCCT clinical autonomic 
neuropathy review, the decision was made by the physician examiner.  Since this was a 
secondary analysis, there were no quality control measures to assess inter-rater reliability in 
place for ED, and, therefore, it is not known if ED is under/over reported in this EDC cohort.  
Previous literature cites the gender of the examiner to affect reported and discussion of ED in 
males with diabetes.  Males were more likely to report ED to male examiners, but with female 
physician examiners in order for a discussion of ED to ensue, the female physician had to have 
posed the question for dialogue to occur.  In the EDC cohort, the males were three times more 
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likely to report ED symptomatology to male examiners then their female physician 
counterparts.  This however, after review of the data, was not statistically significant but 
warrants mentioning.    
A second limitation is that this cohort upon the start of the study was all ready an aged 
cohort for youth-onset diabetes.  The mean age of the males was 27.53 + 7.78 years (range: 
8.47-47.43) and mean duration of diabetes was 19.55 + 7.46 (range: 7.69-37.40) years.  
Although the low enrollment of African Americans was reflective of the population in 
Allegheny County utilizing services at Children’ Hospital of Pittsburgh and of the low 
incidence of T1D seen in the African American population  at the time of the study’s inception 
these results may not be generalizable to other racial groups with diabetes.   This population 
was almost all Caucasian, so it is unknown if these findings hold true for other racial 
populations.    
This EDC longitudinal study is the gold standard of research.  Following this EDC 
cohort provided the benefit of prospectively tracking the development of complications 
associated with diabetes over 18 years of follow-up.  However, problems following a cohort 
over this period of time include loss of patients to follow-up and mortality.   Therefore, it may 
be difficult to generalize these findings to the larger population of men with diabetes and ED 
due to this interval censoring.  The critical factor here lies in the assumption that the reason a 
male was censored was independent of or unrelated to the development of ED. 
This study provided an exploratory descriptive analysis of ED in this cohort of males 
with T1D.  However, due to the small sample size, all arithmetic multiplicative interactions 
between variables, i.e. age at diagnosis of diabetes and ED, were not independently assessed as 
main effects..   
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7.7 IMPLICATION FOR NURSING AND PUBLIC HEALTH 
As previously stated, diabetes is one of the major chronic diseases seen today that imparts 
significant public health and economic burden on society.  Complications from diabetes are 
costly and result in excess morbidity and mortality.  Understanding the long term 
complications of diabetes, the intra-relationships among these complications and the risk 
factors is important.  It is with this understanding that complication rates will decrease and an 
improvement in the quality of life of those affected by diabetes will occur.  Although ED is not 
considered to be a life threatening complication, the development of ED is associated with 
other more life threatening concurrent complications so there is necessity in investigating this 
further.   
Larger prospective studies should evaluate the effect of early treatment and intervention 
to prevent sensory polyneuropathy, control of blood lipids, and depression using standardized 
objective measures specific to ED.  Evaluations of the present sub-clinical neuropathy 
diagnostic procedures, i.e. E/I ratios, should reflect the most sensitive measure to diagnosis 
sub-clinical autonomic neuropathy earlier.  As with the CDSP measures, larger trials should 
evaluate the effect of age, weight, comorbid conditions and ethnicity on these measures.  When 
designing studies of ED in males with T1D, it is necessary to have the participants of those 
studies report the ED event when it actually occurs, thereby assuring that the risk factors can be 
assessed at the time of development.  Having the participant recall the time of the event results 
in under-reporting due to recall bias, presents mathematical issues with interval censoring and 
may not actually reflect the metabolic or disease state at the time of the event occurrence.  
Quality of life should be evaluated using a sexual function specific evaluation tool.  Since 
glycemic control has been shown previously to delay ED from occurring, the self-management 
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behaviors, self-efficacy, knowledge of diabetes and ED, and perceived susceptibility for risk of 
ED should be explored.  It is imperative to have a better understanding of the impact of these 
behaviors, attitudes and beliefs surrounding ED and other diabetes complications if adherence 
to the diabetes treatment regime is to be affected.  Since there have been previous reports 
within the literature that males are reluctant to seek help for ED, qualitative studies are needed 
to explore this further also.  These qualitative studies should identify the recurring themes to 
help understand these behaviors and attitudes of males with respect to their T1D and ED.  
Also, these qualitative studies need to be in place in the adolescent populations as well to 
explore their knowledge of, beliefs and attitudes toward long term reproductive issues of males 
with T1D.  After determination of the above, diabetes education programs can be developed, 
evaluated and implemented specific to reproductive health issues for males with diabetes.   
Diabetes educators should encourage narrative about reproductive issues in males and in teens 
this information should be reviewed as part of their  diabetes education program.   Since it 
appears that CDSP is a significant independent predictor for ED, generated 2 yrs before the 
event, males with diabetes should be assessed frequently for early warnings of sensory 
polyneuropathies.  Further investigation of this area is warranted to determine if by 
preventing/or delaying the polyneuropathy, ED can be prevented or delayed as well. 
It should not be overlooked, however, that sex plays a very important role in the males’ 
life with diabetes, and raising awareness of risk factors of ED and diabetes adds to the 
significance of this study.  It is equally important to note that our study found a difference in 
self-report of ED by gender of the physician.  As nurses we need to therefore be sensitive to 
this issue and develop strategies in interviewing males with diabetes as to these matters.   
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NAME OF STUDY YEAR 
OF 
STUDY 
N 
Ages 
TYPE OF 
STUDY 
ED QUESTION  IDENTIFIED 
RISK FACTORS 
MASSACHUSETTS 
MALE AGING 
STUDY (MMAS) 
1987-
1989 
1290 
40-70 
CROSS-
SECTION 
SEXUAL 
ACTIVITY 
SURVEY-SELF-
REPORT 
DIABETES,HEART 
DISEASE, ANGER, 
DEPRESSION, 
HYPERTENSION, 
HDL, CIGARETTE 
SMOKING, 
EDUCATION, 
OCCUPATION 
 
NATIONAL 
HEALTH LIFE 
SURVEY 
1992 1410 
18-59 
CROSS-
SECTION 
SELF-REPORT; 
“INABILITY TO 
ACHIEVE AN 
ERECTION 
AGE, STRESS, 
SOCIOECONOMIC 
STATUS, RACE 
HEALTH 
PROFESSIONAL 
FOLLOW-UP 
SURVEY 
2000 43,235 
53-90 
CROSS-
SECTION 
SELF-REPORT-
ED ON 
SURVEY 
<PHYSICAL 
ACTIVITY > 20 
HRS OF TV 
VIEWING/WEEK, 
SMOKING, 
DIABETES, 
STROKE, 
CANCER, 
HYPERTENSION 
MANAGED CARE 
RECORD REVIEW 
1995-
2001 
285,43
6 
18-86 
COHORT ED DIAGNOSIS 
IN MEDICAL 
RECORD SELF-
REPORT 
HYPERTENSION 
LIPIDEMIA,  
DIABETES, 
DEPRESSION 
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MULTINATIONAL 
MEN’S ATTITUDE 
TO LIFE EVENTS 
AND SEXUALITY 
2000 28,691 
20-75 
MULTIPL
ENATIO
NS 
CROSS-
SECTION
SELF-REPORT  
SURVEY 
HYPERTENSION, 
LUTS, POOR 
HEALTH 
NATIONAL 
HEALTH AND 
NUTRITIONAL 
EXAMINATION 
SURVEY (NHANES) 
2001-
2002 
10,000 
>20 
CROSS-
SECTION
SELF-REPORT 
UNABLE TO 
KEEP AN 
ERECTION 
DIABETES, 
HYPERTENSION, 
OBESITY,>IN 
HISPANIC MEN 
EDINBURGH 
DIABETIC OUT-
PATIENT 
DEPARTMENT 
STUDY 
Type 1 and type2 
diabetes 
1980 563 
20-59 
CROSS-
SECTION
INTERVIEW-
SELF-REPORT 
RETINOPATHY 
AUTONOMIC 
NEUROPATHY, 
POOR DIABETES 
CONTROL, AGE 
ISCHAEMIC 
HEART DISEASE 
KLEIN ET AL 
WISCONSIN 
COHORT TYPE 1 
DAIBETES 
1996 1210 
>21 
CROSS-
SECTION
“HAS 
DIABETES 
CAUSED 
IMPOTENECE, 
AN INABILITY 
TO HAVE AN 
ERECTION?” 
PERIPHERAL 
NEUROPATHY, 
CAD, >BMI, 
>DURATION OF 
DIABETES, , ON 
B/P MEDS, 
SEVERE 
RETINOPATHY 
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 KLEIN ET AL 
Wisconsin T1D 
2000 365 
21-64 
AFTER 
10 
YEARS 
ABOVE 
STUDY 
SELF-REPORT 
OVER 10 YR 
PERIOD 
HYPERTENSION,
AGE, CHOL, 
SMOKING, 
LOWER 
EXTREMETRY 
PAIN ON 
WALKING 
FEDELE ITALIAN 
STUDY T1D & T2D   
 
 
1998 9868 
20-69 
CROSS-
SECTION 
ARE YOU  
SATISIFED 
WITH YOUR 
SEXUAL 
PERFORMACE  
POOR CONTROL 
OF DIABETES, 
ARTERIAL, 
RENAL, RETINAL 
DISEASE, , 
NEUROPATHY, 
SMOKING BMI 
 
SIU HONG KONG 
STUDY  T1D &T2D 
1999 486  
21-80 
CROSS 
SECTION 
SELF-REPORT 
SURVEY 
AGE, DURATION, 
RETINOPATHY, 
ALBUMINURIA, 
SENSORY POLY-
NEUROPATHY, 
HIGH LEVEL OF 
EDUCATION 
ENZLIN BELGIUM 
STUDY T1D 
2003 240 
>18 
CROSS 
SECTIO 
UDVALG FOR 
KLINISKE 
UNDERSOE-
GELSER 
SEXUAL 
SURVEY 
AGE, BMI, 
DURATION OF 
DIABETES, 
DIABETES 
COMPLICATIONS 
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 DEBERARDIS 
STUDY T2D 
2003 670 EVERY 2 
YEARS 
FOR 
FOLLOW
-UP 
HOW OFTEN 
DO YOU HAVE 
PROBLEMS  TO 
MAINTAIN AN 
ERECTION 
AGE, INSULIN  
HBA1, CHOL, 
SEVERITY OF 
DEPRESSIVE 
SYMPTOMS 
BORTOLOTTI 
ITALIAN STUDY  
1996 9670 
20-70 
CROSS 
SECTION 
SELF-REPORT 
ABILITY TO 
MAINTAIN 
ERECTION 
SMOKING 
DCCT/EDIC 
UROEDIC  STUDY 
T1D unpublished 
results 
2003 571 COHORT INTERNATION
AL INDEX OF 
ERECTILE 
FUNCTION 
(IIEF)“OVER 
THE PAST 4 
WEEKS, HOW 
WOULD YOU 
RATE YOUR 
CONFIDENCE 
TO KEEP AN 
ERECTION?” 
PERIPHERAL 
NEUROPATHY, 
AGE, HBA1 AT  
DCCT BASELINE, 
LUTS,  
DCCT/EDIC 
UROEDIC STUDY 
T1D 
2003 591 COHORT OIIEF 
ORGASMIC 
DYSFUNCTION
,DECREASED 
LIBIDO, 
QUALITY OF 
LIFE 
ED HAS >IMPACT 
ON QOL, AND 
>BOTHER 
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University of Pittsburgh 
Institutional Review Board  
  
 3500 Fifth Avenue 
 Ground Level 
 Pittsburgh, PA 15213 
 (412) 383-1480 
 (412) 383-1508 (fax) 
 
 
MEMORANDUM 
 
TO:  Trevor Orchard, MD 
 
FROM:  Robert Sweet, MD, Vice Chair 
 
DATE:  February 12, 2008 
 
SUBJECT: IRB #980707: The Epidemiology of Diabetes Complications: Phase II 
 
 
Your renewal was reviewed by the Institutional Review Board and approved at the Full Board Meeting 
(Committee A) that met on Tuesday, February 5, 2008. 
 
Please include the following information in the upper right-hand corner of all pages of the consent form: 
 
Approval Date: February 5, 2008 
Renewal Date: February 4, 2009 
University of Pittsburgh 
Institutional Review Board 
IRB #980707 
 
Please note that it is the investigator’s responsibility to report to the IRB any unanticipated problems involving 
risks to subjects or others [see 45 CFR 46.103(b)(5) and 21 CFR 56.108(b)].  The IRB Reference Manual 
(Chapter 3, Section 3.3) describes the reporting requirements for unanticipated problems which include, but 
are not limited to, adverse events.  If you have any questions about this process, please contact the Adverse 
Events Coordinator at 412-383-1504. 
 
The protocol and consent forms, along with a brief progress report must be resubmitted at least one month 
prior to the renewal date noted above as required by FWA00006790 (University of Pittsburgh), 
FWA00006735 (University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital of Pittsburgh), 
FWA00003567 (Magee-Womens Health Corporation), FWA00003338 (University of Pittsburgh Medical 
Center Cancer Institute). 
 
If this research study is subject to FDA regulation, please forward to the IRB all correspondence from the FDA 
regarding the conduct of this study. 
 
Please be advised that your research study may be audited periodically by the University of 
Pittsburgh Research Conduct and Compliance Office. 
 
RS:dj 
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